"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 5558378 A,030-869-230-249-186,1996-09-24,1996,US 55880195 A,1995-11-15,US 55880195 A,1995-11-15,Grappling-type shovel,A grappling-type shovel including a pair of semicircular blades pivotally secured together by a hinge. The hinge includes a pair of pivot plates extending from the inner surfaces of the blades. The pivot plates are joined together by a pivot pin. A pair of elongated handles are secured at their lower ends to the blades. A foot pedal is pivotally secured to the lower end of one of the handles.,BYRD; EDWARD,BYRD EDWARD,,https://lens.org/030-869-230-249-186,Granted Patent,yes,18,9,1,1,0,A01B1/02;;A01C5/02;;A01C5/02;;A01B1/02,A01B1/02;;A01C5/02,294/50.8;;294/60,0,0,,,,EXPIRED
2,US,A,US 5638045 A,172-396-661-707-240,1997-06-10,1997,US 42191395 A,1995-04-13,US 42191395 A,1995-04-13,Vehicle signal light system,"An external signal light system with two intensity levels. The system includes a dual-filament lamp bulb to alert observers that the vehicle brakes are being actuated. A power circuit connected to the vehicle storage battery provides electrical current to the bulb through a pair of serially connected switches. A first switch is closed upon actuation of the automobile's brakes. A second switch, controlled by a relay, delivers electrical current through the power circuit to either one of the bulb filaments in response to the energization state of the vehicle headlights. In the event that the headlights are energized, the second switch directs electrical current to the bulb's high wattage filament upon actuating the brakes. When the headlights are de-energized, however, electrical current is directed to the low wattage filament upon actuation of the brakes.",BYRD; EDWARD,BYRD EDWARD,,https://lens.org/172-396-661-707-240,Granted Patent,yes,10,6,1,1,0,B60Q1/44;;B60Q1/44,B60Q1/44,340/479;;340/469;;340/457.2;;315/82;;315/83;;307/10.8,0,0,,,,EXPIRED
3,GB,A,GB 2291290 A,169-798-732-434-686,1996-01-17,1996,GB 9512488 A,1995-06-20,GB 9412557 A,1994-06-22,Vehicle brake warning light systems,"A motor vehicle light system comprises a forward-facing light (13) which emits light (for example, green light) of a frequency visually different to any other light on the front of the vehicle, and a control circuit (10, 12) such that the forward-facing light (13) is illuminated when the vehicle brakes are applied. The forward facing light warns pedestrians that the vehicle brakes have been applied and comprises low and high wattage filaments 14, 15 for operation when the headlights are off and on respectively. <IMAGE>",BYRD EDWARD,BYRD EDWARD,,https://lens.org/169-798-732-434-686,Patent Application,no,7,1,4,4,0,B60Q1/441,B60Q1/44,H2H HSV3          SVZ;;H2H HSV4          SVZ;;H2H H32           SVZ;;U1S S1821;;U1S S1825,0,0,,,,EXPIRED
4,GB,B,GB 2291290 B,032-483-789-680-277,1998-12-02,1998,GB 9512488 A,1995-06-20,GB 9412557 A,1994-06-22,Motor vehicle light systems,,BYRD EDWARD,BYRD EDWARD,,https://lens.org/032-483-789-680-277,Granted Patent,no,8,0,4,4,0,B60Q1/441,B60Q1/44,H2H HSV3          SVZ;;H2H HSV4          SVZ;;H2H H32           SVZ;;U1S S1821;;U1S S1825,0,0,,,,EXPIRED
5,US,A1,US 2003/0039690 A1,155-251-754-201-210,2003-02-27,2003,US 22664602 A,2002-08-23,US 22664602 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release arginine alpha ketoglutarate,"
   An oral formulation of arginine -ketoglutarate is disclosed which formulation is comprised of arginine -ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine -ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine -ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine -ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine -ketoglutarate formulation. 
",BYRD EDWARD A.,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2002-09-10);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/155-251-754-201-210,Patent Application,yes,28,6,4,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K9/2027;;A61K31/425;;A61K9/5026;;A61K9/2081;;A61K31/197;;A61K31/385;;A61K31/51;;A61K31/64;;A61K9/2054,A61K9/20;;A61K9/22;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64,424/468;;514/565,0,0,,,,EXPIRED
6,CA,A1,CA 2541990 A1,050-708-385-782-792,2005-05-06,2005,CA 2541990 A,2004-10-22,US 69383703 A;;US 94705404 A;;US 2004/0035358 W,2003-10-23,"ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE .ALPHA.-KETOGLUTARATE",,MEDICAL RES INST,BYRD EDWARD A,,https://lens.org/050-708-385-782-792,Patent Application,no,0,0,5,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06;;A61P1/04;;A61P1/10;;A61P1/12;;A61P21/00;;A61P25/00;;A61P25/08;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P27/02;;A61P27/12;;A61P29/00;;A61P3/02;;A61P31/00;;A61P3/06;;A61P39/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K45/06;;A61K9/5026;;A61K31/425;;A61K31/385;;A61K31/51;;A61K9/2027;;A61K9/2081;;A61K9/2054;;A61K31/197;;A61K31/64,A61K9/20;;A61K9/48;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06,,0,0,,,,DISCONTINUED
7,CA,A,CA 260951 A,123-631-605-726-949,1926-05-18,1926,CA 260951D A,,CA 260951T A,,KNOTTER DEVICE,,MILL DEVICES COMPANY,BYRD BRITTEN EDWARD,,https://lens.org/123-631-605-726-949,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
8,US,A1,US 2006/0062853 A1,033-588-764-386-255,2006-03-23,2006,US 94705604 A,2004-09-21,US 94705604 A,2004-09-21,Treating neuromuscular disorders with an oral formulation of creatine derivatives,"Treating human muscle tissue by the oral administration of a formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt of a stearate, e.g. magnesium stearates. The formulation is produced as flowable particles with a sieve size of about 20 to 60 which particles are coated with a shellac to mask taste, avoid moisture uptake, and extend shelf life.",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2005-07-07),https://lens.org/033-588-764-386-255,Patent Application,yes,3,10,1,1,0,A61K9/141;;A61K31/197;;A61K31/205;;A61K33/42;;A61K45/06;;A61K9/141;;A61K31/205;;A61K45/06;;A61K31/197;;A61K33/42,A61K9/14;;A61K31/205;;A61K33/42,424/486;;514/554;;424/601,0,0,,,,DISCONTINUED
9,US,A,US 4003406 A,082-742-519-605-231,1977-01-18,1977,US 58110575 A,1975-05-27,US 58110575 A,1975-05-27,Cam loom apparatus and method,"The invention relates to apparatus wherein loom harnesses are operated by cams driven intermittently by respective drives rather than by cams fixed on a driven shaft. The harnesses are illustrated as being lowered by cams against yieldable resilient means tending to raise the harnesses, and the cams as being aligned with treadles carried longitudinally of the loom. Co-acting means are also provided for connecting respective chain drives at predetermined intervals to bearing members, rotatable on a fixed shaft, which carry cams fixed thereto as well as chain carrying sprockets rotatable thereon. The method contemplates operating the harnesses by timing the steps of rotating each cam in a predetermined sequence, and exerting a yielding force upon each cam tending to resist further rotation after the cam has turned on the fixed shaft through a predetermined arc.",BYRD EDWARD E,BYRD EDWARD E,,https://lens.org/082-742-519-605-231,Granted Patent,yes,4,4,1,1,0,D03C5/02;;D03C5/02,D03C5/02,139/80,0,0,,,,EXPIRED
10,WO,A1,WO 2006/034358 A1,190-160-525-918-942,2006-03-30,2006,US 2005/0033857 W,2005-09-20,US 94705804 A,2004-09-21,ORAL FORMULATION OF CREATINE DERIVATIVES AND METHOD OF MANUFACTURING SAME,"Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt of a stearate, e.g. magnesium stearates. The formulation is produced as flowable particles with a sieve size of about 20 to 60 which particles are coated with a shellac to mask taste, avoid moisture uptake, and extend shelf life.",MEDICAL RES INST;;BYRD EDWARD A,BYRD EDWARD A,,https://lens.org/190-160-525-918-942,Patent Application,yes,1,3,3,3,0,A61K9/1611;;A61K9/1611;;A61K9/1635;;A61K9/1635;;A61K9/1652;;A61K9/1652;;A61K31/22;;A61K31/22;;A61K45/06;;A61K45/06,A61K9/22,,0,0,,,,PENDING
11,US,A1,US 2004/0259895 A1,167-881-045-371-956,2004-12-23,2004,US 69383703 A,2003-10-23,US 69383703 A;;US 41255903 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Oral formulation of lipid soluble thiamine and lipoic acid,"
   A biphasic formulation of lipid soluble thiamine and lipoic acid for oral administration is disclosed. The lipoic acid and lipid soluble thiamine are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation following by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results. 
",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2003-11-10),https://lens.org/167-881-045-371-956,Patent Application,yes,27,4,1,30,0,A61K9/2027;;A61K9/2027;;A61K9/2054;;A61K9/2054;;A61K9/2081;;A61K9/2081;;A61K9/5026;;A61K9/5026;;A61K31/197;;A61K31/197;;A61K31/385;;A61K31/385;;A61K31/425;;A61K31/425;;A61K31/51;;A61K31/51;;A61K31/64;;A61K31/64,A61K9/20;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64,514/276;;X51444,0,0,,,,DISCONTINUED
12,MX,A,MX PA05010200 A,036-743-053-602-763,2006-05-22,2006,MX PA05010200 A,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD.,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER L L C,BYRD EDWARD MORTON,,https://lens.org/036-743-053-602-763,Patent Application,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P/;;B60P1/64,,0,0,,,,ACTIVE
13,US,B2,US 7579020 B2,107-537-341-752-287,2009-08-25,2009,US 2643004 A,2004-12-30,US 2643004 A;;US 22664602 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release arginine alpha-ketoglutarate,"An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2002-09-10);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/107-537-341-752-287,Granted Patent,yes,61,0,4,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K9/2027;;A61K31/425;;A61K9/5026;;A61K9/2081;;A61K31/197;;A61K31/385;;A61K31/51;;A61K31/64;;A61K9/2054,A61K9/20;;A61K9/22;;A61K9/50;;A61K31/195;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64,424/468;;424/451;;424/464;;424/489;;514/557;;514/561,87,81,063-998-322-834-700;;123-248-068-107-912;;051-547-925-337-14X;;010-531-566-705-313;;005-605-683-875-387;;053-379-955-833-948;;053-465-824-915-792;;031-367-729-933-071;;012-592-091-957-69X;;029-100-339-404-225;;053-184-017-150-489;;095-813-654-779-629;;003-195-875-311-437;;096-367-279-792-301;;049-437-541-984-517;;136-332-185-222-913;;107-098-634-091-257;;053-008-139-971-741;;024-148-959-460-931;;115-707-743-539-680;;024-755-423-599-235;;175-408-765-699-93X;;019-414-663-130-237;;015-179-555-670-233;;030-221-908-916-818;;094-960-080-226-585;;034-740-407-491-399;;110-967-259-632-874;;068-899-347-806-798;;003-035-076-618-958;;153-261-508-728-478;;046-473-161-483-488;;006-271-265-291-716;;060-356-627-543-687;;072-416-222-365-138;;078-716-951-717-968;;075-678-520-778-116;;058-702-952-247-205;;018-454-544-168-03X;;059-304-598-890-830;;077-884-177-358-324;;117-845-455-793-64X;;005-974-539-788-506;;082-708-410-600-112;;100-016-623-638-96X;;047-773-735-716-350;;050-192-781-871-880;;065-651-827-509-559;;020-956-274-069-761;;056-764-241-218-759;;006-484-369-493-573;;017-908-174-830-344;;003-697-132-923-985;;054-659-976-072-415;;028-041-208-184-134;;043-475-096-193-627;;138-220-467-755-984;;032-126-882-570-093;;001-616-684-952-506;;001-652-961-791-463;;025-562-409-144-344;;156-530-110-384-996;;018-466-204-074-65X;;035-507-263-580-688;;075-950-081-347-495;;009-168-847-094-513;;008-007-695-645-326;;100-006-825-289-105;;015-135-263-651-693;;000-187-982-586-699;;062-649-390-542-230;;057-930-915-005-512;;071-943-237-387-100;;012-572-225-329-245;;071-797-124-793-724;;051-170-162-047-867;;000-986-976-497-674;;149-783-447-573-989;;090-900-487-996-055;;124-557-307-304-645;;064-700-704-976-095,10.1016/0891-5849(96)00169-4;;8891676;;10.1007/bf00873552;;7595680;;1724477;;10.1007/bf01649442;;10.1111/j.1440-1681.1998.tb02281.x;;9750961;;9097001;;10.2337/diacare.20.4.670;;8480539;;10.1007/bf02027215;;1418040;;10.1016/s0891-5849(97)00371-7;;9607614;;10.1016/0076-6879(79)62212-7;;374970;;2835798;;10.1006/abbi.1996.9849;;9028868;;3990965;;10.1212/wnl.35.5.652;;10.1097/00075197-199901000-00007;;10453328;;8431966;;10.1016/0009-2797(93)90113-d;;2114274;;10.1159/000480918;;10.1016/0090-6980(78)90102-8;;107544;;10.2337/diabetes.45.12.1798;;10.2337/diab.45.12.1798;;8922368;;8150556;;10.1016/0192-0561(94)90119-8;;8054210;;10.1159/000211306;;10.1016/s0304-3940(97)13383-3;;9148247;;10.2337/diabetes.45.2.113;;10.2337/diab.45.2.113;;8549853;;10.1097/00003246-199701000-00016;;8989180;;10.1016/0304-4165(70)90183-2;;4924865;;9275010;;10.1016/s0024-3205(97)00562-6;;10.1006/abbi.1995.9925;;7503564;;10.2337/diab.45.8.1024;;8690147;;10.2337/diabetes.45.8.1024;;10.1016/0006-2952(92)90482-x;;1417985;;1314881;;10.1016/s0022-2275(20)41529-9;;1666624;;10.3109/10715769109105222;;10.1016/s0026-0495(97)90120-7;;9225829;;10.1093/jn/110.8.1525;;7400844;;10.1016/s0021-9258(18)63417-9;;5411544;;10.1016/s0891-5849(98)00048-3;;9680174;;8673022;;8925935;;10.1016/0014-5793(96)00919-2;;2508268;;10.1016/0300-483x(89)90007-3;;2112957;;10.1016/0167-4889(90)90147-6;;7790411;;10.1038/jcbfm.1995.77;;405572;;7587852;;10.2337/diacare.18.8.1160;;10.2337/diab.28.12.1039;;510803;;10.1007/bf02702855;;10.1016/0891-5849(96)00172-4;;8891666;;2948044;;10.1254/jjp.42.275;;10.1254/jjp.42.135;;2948041;;8889497;;10.3109/10715769609149056;;7605337;;10.1016/0006-2952(95)00116-h;;10.1016/s0891-5849(96)00269-9;;8958163;;10.1016/0891-5849(95)00017-r;;7649494;;8270140;;10.1007/bf00401070;;2651222;;10.1016/0891-5849(89)90118-4;;10.1016/0003-9861(89)90497-9;;2505669;;7377755;;10.1002/ana.410070403;;8759036;;10.1016/0006-2952(96)00337-1;;1345759;;10.1038/jcbfm.1992.10;;10.1126/science.114.2952.93;;14854913;;9065743;;10.1016/s0006-2952(96)00764-2;;8387744;;10.1006/abbi.1993.1228;;10.1096/fasebj.12.10.863;;9657526;;7605800;;10.1016/0925-4439(95)00052-6;;1815532;;8635688;;10.1096/fasebj.10.7.8635688;;10.1016/s0891-5849(96)00552-7;;9098099;;9642107;;10.1006/bbrc.1998.8764;;10.1097/00017285-199401000-00004;;10.1016/0091-3057(93)90204-7;;8309958;;9252495;;10.1152/ajpendo.1997.273.1.e185;;10.7883/yoken1952.49.39;;8806036;;1459492;;10.3109/10715769209068167;;1482376;;10.1016/0006-291x(92)90275-p;;10.3109/10715769109105221;;1666623;;3560772;;9211267;;10.1016/s0076-6879(97)79019-0;;10.1007/bf02704658;;10.1007/bf02703474;;10.1016/0006-2952(92)90556-x;;1540197;;9498679;;10.1016/s0378-4347(97)00488-x;;8783212;;10.1016/0028-3908(95)00172-7;;3289882;;10.1055/s-2008-1067770;;10.1007/bf00400603;;8786016;;8523450;;10.1016/0022-2828(95)90012-8,"Armstrong et al., Free Radical Biology and Chemistry, (1996) 21(5):719-726.;;Barbiroli et al., J Neurol, (1995) 242:472-477.;;Baur et al., Klin Wochenschr, (1991) 69:722-724.;;Bilich et al., I-Pharmacodynamics, (1978) 88:93.;;Black et al., Clinical and Experimental Pharmacology and Physiology, (1998) 25:712-714.;;Bloomgarden, Diabetes Care, (Apr. 1997) 20(4):670-673.;;Burkart et al., Agents Actions, (1993) 38:60-65.;;Busse et al., Arzneim-Forsch/Drug Research (1992) 42(6):829-831.;;Bustamante et al., Free Radical Biology and Medicine, (1998) 24(6):1023-1039.;;Carreau, Methods in Enzymology, (1979) 62:152-158.;;Cesolari et al., Rev Exp Enf Ap Digest, (1988) 73(3) 229-232.;;Chen et al., Archives of Biochemistry and Biophysics, (1997) 338(2):165-172.;;Chokroverty et al., Neurology, 35(5):652-9 (1985).;;Cynober, Curr Opin Clin Nutr Metab Care, 2(1):33-7 (1999).;;Devasgayam et al., Chem-Biol Interactions, (1993) 86:79-92.;;Dimpfel et al., Dev Pharmacol Ther, (1990) 14:193-199.;;Egan et al., Prostaglandins, (1978) 16(6):861-869.;;Estrada et al., Diabetes, (Dec. 1996) 45:1798-1804.;;Faust et al., J. Immunopharmac, (1994) 16(1):61-66.;;Fuchs et al., Skin Pharmacol, (1994) 7:278-284.;;Gandhi et al., J Biosci, (Sep. 1985) 9 (1 & 2):117-127.;;Garrett et al., Neuroscience Letters, (1997) 222:191-194.;;Gerbitz et al., Diabetes, (Feb. 1996) 45:113-126.;;Hammarqvist et al., Crit Care Med, (1997) 25(1):78-84.;;Haugaard et al., Biochem Biophys Acta, (1970) 222:583-586.;;Henricksen et al., American Physiological Society, (1990) C648-C653.;;Henricksen et al., Life Sciences, (1997) 61(8):805-812.;;Hofmann et al., Archives of Biochemistry and Biophysics, (1995) 324(1):85-92.;;Jacob et al., Diabetes, (1995) 245-250.;;Jacob et al., Diabetes, (Aug. 1996) 45:1024-1029.;;Kagan et al., Biochemical Pharmacology, (1992) 44(8):1637-1649.;;Kagan et al., Journal of Lipid Research, (1992) 33:385-397.;;Kagan et al., Free Rad Res Comms, (1991) 15(5):265-276.;;Khamaisi et al., Metabolism, (Jul. 1997) 45(7):763-768.;;Kuttan, J. Nutr., 110(8):1525-32 (1980).;;Lavis et al., The Journal of Biologic Chemistry, (Jan. 10, 1970) 245(1):23-31.;;Lodge et al., Journal of Applied Nutrition, (1997) 49 (1 & 2)3-11.;;Lodge et al., Free Radical Biology & Medicine, (1998) 25(3):287-297.;;Matsugo et al., Biochemistry and Molecular Biology International, (Oct. 1995) 37(2)375-383.;;Merin et al., FEBS Letters, (1996) 294:9-13.;;Muller et al., Toxicology, (1989) 58:175-185.;;Muller et al., Biochimica et Biophysica Acta, (1990) 1052:386-389.;;Muller et al., Journal of Cerebral Blood Flow and Metabolism, (1995) 15:624-630.;;Muting et al., MMW Munch Med Wochenschr, 119(16):538-8 (1977).;;Nagamatsu et al., Diabetes Care, (1995) 18(8):1160-1167.;;National Diabetes Data Group Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance, Diabetes (1979) 28:1039-1057.;;Natraj et al., J. Biosci, (1984) 6(1):38-46.;;Nickander et al., Free Radical Biology & Medicine (1996) 21(5):631-639.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:275-2.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:135-140.;;Ou et al., Free Rad Res, (1996) 25(4):337-346.;;Ou et al., Biochemical Pharmacology, (1995) 50(1):123-126.;;Packer et al., Free Radical Biology & Medicine, (1997) 22(1/2):359-378.;;Packer et al., Free Radical Biology & Medicine, (1995) 19(2):227-250.;;Packer, Diabetologica, (1993) 36:1212-1213.;;Pascoe et al., Free Radical Biology & Medicine, (1989) 6:209-224.;;Peinado et al., Archives of Biochemistry and Biophysics, (Sep. 1989) 273(2):389-395.;;Plaitakis et al., Ann Neurol, 7(4):297-303 (1980).;;Podda et al., Biochemical Pharmacology, (1996) 52:627-633.;;Prehn et al., Journal of Cerebral Blood Flow and Metabolism (1992) 12:78-87.;;Reed et al., Science, (1951) 93-94.;;Roy et al., Biochemical Pharmacology, (1997) 53:393-399.;;Scheer et al., Archives of Biochemistry and Biophysics, (May 1, 1993) 302(2):385-390.;;Schmid et al., FASEB Journal, (Jul. 1998) 12:863-870.;;Schonheit et al., Biochimica et Biophysica Acta, (1995) 1271:335-342.;;Segermann et al., Arzneim.-Forsch./Drug Res., (1991) 41(12):1294-1298.;;Sen et al., The FASEB Journal, (May 1996) 10:709-720.;;Sen et al., Free Radical Biology & Medicine, (1997) 22(7):1241-1257.;;Sen et al., Biochemical and Biophysical Research Communications (1998) 247:223-228.;;Simopoulos, Nutrition Today, (Jan./Feb. 1994) 12-16.;;Stoll et al., Pharmacology Biochemistry and Behavior, (1993) 46:799-805.;;Streeper et al., American Physiological Society, (1997) 273(1):E185-E191.;;Sumathi et al., Jpn J Med Sci Biol, (1996) 49:39-48.;;Suzuki et al., Free Rad Res Commsii, (1992) 17(3):211-217.;;Suzuki et al., Biochemical and Biophysical Research Communications,, (Dec. 1992) 189(3):1709-1715.;;Suzuki et al., Free Rad Res Comms, (1991) 15(5) 255-263.;;Szabo et al., Klin Wochenschr, (1986) 64(Suppl. VII):116-122.;;Teichert et al., Methods in Enzymology, (1997) vol. 279.;;Wagh et al., J. Biosci, (Mar. 1987) 11(1):59-74.;;Wagh et al., J. Biosci, (Jun. 1986) 10(2):171-179.;;Wagner et al., Properties and Derivatives of alpha-Lipoic Acid, (Oct. 5, 1956) 5079-5081.;;Wickramasinghe et al., Biochemical Pharmacology, (1992) 43(3) 407-411.;;Witt et al., Journal of Chromatography B, (1998) 705:127-131.;;Wolz et al., Neuropharmacology, (1996) 35(3):369-375.;;Ziegler et al., Deutsche Medizinische Wochenschritt, (Jul. 1, 1988) 113(26) 1071-1074.;;Ziegler et al., Diabetologia, (1995) 38:1425-1433.;;Zimmer et al., J Mol Cell Cardiol, (1995) 27:1895-1903.",EXPIRED
14,US,A1,US 2005/0106246 A1,173-376-073-235-388,2005-05-19,2005,US 2643004 A,2004-12-30,US 2643004 A;;US 22664602 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release arginine alpha-ketoglutarate,"An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.",BYRD EDWARD A.,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2002-09-10);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/173-376-073-235-388,Patent Application,yes,47,21,4,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K9/2027;;A61K31/425;;A61K9/5026;;A61K9/2081;;A61K31/197;;A61K31/385;;A61K31/51;;A61K31/64;;A61K9/2054,A61K9/20;;A61K9/22;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64,424/468;;514/565;;514/554,0,0,,,,EXPIRED
15,US,A1,US 2006/0062849 A1,082-982-426-230-226,2006-03-23,2006,US 94705804 A,2004-09-21,US 94705804 A,2004-09-21,Oral formulation of creatine derivatives and method of manufacturing same,"Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt of a stearate, e.g. magnesium stearates. The formulation is produced as flowable particles with a sieve size of about 20 to 60 which particles are coated with a shellac to mask taste, avoid moisture uptake, and extend shelf life.",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2005-07-07),https://lens.org/082-982-426-230-226,Patent Application,yes,4,10,3,3,0,A61K9/1611;;A61K9/1611;;A61K9/1635;;A61K9/1635;;A61K9/1652;;A61K9/1652;;A61K31/22;;A61K31/22;;A61K45/06;;A61K45/06,A61K9/22;;A61K31/22,424/468;;514/551,0,0,,,,DISCONTINUED
16,US,B2,US 6572888 B2,118-841-139-157-228,2003-06-03,2003,US 75589001 A,2001-01-05,US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release lipoic acid,"
    A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results. 
",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2001-02-06);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/118-841-139-157-228,Granted Patent,yes,9,66,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,424/468;;424/451;;424/452;;424/457;;424/463;;424/464;;424/465;;424/474;;424/475;;424/489;;424/490;;424/400,0,0,,,,EXPIRED
17,US,B2,US 7118762 B2,138-679-056-520-389,2006-10-10,2006,US 41255903 A,2003-04-11,US 41255903 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release lipoic acid,A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results.,MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2001-02-06);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/138-679-056-520-389,Granted Patent,yes,49,20,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/22;;A61K9/14;;A61K9/20;;A61K9/26;;A61K9/28;;A61K9/48;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,424/468;;424/451;;424/452;;424/457;;424/463;;424/464;;424/465;;424/474;;424/475;;424/489;;424/490;;424/400,99,76,032-338-169-057-061;;000-653-912-427-68X;;001-773-617-976-03X;;059-707-732-445-073;;108-136-917-095-128;;063-998-322-834-700;;123-248-068-107-912;;051-547-925-337-14X;;010-531-566-705-313;;005-605-683-875-387;;053-379-955-833-948;;053-465-824-915-792;;031-367-729-933-071;;012-592-091-957-69X;;029-100-339-404-225;;053-184-017-150-489;;096-367-279-792-301;;049-437-541-984-517;;136-332-185-222-913;;053-008-139-971-741;;024-148-959-460-931;;115-707-743-539-680;;024-755-423-599-235;;175-408-765-699-93X;;019-414-663-130-237;;015-179-555-670-233;;030-221-908-916-818;;094-960-080-226-585;;034-740-407-491-399;;110-967-259-632-874;;068-899-347-806-798;;003-035-076-618-958;;046-473-161-483-488;;006-271-265-291-716;;060-356-627-543-687;;072-416-222-365-138;;078-716-951-717-968;;075-678-520-778-116;;058-702-952-247-205;;059-304-598-890-830;;077-884-177-358-324;;117-845-455-793-64X;;005-974-539-788-506;;082-708-410-600-112;;100-016-623-638-96X;;047-773-735-716-350;;050-192-781-871-880;;065-651-827-509-559;;020-956-274-069-761;;056-764-241-218-759;;006-484-369-493-573;;017-908-174-830-344;;054-659-976-072-415;;028-041-208-184-134;;043-475-096-193-627;;138-220-467-755-984;;032-126-882-570-093;;001-616-684-952-506;;001-652-961-791-463;;025-562-409-144-344;;156-530-110-384-996;;018-466-204-074-65X;;035-507-263-580-688;;009-168-847-094-513;;008-007-695-645-326;;100-006-825-289-105;;015-135-263-651-693;;000-187-982-586-699;;062-649-390-542-230;;057-930-915-005-512;;071-943-237-387-100;;012-572-225-329-245;;071-797-124-793-724;;051-170-162-047-867;;000-986-976-497-674;;149-783-447-573-989,8001709;;10.1055/s-0029-1211455;;8817248;;7575750;;8390768;;6404656;;10.1016/0891-5849(96)00169-4;;8891676;;10.1007/bf00873552;;7595680;;1724477;;10.1007/bf01649442;;10.1111/j.1440-1681.1998.tb02281.x;;9750961;;9097001;;10.2337/diacare.20.4.670;;8480539;;10.1007/bf02027215;;1418040;;10.1016/s0891-5849(97)00371-7;;9607614;;10.1016/0076-6879(79)62212-7;;374970;;2835798;;10.1006/abbi.1996.9849;;9028868;;8431966;;10.1016/0009-2797(93)90113-d;;2114274;;10.1159/000480918;;10.1016/0090-6980(78)90102-8;;107544;;8150556;;10.1016/0192-0561(94)90119-8;;8054210;;10.1159/000211306;;10.1016/s0304-3940(97)13383-3;;9148247;;10.2337/diabetes.45.2.113;;10.2337/diab.45.2.113;;8549853;;10.1097/00003246-199701000-00016;;8989180;;10.1016/0304-4165(70)90183-2;;4924865;;9275010;;10.1016/s0024-3205(97)00562-6;;10.1006/abbi.1995.9925;;7503564;;10.2337/diab.45.8.1024;;8690147;;10.2337/diabetes.45.8.1024;;10.1016/0006-2952(92)90482-x;;1417985;;1314881;;10.1016/s0022-2275(20)41529-9;;1666624;;10.3109/10715769109105222;;10.1016/s0026-0495(97)90120-7;;9225829;;10.1016/s0021-9258(18)63417-9;;5411544;;10.1016/s0891-5849(98)00048-3;;9680174;;8673022;;8925935;;10.1016/0014-5793(96)00919-2;;2508268;;10.1016/0300-483x(89)90007-3;;2112957;;10.1016/0167-4889(90)90147-6;;7790411;;10.1038/jcbfm.1995.77;;7587852;;10.2337/diacare.18.8.1160;;10.2337/diab.28.12.1039;;510803;;10.1007/bf02702855;;10.1016/0891-5849(96)00172-4;;8891666;;2948044;;10.1254/jjp.42.275;;10.1254/jjp.42.135;;2948041;;8889497;;10.3109/10715769609149056;;7605337;;10.1016/0006-2952(95)00116-h;;10.1016/s0891-5849(96)00269-9;;8958163;;10.1016/0891-5849(95)00017-r;;7649494;;8270140;;10.1007/bf00401070;;2651222;;10.1016/0891-5849(89)90118-4;;10.1016/0003-9861(89)90497-9;;2505669;;8759036;;10.1016/0006-2952(96)00337-1;;1345759;;10.1038/jcbfm.1992.10;;10.1126/science.114.2952.93;;14854913;;9065743;;10.1016/s0006-2952(96)00764-2;;8387744;;10.1006/abbi.1993.1228;;10.1096/fasebj.12.10.863;;9657526;;7605800;;10.1016/0925-4439(95)00052-6;;1815532;;8635688;;10.1096/fasebj.10.7.8635688;;10.1016/s0891-5849(96)00552-7;;9098099;;9642107;;10.1006/bbrc.1998.8764;;10.1016/0091-3057(93)90204-7;;8309958;;9252495;;10.1152/ajpendo.1997.273.1.e185;;10.7883/yoken1952.49.39;;8806036;;1459492;;10.3109/10715769209068167;;1482376;;10.1016/0006-291x(92)90275-p;;10.3109/10715769109105221;;1666623;;3560772;;9211267;;10.1016/s0076-6879(97)79019-0;;10.1007/bf02704658;;10.1007/bf02703474;;10.1016/0006-2952(92)90556-x;;1540197;;9498679;;10.1016/s0378-4347(97)00488-x;;8783212;;10.1016/0028-3908(95)00172-7,"Guillausseau, PJ, ""Preventative Treatment of Diabetic Microangiopathy: blocking the pathogenic mechanisms,"" Diabete Metab. 20(2 Pt. 2): 219-28 (1994).;;Jacob et al., ""Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid"" Exp. Clin. Endocrinol. Diabetes 104(3):294-8 (1996).;;Jacob et al., ""Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid"" Arzneimittelforschung 45(8):872-4 (Aug. 1995).;;Kahler et al., ""Diabetes mellitus-a free radical-associated disease. Results of adjuvant antioxidant supplementation"" Z Gesamte Inn Med 48(5):223-32 (May 1993).;;Shih, Jason C.H., ""Atherosclerosis in Japanese quail and the effect of lipoic acid"" Avian Models for Research in Atherosclerosis and Cholesterol 42(8):2494-2497 (May 15, 1983).;;""Andrx to File Seven to 10 ANDAs for Controlled Release Generics,"" The Tan Sheet, 2(15):21 (Apr. 11, 1994).;;""Sunsource Melatonex debuts with $6 mil. Ad support; Par, Rexall unveil melatonin products."" The Tan Sheet 4(13):9 (Mar. 25, 1996).;;""Dietary Supplement Statements of Nutritional Support"" The Tan Sheet, 4(18):1 (Apr. 29, 1996).;;""Phenylpropanolamine 75 mg Controlled-Release Daily Dosage Form is Effective"" The Tan Sheet, 2(22):1 (May 30, 1994).;;""La Haye Labs"" The Tan Sheet, 2(27):21 (Jul. 4, 1994).;;""Controlled-release niacin"" The Tan Sheet, 2(36):25 (Sep. 5, 1994).;;""Syntex' EC-Naprosyn"" The Tan Sheet, 2(44):30 (Oct. 31, 1994).;;""Schiff, Rexall Sundown enter whole-food phytonutrients market in Jun."" The Tan Sheet, 3(28):5 (Jul. 10, 1995).;;""Pharmaceutical Resources launching Nutraceutical Resources in melatonin line in Mar."" The Tan Sheet, 4(8):18 (Feb. 19, 1996).;;""Dietary Supplement Statements of Nutrional Support"" The Tan Sheet, 4(31):1 (Jul. 29, 1996).;;""Dietary Supplement Statments of Nutritional Support"" The Tan Sheet, 4(39):1 (Sep. 23, 1996).;;""In Brief: Natrol"" The Tan Sheet, 4(17):21 (Apr. 22, 1996).;;""Bock Prenate Ultra touted for lower toxicity in cases of accidental ingestion"" The Tan Sheet, 4(35):10 (Aug. 26, 1996).;;""Leiner folate/neural tube defect claim subject of FDA ""courtesy letter"""" The Tan Sheet, 5(2):1 (Jan. 13, 1997).;;""Ascent Pediatrics acetaminophen controlled-release beads NDA expected by end of 1997"" The Tan Sheet, 5(19):13 (May 12, 1997).;;Armstrong et al., Free Radical Biology and Chemistry, (1996) 21(5):719-726.;;Barbiroli et al., J Neurol, (1995) 242:472-477.;;Baur et al., Klin Wochenschr, (1991) 69:722-724.;;Bilich et al., I-Pharmacodynamics, (1978) 88:93.;;Black et al., Clinical and Experimental Pharmacology and Physiology, (1998) 25:712-714.;;Bloomgarden, Diabetes Care, (Apr. 1997) 20(4):670-673.;;Burkart et al., Agents Actions(1993) 38:60-65.;;Busse et al., Arzneim-Forsch/Drug Research (1992) 42(6):829-831.;;Bustamante et al., Free Radical Biology and Medicine, (1998) 24(6):1023-1039.;;Carreau, Methods in Enzymology, (1979) 62:152-158.;;Cesolari et al., Rev Exp Erif Ap Digest, (1988) 73(3) 229-232.;;Chen et al., Archives of Biochemistry and Biophysics, (1997) 338(2):165-172.;;Devasgayam et al., Chem-Biol Interactions, (1993) 86:79-92.;;Dimpfel et al., Dev Pharmacol Ther, (1990) 14:193-199.;;Egan et al., Prostaglandins, (1978) 16(6):861-869.;;Estrada et al., Diabetes, (Dec. 1996) 45:1498-1804.;;Faust et al., J Immunopharmac, (1994) 16(1):61-66.;;Fuchs et al., Skin Pharmacol, (1994) 7:278-284.;;Gandhi et al., J Biosci(Sep. 1985) 9(1 & 2):117-127.;;Garrett et al., Neuroscience Letters, (1997) 222:191-194.;;Gerbitz et al., Diabetes, (Feb. 1996) 45:113-126.;;Hammarqvist et al., Crit Care Med, (1997) 25(1):78-84.;;Haugaard et al., Biochem Biophys Acta, (1970) 222:583-586.;;Henricksen et al., American Physiological Society, (1990) C648-C653.;;Henricksen et al., Life Sciences(1997) 61(8):805-812.;;Hofmann et al., Archives of Biochemistry and Biophysics(1995) 324(1):85-92.;;Jacob et al., Diabetes, (1995) 245-250.;;Jacob et al., Diabetes(Aug. 1996) 45:1024-1029.;;Kagan et al., Biochemical Pharmacology(1992) 44(8): 1637-1649.;;Kagan et al., Journal of Lipid Research, (1992) 33:385-397.;;Kagan et al., Free Rad Res Comms, (1991) 15(5):265-276.;;Khamaisi et al., Metabolism, (Jul. 1997) 45(7):763-768.;;Lavis et al., The Journal of Biologic Chemistry, (Jan. 110, 1970) 245(1):23-31.;;Lodge et al., Journal of Applied Nutrition, (1997) 49 (1 & 2)3-11.;;Lodge et al., Free Radical Biology & Medicine, (1998) 25(3):287-297.;;Matsugo et al., Biochemistry and Molecular Biology International, (Oct. 1995) 37(2)375-383.;;Merin et al., FEBS Letters, (1996) 294:9-13.;;Muller at al., Toxicology(1989) 58:175-185.;;Muller et al., Biochimica et Biophysica Acta, (1990) 1052:386-389.;;Muller et al., Journal of Cerebral Blood Flow and Metabolism, (1995) 15:624-630.;;Nagamatsu et al., Diabetes Care, (1995) 18(8):1160-1167.;;National Diabetes Data Group Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance, Diabetes (1979) 28:1039-1057.;;Natraj et al., J. Biosci, (1984) 6(1):38-46.;;Nickander et al., Free Radical Biology & Medicine (1996) 21(5): 631-639.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:275-2.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:135-140.;;Ou et al., Free Rad Res, (1996) 25(4):337-346.;;Ou et al., Biochemial Pharmacology, (1995) 50(1):123-126.;;Packer et al., Free Radical Biology & Medicine, (1997) 22(1/2):359-378.;;Packer et al., Free Radical Biology & Medicine, (1995) 19(2):227-250.;;Packer, Diabetologica, (1993) 36:1212-1213.;;Pascoe et al., Free Radical Biology & Medicine, (1989) 6:209-224.;;Peinado et al., Archives of Biochemistry and Biophysics, (Sep. 1989) 273(2):389-395.;;Podda et al., Biochemical Pharmacology, (1996) 52:627-633.;;Prehn et al., Journal of Cerebral Blood Flow and Metabolism (1992) 12:78-87.;;Reed et al., Science, (1951) 93-94.;;Roy et al., Biochemical Pharmacology, (1997) 53:393-399.;;Scheer et al., Archives of Biochemistry and Biophysics, (May 1, 1993) 302(2):385-390.;;Schmid et al., FASEB Journal, (Jul. 1998) 12:863-870.;;Schonheit et al., Biochimica et Biophysica Acta, (1995) 1271:335-342.;;Segermann et al., Arzneim.-Forsch./Drug Res., (1991) 41(12):1294-1298.;;Sen et al., The FASEB Journal, (May 1996) 10:709-720.;;Sen et al., Free Radical Biology & Medicine, (1997) 22(7):1241-1257.;;Sen et al., Biochemical and Biophysical Research Communications (1998) 247:223-228.;;Simopoulod, Nutrition Today, (Jan./Feb. 1994) 12-16.;;Stoll et al., Pharmacology Biochemistry and Behavior, (1993) 46:799-805.;;Streeper et al., American Physiological Society(1997) 273(1):E185-E191.;;Sumathi et al., Jpn J Med Sci Biol, (1996) 49:39-48.;;Suzuki et al., Free Rad Res Commsii(1992) 17(3):211-217.;;Suzuki et al., Biochemical and Biophysical Research Communications,, (Dec. 1992) 189(3):1709-1715.;;Suzuki et al., Free Rad Res Comms, (1991) 15(5) 255-263.;;Szabo et al., Klin Wochenschr, (1986) 64(Suppl. VII):116-122.;;Teichert et al., Methods in Enzymology, (1997) vol. 279.;;Wagh et al., J. Biosci, (Mar. 1987) 11(1):59-74.;;Wagh et al., J. Biosci, (Jun. 1986) 10(2):171-179.;;Wagner et al., Properties and Derivatives of a-Lipoic Acid, (Oct. 5, 1956) 5079-5081.;;Wickramasinghe et al., Biochemical Pharmacology, (1992) 43(3) 407-411.;;Witt et al., Journal of Chromatography B, (1998) 705:127-131.;;Wolz et al., Neruopharmacology(1996) 35(3):369-375.",EXPIRED
18,US,B2,US 6905707 B2,165-716-689-405-654,2005-06-14,2005,US 22664602 A,2002-08-23,US 22664602 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release arginine alpha ketoglutarate,"An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2002-09-10);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/165-716-689-405-654,Granted Patent,yes,31,8,4,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K9/2027;;A61K31/425;;A61K9/5026;;A61K9/2081;;A61K31/197;;A61K31/385;;A61K31/51;;A61K31/64;;A61K9/2054,A61K9/20;;A61K9/22;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64,424/468;;424/464;;424/465;;514/557;;514/561,87,81,063-998-322-834-700;;123-248-068-107-912;;051-547-925-337-14X;;010-531-566-705-313;;005-605-683-875-387;;053-379-955-833-948;;053-465-824-915-792;;031-367-729-933-071;;012-592-091-957-69X;;029-100-339-404-225;;053-184-017-150-489;;095-813-654-779-629;;003-195-875-311-437;;096-367-279-792-301;;049-437-541-984-517;;136-332-185-222-913;;107-098-634-091-257;;053-008-139-971-741;;024-148-959-460-931;;115-707-743-539-680;;024-755-423-599-235;;175-408-765-699-93X;;019-414-663-130-237;;015-179-555-670-233;;030-221-908-916-818;;094-960-080-226-585;;034-740-407-491-399;;110-967-259-632-874;;068-899-347-806-798;;003-035-076-618-958;;153-261-508-728-478;;046-473-161-483-488;;006-271-265-291-716;;060-356-627-543-687;;072-416-222-365-138;;078-716-951-717-968;;075-678-520-778-116;;058-702-952-247-205;;018-454-544-168-03X;;059-304-598-890-830;;077-884-177-358-324;;117-845-455-793-64X;;005-974-539-788-506;;082-708-410-600-112;;100-016-623-638-96X;;047-773-735-716-350;;050-192-781-871-880;;065-651-827-509-559;;020-956-274-069-761;;056-764-241-218-759;;006-484-369-493-573;;017-908-174-830-344;;003-697-132-923-985;;054-659-976-072-415;;028-041-208-184-134;;043-475-096-193-627;;138-220-467-755-984;;032-126-882-570-093;;001-616-684-952-506;;001-652-961-791-463;;025-562-409-144-344;;156-530-110-384-996;;018-466-204-074-65X;;035-507-263-580-688;;075-950-081-347-495;;009-168-847-094-513;;008-007-695-645-326;;100-006-825-289-105;;015-135-263-651-693;;000-187-982-586-699;;062-649-390-542-230;;057-930-915-005-512;;071-943-237-387-100;;012-572-225-329-245;;071-797-124-793-724;;051-170-162-047-867;;000-986-976-497-674;;149-783-447-573-989;;090-900-487-996-055;;124-557-307-304-645;;064-700-704-976-095,10.1016/0891-5849(96)00169-4;;8891676;;10.1007/bf00873552;;7595680;;1724477;;10.1007/bf01649442;;10.1111/j.1440-1681.1998.tb02281.x;;9750961;;9097001;;10.2337/diacare.20.4.670;;8480539;;10.1007/bf02027215;;1418040;;10.1016/s0891-5849(97)00371-7;;9607614;;10.1016/0076-6879(79)62212-7;;374970;;2835798;;10.1006/abbi.1996.9849;;9028868;;3990965;;10.1212/wnl.35.5.652;;10.1097/00075197-199901000-00007;;10453328;;8431966;;10.1016/0009-2797(93)90113-d;;2114274;;10.1159/000480918;;10.1016/0090-6980(78)90102-8;;107544;;10.2337/diabetes.45.12.1798;;10.2337/diab.45.12.1798;;8922368;;8150556;;10.1016/0192-0561(94)90119-8;;8054210;;10.1159/000211306;;10.1016/s0304-3940(97)13383-3;;9148247;;10.2337/diabetes.45.2.113;;10.2337/diab.45.2.113;;8549853;;10.1097/00003246-199701000-00016;;8989180;;10.1016/0304-4165(70)90183-2;;4924865;;9275010;;10.1016/s0024-3205(97)00562-6;;10.1006/abbi.1995.9925;;7503564;;10.2337/diab.45.8.1024;;8690147;;10.2337/diabetes.45.8.1024;;10.1016/0006-2952(92)90482-x;;1417985;;1314881;;10.1016/s0022-2275(20)41529-9;;1666624;;10.3109/10715769109105222;;10.1016/s0026-0495(97)90120-7;;9225829;;10.1093/jn/110.8.1525;;7400844;;10.1016/s0021-9258(18)63417-9;;5411544;;10.1016/s0891-5849(98)00048-3;;9680174;;8673022;;8925935;;10.1016/0014-5793(96)00919-2;;2508268;;10.1016/0300-483x(89)90007-3;;2112957;;10.1016/0167-4889(90)90147-6;;7790411;;10.1038/jcbfm.1995.77;;405572;;7587852;;10.2337/diacare.18.8.1160;;10.2337/diab.28.12.1039;;510803;;10.1007/bf02702855;;10.1016/0891-5849(96)00172-4;;8891666;;2948044;;10.1254/jjp.42.275;;10.1254/jjp.42.135;;2948041;;8889497;;10.3109/10715769609149056;;7605337;;10.1016/0006-2952(95)00116-h;;10.1016/s0891-5849(96)00269-9;;8958163;;10.1016/0891-5849(95)00017-r;;7649494;;8270140;;10.1007/bf00401070;;2651222;;10.1016/0891-5849(89)90118-4;;10.1016/0003-9861(89)90497-9;;2505669;;7377755;;10.1002/ana.410070403;;8759036;;10.1016/0006-2952(96)00337-1;;1345759;;10.1038/jcbfm.1992.10;;10.1126/science.114.2952.93;;14854913;;9065743;;10.1016/s0006-2952(96)00764-2;;8387744;;10.1006/abbi.1993.1228;;10.1096/fasebj.12.10.863;;9657526;;7605800;;10.1016/0925-4439(95)00052-6;;1815532;;8635688;;10.1096/fasebj.10.7.8635688;;10.1016/s0891-5849(96)00552-7;;9098099;;9642107;;10.1006/bbrc.1998.8764;;10.1097/00017285-199401000-00004;;10.1016/0091-3057(93)90204-7;;8309958;;9252495;;10.1152/ajpendo.1997.273.1.e185;;10.7883/yoken1952.49.39;;8806036;;1459492;;10.3109/10715769209068167;;1482376;;10.1016/0006-291x(92)90275-p;;10.3109/10715769109105221;;1666623;;3560772;;9211267;;10.1016/s0076-6879(97)79019-0;;10.1007/bf02704658;;10.1007/bf02703474;;10.1016/0006-2952(92)90556-x;;1540197;;9498679;;10.1016/s0378-4347(97)00488-x;;8783212;;10.1016/0028-3908(95)00172-7;;3289882;;10.1055/s-2008-1067770;;10.1007/bf00400603;;8786016;;8523450;;10.1016/0022-2828(95)90012-8,"Armstrong et al., Free Radical Biology and Chemistry, (1996) 21(5):719-726.;;Barbiroli et al., J Neurol, (1995) 242:472-477.;;Baur et al., Klin Wochenschr, (1991) 69:722-724.;;Bilich et al., I-Pharmacodynamics, (1978) 88:93.;;Black et al., Clinical and Experimental Pharmacology and Physiology, (1998) 25:712-714.;;Bloomgarden, Diabetes Care, (Apr. 1997) 20(4):670-673.;;Burkart et al., Agents Actions, (1993) 38:60-65.;;Busse et al., Arzneim-Forsch/Drug Research (1992) 42(6):829-831.;;Bustamante et al., Free Radical Biology and Medicine, (1998) 24(6):1023-1039.;;Carreau, Methods in Enzymology, (1979) 62:152-158.;;Cesolari et al., Rev Exp Enf Ap Digest, (1988) 73(3) 229-232.;;Chen et al., Archives of Biochemistry and Biophysics, (1997) 338(2):165-172.;;Chokroverty et al., Neurology, 35(5):652-9 (1985).;;Cynober, Curr Opin Clin Nutr Metab Care, 2(1):33-7 (1999).;;Devasgayam et al., Chem-Biol Interactions, (1993) 86:79-92.;;Dimpfel et al., Dev Pharmacol Ther, (1990) 14:193-199.;;Egan et al., Prostaglandins, (1978) 16(6):861-869.;;Estrada et al., Diabetes, (Dec. 1996) 45:1798-1804.;;Faust et al., J. Immunopharmac, (1994) 16(1):61-66.;;Fuchs et al., Skin Pharmacol, (1994) 7:278-284.;;Gandhi et al., J Biosci, (Sep. 1985) 9 (1 & 2):117-127.;;Garrett et al., Neuroscience Letters, (1997) 222:191-194.;;Gerbitz et al., Diabetes, (Feb. 1996) 45:113-126.;;Hammarqvist et al., Crit Care Med, (1997) 25(1):78-84.;;Haugaard et al., Biochem Biophys Acta, (1970) 222:583-586.;;Henricksen et al., American Physiological Society, (1990) C648-C653.;;Henricksen et al., Life Sciences, (1997) 61(8):805-812.;;Hofmann et al., Archives of Biochemistry and Biophysics, (1995) 324(1): 85-92.;;Jacob et al., Diabetes, (1995) 245-250.;;Jacob et al., Diabetes, (Aug. 1996) 45:1024-1029.;;Kagan et al., Biochemical Pharmacology, (1992) 44(8):1637-1649.;;Kagan et al., Journal of Lipid Research, (1992) 33:385-397.;;Kagan et al., Free Rad Res Comms, (1991) 15(5):265-276.;;Khamaisi et al., Metabolism, (Jul. 1997) 45(7):763-768.;;Kuttan, J. Nutr., 110(8):1525-32 (1980).;;Lavis et al., The Journal of Biologic Chemistry, (Jan. 10, 1970) 245(1):23-31.;;Lodge et al., Journal of Applied Nutrition, (1997) 49 (1 & 2)3-11.;;Lodge et al., Free Radical Biology & Medicine, (1998) 25(3):287-297.;;Matsugo et al., Biochemistry and Molecular Biology International, (Oct. 1995) 37(2)375-383.;;Merin et al., FEBS Letters, (1996) 294:9-13.;;Muller et al., Toxicology, (1989) 58:175-185.;;Muller et al., Biochimica et Biophysica Acta, (1990) 1052:386-389.;;Muller et al., Journal of Cerebral Blood Flow and Metabolism, (1995) 15:624-630.;;Muting et al., MMW Munch Med Wochenschr, 119(16):538-8 (1977).;;Nagamatsu et al., Diabetes Care, (1995) 18(8):1160-1167.;;National Diabetes Data Group Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance, Diabetes (1979) 28:1039-1057.;;Natraj et al., J Biosci, (1984) 6(1):38-46.;;Nickander et al., Free Radical Biology & Medicine (1996) 21(5): 631-639.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:275-2.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:135-140.;;Ou et al., Free Rad Res, (1996) 25(4):337-346.;;Ou et al., Biochemical Pharmacology, (1995) 50(1):123-126.;;Packer et al., Free Radical Biology & Medicine, (1997) 22(1/2): 359-378.;;Packer et al., Free Radical Biology & Medicine, (1995) 19(2): 227-250.;;Packer, Diabetologica, (1993) 36:1212-1213.;;Pascoe et al., Free Radical Biology & Medicine, (1989) 6:209-224.;;Peinado et al., Archives of Biochemistry and Biophysics, (Sep. 1989) 273(2):389-395.;;Plaitakis et al., Ann Neurol, 7(4):297-303 (1980).;;Podda et al., Biochemical Pharmacology, (1996) 52:627-633.;;Prehn et al., Journal of Cerebral Blood Flow and Metabolism (1992) 12:78-87.;;Reed et al., Science, (1951) 93-94.;;Roy et al., Biochemical Pharmacology, (1997) 53:393-399.;;Scheer et al., Archives of Biochemistry and Biophysics, (May 1, 1993) 302(2):385-390.;;Schmid et al., FASEB Journal, (Jul. 1998) 12:863-870.;;Schonheit et al., Biochimica et Biophysica Acta, (1995) 1271:335-342.;;Segermann et al., Arzneim.-Forsch/Drug Res., (1991) 41(12):1294-1298.;;Sen et al., The FASEB Journal, (May 1996) 10:709-720.;;Sen et al., Free Radical Biology & Medicine, (1997) 22(7):1241-1257.;;Sen et al., Biochemical and Biophysical Research Communications (1998) 247:223-238.;;Simopoulos, Nutrition Today, (Jan./Feb. 1994) 12-16.;;Stoll et al., Pharmacology Biochemistry and Behavior, (1993) 46:799-805.;;Streeper et al., American Physiological Society, (1997) 273(1):E185-E191.;;Sumathi et al., Jpn J Med Sci Biol, (1996) 49:39-48.;;Suzuki et al., Free Rad Res Commsii, (1992) 17(3):211-217.;;Suzuki et al., Biochemical and Biophysical Research Communications, (Dec. 1992) 189(3):1709-1715.;;Suzuki et al., Free Rad Res Comms, (1991) 15(5) 255-263.;;Szabo et al., Klin Wochenschr, (1986) 64(Suppl. VII):116-122.;;Teichert et al., Methods in Enzymology, (1997) vol. 279.;;Wagh et al., J. Biosci, (Mar. 1987) 11(1):59-74.;;Wagh et al., J. Biosci, (Jun. 1986) 10(2):171-179.;;Wagner et al., Properties and Derivatives of alpha-Lipoic Acid, (Oct. 5, 1956) 5079-5081.;;Wickramasinghe et al., Biochemical Pharmacology, (1992) 43(3) 407-411.;;Witt et al., Journal of Chromatography B, (1998) 705:127-131.;;Wolz et al., Neuropharmacology, (1996) 35(3):369-375.;;Ziegler et al., Deutsch Medizinische Wochenschritt, (Jul. 1, 1988) 113(26) 1071-1074.;;Ziegler et al., Diabetologia, (1995) 38:1425-1433.;;Zimmer et al., J Mol Cell Cardiol, (1995) 27:1895-1903.",EXPIRED
19,US,A1,US 2005/0085498 A1,000-468-974-679-52X,2005-04-21,2005,US 94705404 A,2004-09-21,US 94705404 A;;US 69383703 A;;US 41255903 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,"Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate","A formulation comprised of four active components which are a lipid soluble thiamine, lipoic acid, arginine α-ketoglutarate, and a creatine derivative for oral administration is disclosed. The active components may be combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation following by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to obtain a range of beneficial effects including reducing serum glucose levels and maintaining those reduced glucose levels over time to treat diabetic polyneuropathy as well as improving circulation and increasing muscle performance.",BYRD EDWARD A.,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2004-10-11),https://lens.org/000-468-974-679-52X,Patent Application,yes,35,17,5,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06;;A61P1/04;;A61P1/10;;A61P1/12;;A61P21/00;;A61P25/00;;A61P25/08;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P27/02;;A61P27/12;;A61P29/00;;A61P3/02;;A61P31/00;;A61P3/06;;A61P39/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K45/06;;A61K9/5026;;A61K31/425;;A61K31/385;;A61K31/51;;A61K9/2027;;A61K9/2081;;A61K9/2054;;A61K31/197;;A61K31/64,A61K9/20;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06,514/275;;514/440;;514/563;;514/565,0,0,,,,DISCONTINUED
20,WO,A3,WO 2007/019540 A3,029-510-283-453-037,2007-06-28,2007,US 2006/0030984 W,2006-08-08,US 19991905 A,2005-08-08,CONTROLLED RELEASE ALPHA-LIPOIC ACID FORMULATION WITH AN INOSITOL COMPOUND,A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation followed by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results.,MEDICAL RES INST;;BYRD EDWARD A,BYRD EDWARD A,,https://lens.org/029-510-283-453-037,Search Report,yes,4,0,3,3,0,A61K31/385;;A61K31/385;;A61K9/0007;;A61K9/0007;;A61K9/2027;;A61K9/2027;;A61K9/2054;;A61K9/2054;;A61K9/2081;;A61K9/2081;;A61K9/5026;;A61K9/5026;;A61K31/197;;A61K31/197;;A61K31/425;;A61K31/425;;A61K31/51;;A61K31/51;;A61K31/64;;A61K31/64;;A61K31/663;;A61K31/663;;A61K31/704;;A61K31/704,A01N43/04;;A61K9/20;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;C07H1/08;;C13K5/00,,0,0,,,,PENDING
21,WO,A2,WO 2007/019540 A2,056-924-436-108-226,2007-02-15,2007,US 2006/0030984 W,2006-08-08,US 19991905 A,2005-08-08,CONTROLLED RELEASE ALPHA-LIPOIC ACID FORMULATION WITH AN INOSITOL COMPOUND,A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation followed by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results.,MEDICAL RES INST;;BYRD EDWARD A,BYRD EDWARD A,,https://lens.org/056-924-436-108-226,Patent Application,yes,0,8,3,3,0,A61K31/385;;A61K31/385;;A61K9/0007;;A61K9/0007;;A61K9/2027;;A61K9/2027;;A61K9/2054;;A61K9/2054;;A61K9/2081;;A61K9/2081;;A61K9/5026;;A61K9/5026;;A61K31/197;;A61K31/197;;A61K31/425;;A61K31/425;;A61K31/51;;A61K31/51;;A61K31/64;;A61K31/64;;A61K31/663;;A61K31/663;;A61K31/704;;A61K31/704,A61K9/22;;A61K9/20;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K31/663;;A61K31/704,,0,0,,,,PENDING
22,WO,A1,WO 2005/039539 A1,062-791-506-863-659,2005-05-06,2005,US 2004/0035358 W,2004-10-22,US 69383703 A;;US 94705404 A,2003-10-23,"ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE alpha-KETOGLUTARATE","A formulation comprised of four active components which are a lipid soluble thiamine, lipoic acid, arginine a-ketoglutarate, and a creatine derivative for oral administration is disclosed. The active components may be combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation following by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to obtain a range of beneficial effects including reducing serum glucose levels and maintaining those reduced glucose levels over time to treat diabetic polyneuropathy as well as improving circulation and increasing muscle performance.",MEDICAL RES INST;;BYRD EDWARD A,BYRD EDWARD A,,https://lens.org/062-791-506-863-659,Patent Application,yes,1,13,5,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06;;A61P1/04;;A61P1/10;;A61P1/12;;A61P21/00;;A61P25/00;;A61P25/08;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P27/02;;A61P27/12;;A61P29/00;;A61P3/02;;A61P31/00;;A61P3/06;;A61P39/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K45/06;;A61K9/5026;;A61K31/425;;A61K31/385;;A61K31/51;;A61K9/2027;;A61K9/2081;;A61K9/2054;;A61K31/197;;A61K31/64,A61K9/20;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06,,0,0,,,,PENDING
23,US,A1,US 2003/0228362 A1,012-867-797-809-197,2003-12-11,2003,US 41255903 A,2003-04-11,US 41255903 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release lipoic acid,"
   A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results. 
",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2001-02-06);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/012-867-797-809-197,Patent Application,yes,30,3,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K9/00;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,424/468;;514/369;;X51444;;514/592;;514/635,0,0,,,,EXPIRED
24,US,A1,US 2001/0028896 A1,119-593-944-178-693,2001-10-11,2001,US 75589001 A,2001-01-05,US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release lipoic acid,"
   A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results. 
",BYRD EDWARD A.,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2001-02-06);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/119-593-944-178-693,Patent Application,yes,0,47,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/00;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,424/457;;X51444;;514/369,0,0,,,,EXPIRED
25,EP,A1,EP 1680093 A1,119-872-172-584-019,2006-07-19,2006,EP 04796350 A,2004-10-22,US 2004/0035358 W;;US 69383703 A;;US 94705404 A,2003-10-23,"ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE ALPHA-KETOGLUTARATE",,MEDICAL RES INST,BYRD EDWARD A,,https://lens.org/119-872-172-584-019,Patent Application,yes,0,0,5,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06;;A61P1/04;;A61P1/10;;A61P1/12;;A61P21/00;;A61P25/00;;A61P25/08;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P27/02;;A61P27/12;;A61P29/00;;A61P3/02;;A61P31/00;;A61P3/06;;A61P39/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K45/06;;A61K9/5026;;A61K31/425;;A61K31/385;;A61K31/51;;A61K9/2027;;A61K9/2081;;A61K9/2054;;A61K31/197;;A61K31/64,A61K9/20;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K45/06,,0,0,,,,DISCONTINUED
26,US,A1,US 2006/0024367 A1,119-223-772-599-134,2006-02-02,2006,US 19991905 A,2005-08-08,US 19991905 A;;US 41255903 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release alpha lipoic acid formulation with an inositol compound,A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation followed by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results.,BYRD EDWARD A,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2005-10-18),https://lens.org/119-223-772-599-134,Patent Application,yes,10,6,3,3,0,A61K31/385;;A61K31/385;;A61K9/0007;;A61K9/0007;;A61K9/2027;;A61K9/2027;;A61K9/2054;;A61K9/2054;;A61K9/2081;;A61K9/2081;;A61K9/5026;;A61K9/5026;;A61K31/197;;A61K31/197;;A61K31/425;;A61K31/425;;A61K31/51;;A61K31/51;;A61K31/64;;A61K31/64;;A61K31/663;;A61K31/663;;A61K31/704;;A61K31/704,A61K9/22;;A61K9/20;;A61K9/50;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61K31/663;;A61K31/704,424/468;;514/25;;514/102;;514/440,0,0,,,,DISCONTINUED
27,US,A1,US 2006/0128806 A1,167-587-362-844-246,2006-06-15,2006,US 24079005 A,2005-09-30,US 24079005 A;;US 2643004 A;;US 22664602 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release arginine alpha-ketoglutarate,"An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.",MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2006-02-09),https://lens.org/167-587-362-844-246,Patent Application,yes,8,0,1,30,0,A61K9/2009;;A61K9/2013;;A61K9/205;;A61K9/2063;;A61K31/198;;A61K31/198;;A61K9/2013;;A61K9/205;;A61K9/2009;;A61K9/2063,A61K31/198;;A61K9/22,514/565;;424/468,0,0,,,,DISCONTINUED
28,US,A1,US 2006/0188574 A1,061-688-646-547-728,2006-08-24,2006,US 38241406 A,2006-05-09,US 38241406 A;;US 41255903 A;;US 75589001 A;;US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results.,MEDICAL RES INST,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2001-02-06),https://lens.org/061-688-646-547-728,Patent Application,yes,27,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,424/468,0,0,,,,DISCONTINUED
29,US,A1,US 2007/0071815 A1,012-621-531-482-406,2007-03-29,2007,US 56182106 A,2006-11-20,US 56182106 A;;US 94705804 A,2004-09-21,ORAL FORMULATION OF CREATINE DERIVATIVES AND METHOD OF MANUFACTURING SAME,"Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt of a stearate, e.g. magnesium stearates. The formulation is produced as flowable particles with a sieve size of about 20 to 60 which particles are coated with a shellac to mask taste, avoid moisture uptake, and extend shelf life.",BYRD EDWARD A,BYRD EDWARD A,MEDICAL RESEARCH INSTITUTE (2005-07-07),https://lens.org/012-621-531-482-406,Patent Application,yes,4,7,3,3,0,A61K9/1611;;A61K9/1611;;A61K9/1635;;A61K9/1635;;A61K9/1652;;A61K9/1652;;A61K31/22;;A61K31/22;;A61K45/06;;A61K45/06,A61K31/205;;A61K9/20;;A61K9/22,424/464;;424/468;;514/554,0,0,,,,DISCONTINUED
30,US,A,US 5627172 A,040-560-479-050-057,1997-05-06,1997,US 20608994 A,1994-03-04,US 20608994 A,1994-03-04,Method for reduction of serum blood lipids or lipoprotein fraction,"A method is disclosed for lowering the concentration of a serum lipid or lipoprotein component in a mammal, including the step of administering to a mammal in need of such treatment a hypolipidemic, therapeutically effective amount of at least one creatine derivative.",NATURAL SUPPLEMENT ASS INC,ALMADA ANTHONY;;BYRD EDWARD,NATURAL SUPPLEMENT ASSOCIATION INC (1996-03-22);;EXPERIMENTAL & APPLIED SCIENCES INC (1994-02-28);;EXPERIMENTAL & APPLIED SCIENCES INC. (COLORADO CORPORATION) (1996-01-12),https://lens.org/040-560-479-050-057,Granted Patent,yes,3,23,1,1,0,A61K31/198;;A61K31/662;;A61K31/662;;A61K31/198,A61K31/198,514/120;;514/551;;514/564;;514/824,3,3,010-259-854-807-613;;036-830-721-876-328;;022-269-332-793-140,10.1111/j.1600-0838.1993.tb00378.x;;10.1042/cs0840565;;8504634;;7207523;;10.1056/nejm198104093041503,"Balsom, et al., Creatine Supplementation and Dynamic High Intensity Intermittent Exercise, Scand. J. Med. Sci. Sports 1993, 3:143 149.;;Greenhaff, et al., Influence of Oral Creatine Supplementation of Muscle Torque During Repeated Bouts of Maximal Voluntary Exercise In Man, Clinical Science (1993) 84, 565 571 (Printed in Great Britain).;;Sipil a , et al. Supplementary Creatine As A Treatment For Gyrate Atrophy Of The Choroid And Retina, N. Eng. J. Med., Apr. 9, 1981, 867 870.",EXPIRED
31,EP,B1,EP 1082107 B1,097-225-769-884-965,2005-10-26,2005,EP 99924394 A,1999-05-19,US 9911178 W;;US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,,MEDICAL RES INST,BYRD EDWARD A;;JANJIKHEL RAJIV,MEDICAL RESEARCH INSTITUTE (2005-11-02),https://lens.org/097-225-769-884-965,Granted Patent,yes,4,4,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,EXPIRED
32,EP,B8,EP 1082107 B8,169-085-409-362-192,2005-12-28,2005,EP 99924394 A,1999-05-19,US 9911178 W;;US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,,MEDICAL RES INST,BYRD EDWARD A;;JANJIKHEL RAJIV,MEDICAL RESEARCH INSTITUTE (2005-11-02),https://lens.org/169-085-409-362-192,Amended Patent,yes,4,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,EXPIRED
33,WO,A1,WO 1999/061004 A1,017-309-440-817-00X,1999-12-02,1999,US 9911178 W,1999-05-19,US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials protect the lipoic acid from chemical degradation in the gastrointestinal tract and provide for gradual release of the lipoic acid. These combined features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired results.,MEDICAL RESEARCH INST,BYRD EDWARD A;;JANJIKHEL RAJIV,,https://lens.org/017-309-440-817-00X,Patent Application,yes,1,14,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/20;;A61K9/22;;A61K9/00;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,PATENTED
34,EP,A1,EP 1082107 A1,134-794-839-103-221,2001-03-14,2001,EP 99924394 A,1999-05-19,US 9911178 W;;US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,,MEDICAL RES INST,BYRD EDWARD A;;JANJIKHEL RAJIV,MEDICAL RESEARCH INSTITUTE (2005-11-02),https://lens.org/134-794-839-103-221,Patent Application,yes,0,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,EXPIRED
35,CN,A,CN 1780748 A,004-587-242-706-50X,2006-05-31,2006,CN 200480011217 A,2004-03-18,US 39586103 A,2003-03-24,"Device for loading and unloading a storage container with respect to a transport vehicle,system and method related",,PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY A BYRD EDWARD,,https://lens.org/004-587-242-706-50X,Patent Application,no,0,10,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
36,CA,C,CA 2332790 C,153-317-981-106-500,2007-08-21,2007,CA 2332790 A,1999-05-19,US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A;;US 9911178 W,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,A controlled release formulation of lipoic acid is disclosed. The lipoic aci d is combined with excipient materials in such a way that those materials protect the lipoic acid from chemical degradation in the gastrointestinal tract and provide for gradual release of the lipoic acid. These combined features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired results.,MEDICAL RES INST,JANJIKHEL RAJIV;;BYRD EDWARD A,,https://lens.org/153-317-981-106-500,Granted Patent,no,0,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K31/385;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,EXPIRED
37,AU,A,AU 1999/040903 A,176-116-894-214-021,1999-12-13,1999,AU 1999/040903 A,1999-05-19,US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A;;US 9911178 W,1998-05-28,Controlled release lipoic acid,,MEDICAL RES INSTITUTE,BYRD EDWARD A;;JANJIKHEL RAJIV,,https://lens.org/176-116-894-214-021,Patent Application,no,0,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,DISCONTINUED
38,US,B1,US 6197340 B1,069-406-441-659-665,2001-03-06,2001,US 28824599 A,1999-04-08,US 28824599 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Controlled release lipoic acid,A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials protect the lipoic acid from chemical degradation in the gastrointestinal tract and provide for gradual release of the lipoic acid. These combined features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired results.,MEDICAL RES INST,BYRD EDWARD A;;JANJIKHEL RAJIV,MEDICAL RESEARCH INSTITUTE (1999-06-14);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/069-406-441-659-665,Granted Patent,yes,33,38,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,424/468;;424/451;;424/452;;424/457;;424/463;;424/464;;424/465;;424/474;;424/475;;424/489;;424/490;;424/400,82,76,063-998-322-834-700;;123-248-068-107-912;;051-547-925-337-14X;;010-531-566-705-313;;005-605-683-875-387;;053-379-955-833-948;;053-465-824-915-792;;031-367-729-933-071;;012-592-091-957-69X;;029-100-339-404-225;;053-184-017-150-489;;096-367-279-792-301;;049-437-541-984-517;;136-332-185-222-913;;107-098-634-091-257;;053-008-139-971-741;;024-148-959-460-931;;115-707-743-539-680;;024-755-423-599-235;;175-408-765-699-93X;;019-414-663-130-237;;015-179-555-670-233;;030-221-908-916-818;;094-960-080-226-585;;034-740-407-491-399;;110-967-259-632-874;;068-899-347-806-798;;003-035-076-618-958;;046-473-161-483-488;;006-271-265-291-716;;060-356-627-543-687;;072-416-222-365-138;;078-716-951-717-968;;075-678-520-778-116;;058-702-952-247-205;;059-304-598-890-830;;077-884-177-358-324;;117-845-455-793-64X;;005-974-539-788-506;;082-708-410-600-112;;100-016-623-638-96X;;047-773-735-716-350;;050-192-781-871-880;;065-651-827-509-559;;020-956-274-069-761;;056-764-241-218-759;;006-484-369-493-573;;017-908-174-830-344;;054-659-976-072-415;;028-041-208-184-134;;043-475-096-193-627;;138-220-467-755-984;;032-126-882-570-093;;001-616-684-952-506;;001-652-961-791-463;;025-562-409-144-344;;156-530-110-384-996;;018-466-204-074-65X;;035-507-263-580-688;;075-950-081-347-495;;009-168-847-094-513;;008-007-695-645-326;;100-006-825-289-105;;015-135-263-651-693;;000-187-982-586-699;;062-649-390-542-230;;057-930-915-005-512;;071-943-237-387-100;;012-572-225-329-245;;071-797-124-793-724;;051-170-162-047-867;;000-986-976-497-674;;149-783-447-573-989;;090-900-487-996-055;;124-557-307-304-645;;064-700-704-976-095,10.1016/0891-5849(96)00169-4;;8891676;;10.1007/bf00873552;;7595680;;1724477;;10.1007/bf01649442;;10.1111/j.1440-1681.1998.tb02281.x;;9750961;;9097001;;10.2337/diacare.20.4.670;;8480539;;10.1007/bf02027215;;1418040;;10.1016/s0891-5849(97)00371-7;;9607614;;10.1016/0076-6879(79)62212-7;;374970;;2835798;;10.1006/abbi.1996.9849;;9028868;;8431966;;10.1016/0009-2797(93)90113-d;;2114274;;10.1159/000480918;;10.1016/0090-6980(78)90102-8;;107544;;10.2337/diabetes.45.12.1798;;10.2337/diab.45.12.1798;;8922368;;8150556;;10.1016/0192-0561(94)90119-8;;8054210;;10.1159/000211306;;10.1016/s0304-3940(97)13383-3;;9148247;;10.2337/diabetes.45.2.113;;10.2337/diab.45.2.113;;8549853;;10.1097/00003246-199701000-00016;;8989180;;10.1016/0304-4165(70)90183-2;;4924865;;9275010;;10.1016/s0024-3205(97)00562-6;;10.1006/abbi.1995.9925;;7503564;;10.2337/diab.45.8.1024;;8690147;;10.2337/diabetes.45.8.1024;;10.1016/0006-2952(92)90482-x;;1417985;;1314881;;10.1016/s0022-2275(20)41529-9;;1666624;;10.3109/10715769109105222;;10.1016/s0026-0495(97)90120-7;;9225829;;10.1016/s0021-9258(18)63417-9;;5411544;;10.1016/s0891-5849(98)00048-3;;9680174;;8673022;;8925935;;10.1016/0014-5793(96)00919-2;;2508268;;10.1016/0300-483x(89)90007-3;;2112957;;10.1016/0167-4889(90)90147-6;;7790411;;10.1038/jcbfm.1995.77;;7587852;;10.2337/diacare.18.8.1160;;10.2337/diab.28.12.1039;;510803;;10.1007/bf02702855;;10.1016/0891-5849(96)00172-4;;8891666;;2948044;;10.1254/jjp.42.275;;10.1254/jjp.42.135;;2948041;;8889497;;10.3109/10715769609149056;;7605337;;10.1016/0006-2952(95)00116-h;;10.1016/s0891-5849(96)00269-9;;8958163;;10.1016/0891-5849(95)00017-r;;7649494;;8270140;;10.1007/bf00401070;;2651222;;10.1016/0891-5849(89)90118-4;;10.1016/0003-9861(89)90497-9;;2505669;;8759036;;10.1016/0006-2952(96)00337-1;;1345759;;10.1038/jcbfm.1992.10;;10.1126/science.114.2952.93;;14854913;;9065743;;10.1016/s0006-2952(96)00764-2;;8387744;;10.1006/abbi.1993.1228;;10.1096/fasebj.12.10.863;;9657526;;7605800;;10.1016/0925-4439(95)00052-6;;1815532;;8635688;;10.1096/fasebj.10.7.8635688;;10.1016/s0891-5849(96)00552-7;;9098099;;9642107;;10.1006/bbrc.1998.8764;;10.1097/00017285-199401000-00004;;10.1016/0091-3057(93)90204-7;;8309958;;9252495;;10.1152/ajpendo.1997.273.1.e185;;10.7883/yoken1952.49.39;;8806036;;1459492;;10.3109/10715769209068167;;1482376;;10.1016/0006-291x(92)90275-p;;10.3109/10715769109105221;;1666623;;3560772;;9211267;;10.1016/s0076-6879(97)79019-0;;10.1007/bf02704658;;10.1007/bf02703474;;10.1016/0006-2952(92)90556-x;;1540197;;9498679;;10.1016/s0378-4347(97)00488-x;;8783212;;10.1016/0028-3908(95)00172-7;;3289882;;10.1055/s-2008-1067770;;10.1007/bf00400603;;8786016;;8523450;;10.1016/0022-2828(95)90012-8,"Armstrong et al., Free Radical Biology and Chemistry, (1996) 21(5):719-726.;;Barbiroli et al., J Neurol, (1995) 242:472-477.;;Baur et al., Klin Wochenschr, (1991) 69:722-724.;;Bilich et al., I-Pharmacodynamics, (1978) 88:93.;;Black et al., Clinical and Experimental Pharmacology and Physiology, (1998) 25:712-714.;;Bloomgarden, Diabetes Care, (Apr. 1997) 20(4):670-673.;;Burkart et al., Agents Actions, (1993) 38:60-65.;;Busse et al., Arzneim-Forsch/Drug Research (1992) 42(6):829-831.;;Bustamante et al., Free Radical Biology and Medicine, (1998) 24(6):1023-1039.;;Carreau, Methods in Enzymology, (1979) 62:152-158.;;Cesolari et al., Rev Exp Enf Ap Digest, (1988) 73(3) 229-232.;;Chen et al., Archives of Biochemistry and Biophysics, (1997) 338(2):165-172.;;Devasgayam et al., Chem-Biol Interactions, (1993) 86:79-92.;;Dimpfel et al., Dev Pharmacol Ther, (1990) 14:193-199.;;Egan et al., Prostaglandins, (1978) 16(6):861-869.;;Estrada et al., Diabetes, (Dec. 1996) 45:1798-1804.;;Faust et al., J. Immunopharmac, (1994) 16(1):61-66.;;Fuchs et al., Skin Pharmacol, (1994) 7:278-284.;;Gandhi et al., J Biosci, (Sep. 1985) 9 (1 & 2):117-127.;;Garrett et al., Neuroscience Letters, (1997) 222:191-194.;;Gerbitz et al., Diabetes, (Feb. 1996) 45:113-126.;;Hammarqvist et al., Crit Care Med, (1997) 25(1):78-84.;;Haugaard et al., Biochem Biophys Acta, (1970) 222:583-586.;;Henricksen et al., American Physiological Society, (1990) C648-C653.;;Henricksen et al., Life Sciences, (1997) 61(8):805-812.;;Hofmann et al., Archives of Biochemistry and Biophysics, (1995) 324(1):85-92.;;Jacob et al., Diabetes, (1995) 245-250.;;Jacob et al., Diabetes, (Aug. 1996) 45:1024-1029.;;Kagan et al., Biochemical Pharmacology, (1992) 44(8):1637-1649.;;Kagan et al., Journal of Lipid Research, (1992) 33:385-397.;;Kagan et al., Free Rad Res Comms, (1991) 15(5):265-276.;;Khamaisi et al., Metabolism, (Jul. 1997) 45(7):763-768.;;Lavis et al., The Journal of Biologic Chemistry, (Jan. 10, 1970) 245(1):23-31.;;Lodge et al., Journal of Applied Nutrition, (1997) 49 (1 & 2)3-11.;;Lodge et al., Free Radical Biology & Medicine, (1998) 25(3):287-297.;;Matsugo et al., Biochemistry and Molecular Biology International, (Oct. 1995) 37(2)375-383.;;Merin et al., FEBS Letters, (1996) 294:9-13.;;Muller et al., Toxicology, (1989) 58:175-185.;;Muller et al., Biochimica et Biophysica Acta, (1990) 1052:386-389.;;Muller et al., Journal of Cerebral Blood Flow and Metabolism, (1995) 15:624-630.;;Nagamatsu et al., Diabetes Care, (1995) 18(8):1160-1167.;;National Diabetes Data Group Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance, Diabetes (1979) 28:1039-1057.;;Natraj et al., J. Biosci, (1984) 6(1):38-46.;;Nickander et al., Free Radical Biology & Medicine (1996) 21(5):631-639.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:275-280.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:135-140.;;Ou et al., Free Rad Res, (1996) 25(4):337-346.;;Ou et al., Biochemial Pharmacology, (1995) 50(1):123-126.;;Packer et al., Free Radical Biology & Medicine, (1997) 22(1/2):359-378.;;Packer et al., Free Radical Biology & Medicine, (1995) 19(2):227-250.;;Packer, Diabetologica, (1993) 36:1212-1213.;;Pascoe et al., Free Radical Biology & Medicine, (1989) 6:209-224.;;Peinado et al., Archives of Biochemistry and Biophysics, (Sep. 1989) 273(2):389-395.;;Podda et al., Biochemical Pharmacology, (1996) 52:627-633.;;Prehn et al., Journal of Cerebral Blood Flow and Metabolism (1992) 12:78-87.;;Reed et al., Science, (1951) 93-94.;;Roy et al., Biochemical Pharmacology, (1997) 53:393-399.;;Scheer et al., Archives of Biochemistry and Biophysics, (May 1, 1993) 302(2):385-390.;;Schmid et al., FASEB Journal, (Jul. 1998) 12:863-870.;;Schonheit et al., Biochimica et Biophysica Acta, (1995) 1271:335-342.;;Segermann et al., Arzneim.-Forsch./Drug Res., (1991) 41(12):1294-1298.;;Sen et al., The FASEB Journal, (May 1996) 10:709-720.;;Sen et al., Free Radical Biology & Medicine, (1997) 22(7):1241-1257.;;Sen et al., Biochemical and Biophysical Research Communications (1998) 247:223-228.;;Simopoulos, Nutrition Today, (Jan./Feb. 1994) 12-16.;;Stoll et al., Pharmacology Biochemistry and Behavior, (1993) 46:799-805.;;Streeper et al., American Physiological Society, (1997) 273(1):E185-E191.;;Sumathi et al., Jpn J Med Sci Biol, (1996) 49:39-48.;;Suzuki et al., Free Rad Res Commsii, (1992) 17(3):211-217.;;Suzuki et al., Biochemical and Biophysical Research Communications,, (Dec. 1992) 189(3):1709-1715.;;Suzuki et al., Free Rad Res Comms, (1991) 15(5) 255-263.;;Szabo et al., Klin Wochenschr, (1986) 64(Suppl. VII):116-122.;;Teichert et al., Methods in Enzymology, (1997) vol. 279.;;Wagh et al., J. Biosci, (Mar. 1987) 11(1):59-74.;;Wagh et al., J. Biosci, (Jun. 1986) 10(2):171-179.;;Wagner et al., Properties and Derivatives of alpha-Lipoic Acid, (Oct. 5, 1956) 5079-5081.;;Wickramasinghe et al., Biochemical Pharmacology, (1992) 43(3) 407-411.;;Witt et al., Journal of Chromatography B, (1998) 705:127-131.;;Wolz et al., Nerupharmacology, (1996) 35(3):369-375.;;Ziegler et al., Deutsche Medizinische Wochenschritt, (Jul. 1, 1988) 113(26) 1071-1074.;;Ziegler et al., Diabetologia, (1995) 38:1425-1433.;;Zimmer et al., J Mol Cell Cardiol, (1995) 27:1895-1903.",EXPIRED
39,ES,T3,ES 2251195 T3,084-560-308-503-097,2006-04-16,2006,ES 99924394 T,1999-05-19,US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A,1998-05-28,ACIDO LIPOICO DE LIBERACION LENTA.,"Una formulación de dosificación oral consistente en una cantidad terapéuticamente efectiva de ácido lipoico y un material excipiente, donde la formulación: (a) protege al ácido lipoico de la degradación química en el tracto gastrointestinal de un paciente y (b) libera el ácido lipoico de un modo controlado, de tal forma que el ácido lipoico se mantiene en el plasma sanguíneo en un nivel terapéutico a lo largo de un período de 4 horas o más.",MEDICAL RES INST,BYRD EDWARD A;;JANJIKHEL RAJIV,,https://lens.org/084-560-308-503-097,Granted Patent,no,0,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,EXPIRED
40,US,B1,US 6191162 B1,057-533-053-307-269,2001-02-20,2001,US 28825399 A,1999-04-08,US 28825399 A;;US 11262398 A;;US 10260598 P;;US 8720398 P,1998-05-28,Method of reducing serum glucose levels,A controlled release formulation of lipoic acid is administered to a patient resulting in reduced serum glucose levels. The formulation comprises a pharmaceutically acceptable carrier and is designed to prevent degradation of the lipoic acid in the gastrointestinal tract and to release the lipoic acid in a controlled manner thereby obtaining a desired lipoic acid serum level over an extended period resulting in reduced serum glucose levels over that period.,MEDICAL RES INST,BYRD EDWARD A;;JANJIKHEL RAJIV,MEDICAL RESEARCH INSTITUTE (1999-06-14);;NATURE ACQUISITION LLC (2014-12-01),https://lens.org/057-533-053-307-269,Granted Patent,yes,33,59,1,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/385;;A61K31/425;;A61K31/64;;A61K9/2027;;A61K31/425;;A61K31/385;;A61K31/64;;A61K9/2081;;A61K9/5026;;A61K9/2054,A61K9/20;;A61K9/50;;A61K31/385;;A61K31/425;;A61K31/64,514/440;;514/866,82,76,063-998-322-834-700;;123-248-068-107-912;;051-547-925-337-14X;;010-531-566-705-313;;005-605-683-875-387;;053-379-955-833-948;;053-465-824-915-792;;031-367-729-933-071;;012-592-091-957-69X;;029-100-339-404-225;;053-184-017-150-489;;096-367-279-792-301;;049-437-541-984-517;;136-332-185-222-913;;107-098-634-091-257;;053-008-139-971-741;;024-148-959-460-931;;115-707-743-539-680;;024-755-423-599-235;;175-408-765-699-93X;;019-414-663-130-237;;015-179-555-670-233;;030-221-908-916-818;;094-960-080-226-585;;034-740-407-491-399;;110-967-259-632-874;;068-899-347-806-798;;003-035-076-618-958;;046-473-161-483-488;;006-271-265-291-716;;060-356-627-543-687;;072-416-222-365-138;;078-716-951-717-968;;075-678-520-778-116;;058-702-952-247-205;;059-304-598-890-830;;077-884-177-358-324;;117-845-455-793-64X;;005-974-539-788-506;;082-708-410-600-112;;100-016-623-638-96X;;047-773-735-716-350;;050-192-781-871-880;;065-651-827-509-559;;020-956-274-069-761;;056-764-241-218-759;;006-484-369-493-573;;017-908-174-830-344;;054-659-976-072-415;;028-041-208-184-134;;043-475-096-193-627;;138-220-467-755-984;;032-126-882-570-093;;001-616-684-952-506;;001-652-961-791-463;;025-562-409-144-344;;156-530-110-384-996;;018-466-204-074-65X;;035-507-263-580-688;;075-950-081-347-495;;009-168-847-094-513;;008-007-695-645-326;;100-006-825-289-105;;015-135-263-651-693;;000-187-982-586-699;;062-649-390-542-230;;057-930-915-005-512;;071-943-237-387-100;;012-572-225-329-245;;071-797-124-793-724;;051-170-162-047-867;;000-986-976-497-674;;149-783-447-573-989;;090-900-487-996-055;;124-557-307-304-645;;064-700-704-976-095,10.1016/0891-5849(96)00169-4;;8891676;;10.1007/bf00873552;;7595680;;1724477;;10.1007/bf01649442;;10.1111/j.1440-1681.1998.tb02281.x;;9750961;;9097001;;10.2337/diacare.20.4.670;;8480539;;10.1007/bf02027215;;1418040;;10.1016/s0891-5849(97)00371-7;;9607614;;10.1016/0076-6879(79)62212-7;;374970;;2835798;;10.1006/abbi.1996.9849;;9028868;;8431966;;10.1016/0009-2797(93)90113-d;;2114274;;10.1159/000480918;;10.1016/0090-6980(78)90102-8;;107544;;10.2337/diabetes.45.12.1798;;10.2337/diab.45.12.1798;;8922368;;8150556;;10.1016/0192-0561(94)90119-8;;8054210;;10.1159/000211306;;10.1016/s0304-3940(97)13383-3;;9148247;;10.2337/diabetes.45.2.113;;10.2337/diab.45.2.113;;8549853;;10.1097/00003246-199701000-00016;;8989180;;10.1016/0304-4165(70)90183-2;;4924865;;9275010;;10.1016/s0024-3205(97)00562-6;;10.1006/abbi.1995.9925;;7503564;;10.2337/diab.45.8.1024;;8690147;;10.2337/diabetes.45.8.1024;;10.1016/0006-2952(92)90482-x;;1417985;;1314881;;10.1016/s0022-2275(20)41529-9;;1666624;;10.3109/10715769109105222;;10.1016/s0026-0495(97)90120-7;;9225829;;10.1016/s0021-9258(18)63417-9;;5411544;;10.1016/s0891-5849(98)00048-3;;9680174;;8673022;;8925935;;10.1016/0014-5793(96)00919-2;;2508268;;10.1016/0300-483x(89)90007-3;;2112957;;10.1016/0167-4889(90)90147-6;;7790411;;10.1038/jcbfm.1995.77;;7587852;;10.2337/diacare.18.8.1160;;10.2337/diab.28.12.1039;;510803;;10.1007/bf02702855;;10.1016/0891-5849(96)00172-4;;8891666;;2948044;;10.1254/jjp.42.275;;10.1254/jjp.42.135;;2948041;;8889497;;10.3109/10715769609149056;;7605337;;10.1016/0006-2952(95)00116-h;;10.1016/s0891-5849(96)00269-9;;8958163;;10.1016/0891-5849(95)00017-r;;7649494;;8270140;;10.1007/bf00401070;;2651222;;10.1016/0891-5849(89)90118-4;;10.1016/0003-9861(89)90497-9;;2505669;;8759036;;10.1016/0006-2952(96)00337-1;;1345759;;10.1038/jcbfm.1992.10;;10.1126/science.114.2952.93;;14854913;;9065743;;10.1016/s0006-2952(96)00764-2;;8387744;;10.1006/abbi.1993.1228;;10.1096/fasebj.12.10.863;;9657526;;7605800;;10.1016/0925-4439(95)00052-6;;1815532;;8635688;;10.1096/fasebj.10.7.8635688;;10.1016/s0891-5849(96)00552-7;;9098099;;9642107;;10.1006/bbrc.1998.8764;;10.1097/00017285-199401000-00004;;10.1016/0091-3057(93)90204-7;;8309958;;9252495;;10.1152/ajpendo.1997.273.1.e185;;10.7883/yoken1952.49.39;;8806036;;1459492;;10.3109/10715769209068167;;1482376;;10.1016/0006-291x(92)90275-p;;10.3109/10715769109105221;;1666623;;3560772;;9211267;;10.1016/s0076-6879(97)79019-0;;10.1007/bf02704658;;10.1007/bf02703474;;10.1016/0006-2952(92)90556-x;;1540197;;9498679;;10.1016/s0378-4347(97)00488-x;;8783212;;10.1016/0028-3908(95)00172-7;;3289882;;10.1055/s-2008-1067770;;10.1007/bf00400603;;8786016;;8523450;;10.1016/0022-2828(95)90012-8,"Armstrong et al., Free Radical Biology and Chemistry, (1996) 21(5):719-726.;;Barbiroli et al., J Neurol, (1995) 242:472-477.;;Baur et al., Klin Wochenschr, (1991) 69:722-724.;;Bilich et al., I-Pharmacodynamics, (1978) 88:93.;;Black et al., Clinical and Experimental Pharmacology and Physiology, (1998) 25:712-714.;;Bloomgarden, Diabetes Care, (Apr. 1997) 20(4):670-673.;;Burkart et al., Agents Actions, (1993) 38:60-65.;;Busse et al., Arzneim-Forsch/Drug Research (1992) 42(6):829-831.;;Bustamante et al., Free Radical Biology and Medicine, (1998) 24(6):1023-1039.;;Carreau, Methods in Enzymology, (1979) 62:152-158.;;Cesolari et al., Rev Exp Enf Ap Digest, (1988) 73(3) 229-232.;;Chen et al., Archives of Biochemistry and Biophysics, (1997) 338(2):165-172.;;Devasgayam et al., Chem-Biol Interactions, (1993) 86:79-92.;;Dimpfel et al., Dev Pharmacol Ther, (1990) 14:193-199.;;Egan et al., Prostaglandins, (1978) 16)6):861-869.;;Estrada et al., Diabetes, (Dec. 1996) 45:1798-1804.;;Faust et al., J. Immunopharmac, (1994) 16(1):61-66.;;Fuchs et al., Skin Pharmacol, (1994) 7:278-284.;;Gandhi et al., J Biosci, (Sep. 1985) 9 (1 & 2):117-127.;;Garrett et al., Neuroscience Letters, (1997) 222:191-194.;;Gerbitz et al., Diabetes, (Feb. 1996) 45:113-126.;;Hammarqvist et al., Crit Care Med, (1997) 25(1):78-84.;;Haugaard et al., Biochem Biophys Acta, (1970) 222:583-586.;;Henricksen et al., American Physiological Society, (1990) C648-C653.;;Henricksen et al., Life Sciences, (1997) 61(8):805-812.;;Hofmann et al., Archives of Biochemistry and Biophysics, (1995) 324(1):85-92.;;Jacob et al., Diabetes, (1995) 245-250.;;Jacob et al., Diabetes, (Aug. 1996) 45:1024-1029.;;Kagan et al., Biochemical Pharmacology, (1992) 44(8):1637-1649.;;Kagan et al., Journal of Lipid Research, (1992) 33:385-397.;;Kagan, et al., Free Rad Res Comms, (1991) 15(5):265-276.;;Khamaisi et al., Metabolism, (Jul. 1997) 45(7):763-768.;;Lavis et al., The Journal of Biologic Chemistry, (Jan. 10, 1970) 245(1):23-31.;;Lodge et al., Journal of Applied Nutrition, (1997) 49 (1 & 2)3-11.;;Lodge et al., Free Radical Biology & Medicine, (1998) 25(3):287-297.;;Matsugo et al., Biochemistry and Molecular Biology International, (Oct. 1995) 37(2)375-383.;;Merin et al., FEBS Letters, (1996) 294:9-13.;;Muller et al., Toxicology, (1989) 58:175-185.;;Muller et al., Biochimica et Biophysica Acta, (1990) 1052:386-389.;;Muller et al., Journal of Cerebral Blood Flow and Metabolism, (1995) 15:624-630.;;Nagamatsu et al., Diabetes Care, (1995) 18(8):1160-1167.;;National Diabetes Data Group Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance, Diabetes (1979) 28:1039-1057.;;Natraj et al., J. Biosci, (1984) 6(1):38-46.;;Nickander et al., Free Radical Biology & Medicine (1996) 21(5):631-639.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:275-280.;;Ohmori et al., Japan J. Pharmacol, (1986) 42:135-140.;;Ou et al., Free Rad Res, (1996) 25(4):337-346.;;Ou et al., Biochemial Pharmacology, (1995) 50(1):123-126.;;Packer et al., Free Radical Biology & Medicine, (1997) 22(1/2):359-378.;;Packer et al., Free Radical Biology & Medicine, (1995) 19(2):227-250.;;Packer, Diabetologica, (1993) 36:1212-1213.;;Pascoe et al., Free Radical Biology & Medicine, (1989) 6:209-224.;;Peinado et al., Archives of Biochemistry and Biophysics, (Sep. 1989) 273(2):389-395.;;Podda et al., Biochemical Pharmacology, (1996) 52:627-633.;;Prehn et al., Journal of Cerebral Blood Flow and Metabolism (1992) 12:78-87.;;Reed et al., Science, (1951) 93-94.;;Roy et al., Biochemical Pharmacology, (1997) 53:393-399.;;Scheer et al., Archives of Biochemistry and Biophysics, (May 1, 1993) 302(2):385-390.;;Schmid et al., FASEB Journal, (Jul. 1998) 12:863-870.;;Schonheit et al., Biochimica et Biophysica Acta, (1995) 1271:335-342.;;Segermann et al., Arzneim.-Forsch./Drug Res., (1991) 41(12):1294-1298.;;Sen et al., The FASEB Journal, (May 1996) 10:709-720.;;Sen et al., Free Radical Biology & Medicine, (1997) 22(7):1241-1257.;;Sen et al., Biochemical and Biophysical Research Communications (1998) 247:223-228.;;Simopoulos, Nutrition Today, (Jan./Feb. 1994) 12-16.;;Stoll et al., Pharmacology Biochemistry and Behavior, (1993) 46:799-805.;;Streeper et al., American Physiological Society, (1997) 273(1):E185-E191.;;Sumathi et al., Jpn J Med Sci Biol, (1996) 49:39-48.;;Suzuki et al., Free Rad Res Commsii, (1992) 17(3):211-217.;;Suzuki et al., Biochemical and Biophysical Research Communications,, (Dec. 1992) 189(3):1709-1715.;;Suzuki et al., Free Rad Res Comms, (1991) 15(5) 255-263.;;Szabo et al., Klin Wochenschr, (1986) 64(Suppl. VII):116-122.;;Teichert et al., Methods in Enzymology, (1997) vol. 279.;;Wagh et al., J. Biosci, (Mar. 1987) 11(1):59-74.;;Wagh et al., J. Biosci, (Jun. 1986) 10(2):171-179.;;Wagner et al., Properties and Derivatives of alpha-Lipoic Acid, (Oct. 5, 1956) 5079-5081.;;Wickramasinghe et al., Biochemical Pharmacology, (1992) 43(3) 407-411.;;Witt et al., Journal of Chromatography B, (1998) 705:127-131.;;Wolz et al., Neruopharmacology, (1996) 35(3):369-375.;;Ziegler et al., Deutsche Medizinische Wochenschritt, (Jul. 1, 1988) 113(26) 1071-1074.;;Ziegler et al., Diabetologia, (1995) 38:1425-1433.;;Zimmer et al., J Mol Cell Cardiol, (1995) 27:1895-1903.",EXPIRED
41,CA,A1,CA 2332790 A1,165-316-685-233-856,1999-12-02,1999,CA 2332790 A,1999-05-19,US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A;;US 9911178 W,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials protect the lipoic acid from chemical degradation in the gastrointestinal tract and provide for gradual release of the lipoic acid. These combined features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired results.,MEDICAL RES INST,JANJIKHEL RAJIV;;BYRD EDWARD A,,https://lens.org/165-316-685-233-856,Patent Application,no,0,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,0,0,,,,EXPIRED
42,EP,A4,EP 1082107 A4,197-429-033-139-25X,2002-06-12,2002,EP 99924394 A,1999-05-19,US 9911178 W;;US 8720398 P;;US 11262398 A;;US 10260598 P;;US 28824599 A,1998-05-28,CONTROLLED RELEASE LIPOIC ACID,,MEDICAL RES INST,BYRD EDWARD A;;JANJIKHEL RAJIV,MEDICAL RESEARCH INSTITUTE (2005-11-02),https://lens.org/197-429-033-139-25X,Search Report,no,3,0,18,30,0,A61K9/2027;;A61K9/2054;;A61K9/2081;;A61K9/5026;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/51;;A61K31/64;;A61P3/10;;A61K31/425;;A61K31/51;;A61K9/2054;;A61K31/64;;A61K31/197;;A61K9/2027;;A61K31/385;;A61K9/2081;;A61K9/5026,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/50;;A61K9/52;;A61K31/155;;A61K31/197;;A61K31/385;;A61K31/425;;A61K31/426;;A61K31/51;;A61K31/64;;A61K47/02;;A61K47/14;;A61K47/32;;A61K47/38;;A61P3/10,,1,0,,,See also references of WO 9961004A1,EXPIRED
43,US,A,US 3228149 A,040-863-469-143-653,1966-01-11,1966,US 30327763 A,1963-08-20,US 30327763 A,1963-08-20,Method and means for grinding card flats,,GREENWOOD MILLS INC,STILL CONWAY L;;BYRD EDWARD E,,https://lens.org/040-863-469-143-653,Granted Patent,no,4,2,1,1,0,B24B19/18;;B24B19/18,B24B19/18,,0,0,,,,EXPIRED
44,AU,A,AU 1971/033668 A,021-453-265-260-080,1973-03-29,1973,AU 1971/033668 A,1971-09-20,US 7395470 A,1970-09-21,DATA INTERPRETATION TERMINAL,,SEARLE MEDIDATA INC,RAWSON EDWARD BYRD;;DOWLING JOHN BLAIR,,https://lens.org/021-453-265-260-080,Patent Application,no,0,1,9,9,0,G16H10/60;;G16H10/60;;G16H40/63;;G16H40/63,G06F19/00,,0,0,,,,EXPIRED
45,CH,A,CH 541833 A,120-253-384-935-709,1973-09-15,1973,CH 1119171 A,1971-07-29,US 5999670 A,1970-07-31,Datenübermittlungsanlage,,SEARLE MEDIDATA INC,EDWARD BYRD RAWSON;;JOSEPH BRINTON FERGUSON,,https://lens.org/120-253-384-935-709,Granted Patent,no,0,0,9,9,0,G06F13/34;;G06F13/34,G06F13/34,,0,0,,,,EXPIRED
46,US,A,US 1340486 A,153-729-444-818-335,1920-05-18,1920,US 28884719 A,1919-04-09,US 28884719 A;;US 20775517 A,1917-12-18,Transmission-gearing,,EDWARD JACKSON ROBERT;;YEARWOOD BYRD O,EDWARD JACKSON ROBERT;;YEARWOOD BYRD O,,https://lens.org/153-729-444-818-335,Granted Patent,no,0,1,1,1,0,F23K3/00;;F23K3/00;;F23K2203/002;;F23K2203/002;;Y10T74/1534;;Y10T74/1534,F23K3/00,,0,0,,,,EXPIRED
47,ES,T3,ES 2352437 T3,061-076-460-731-263,2011-02-18,2011,ES 04757820 T,2004-03-18,US 39586103 A,2003-03-24,DISPOSITIVO PARA CARGAR Y DESCARGAR UN CONTENEDOR DE ALMACENAMIENTO CON RESPECTO A UN VEHICULO DE TRANSPORTE Y SISTEMA Y METODO ASOCIADOS.,"Un dispositivo adaptado para ser acoplado de manera operable con un vehículo (100) de transporte de manera que es capaz de cargar un contenedor (200) sobre el vehículo (100) desde una superficie, descargar el contenedor (200) desde el vehículo (100) hasta la superficie, y que coopera con el vehículo (100) para transportar el contenedor (200), teniendo el vehículo (100) un extremo delantero (112) y un extremo trasero (114), comprendiendo el citado dispositivo: un par de miembros de elevación horizontales (300) capaces de ser separados lateralmente al menos una anchura del contenedor (200), teniendo cada miembro de elevación (300) un extremo delantero (305) y un extremo trasero (310) y estando configurado para ser movible verticalmente con respecto al vehículo (100); un miembro movible verticalmente (320) acoplado de manera operable con los extremos delanteros (305) de los miembros de elevación (300) de manera que los miembros de elevación (300) son capaces de moverse verticalmente en correspondencia con el miembro movible verticalmente (320), y de manera que los extremos traseros (310) de los miembros de elevación (300) no están soportados; una brida (550) capaz de ser acoplada de manera operable entre el contenedor (200) y cada miembro de elevación (300) de manera que sujeta los miembros de elevación (300) al contenedor (200); y un dispositivo de traslación (500) acoplado con el vehículo (100) para ser movible longitudinalmente con respecto al mismo, estando el dispositivo de traslación (500) acoplado de manera operable con el miembro movible verticalmente (320) y estando configurado para soportar los miembros de elevación (300), estando también el dispositivo de traslación (500) configurado para descargar el contenedor (200), después de que el contenedor (200) es elevado por encima del vehículo (100) por el miembro movible verticalmente (320) y los miembros de elevación (300), moviendo longitudinalmente el contenedor (200) a lo largo del vehículo (100) por encima de un plano vertical definido por el extremo trasero (114) de él, tras lo cual el contenedor (200) es bajado hasta la superficie por el miembro movible verticalmente (320) y los miembros de elevación (300), estando también el dispositivo de traslación (500) configurado para cargar el contenedor (200) sobre el vehículo (100), después de que el contenedor (200) es elevado desde la superficie por el miembro movible verticalmente (320) y los miembros de elevación (300) por encima de un plano horizontal definido por el extremo trasero (114) del vehículo (100), moviendo longitudinalmente el contenedor (200) a lo largo del vehículo (100) hacia el extremo delantero (112) de él, tras lo cual el contenedor (200) es bajado sobre el vehículo (100) por el miembro movible verticalmente (320) y los miembros de elevación (300).",PACK RAT MINI MOVER L L C,BYRD EDWARD;;LOCKAMY TIMOTHY;;THISSE THOR,,https://lens.org/061-076-460-731-263,Granted Patent,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
48,AU,A,AU 1971/033667 A,143-458-207-409-875,1973-03-29,1973,AU 1971/033667 A,1971-09-20,US 7397370 A,1970-09-21,MEDICAL TEST DATA ENTRY TERMINAL,,SEARLE MEDIDATA INC,RAWSON EDWARD BYRD;;DOWLING JOHN BLAIR,,https://lens.org/143-458-207-409-875,Patent Application,no,0,0,9,9,0,A61B5/00;;Y10S283/90;;G16H10/60;;Y02A90/10;;A61B5/00;;Y10S715/968;;Y10S283/90;;G16H10/60;;Y02A90/10,A61B5/00;;G06F19/00,,0,0,,,,EXPIRED
49,AT,T1,AT E482847 T1,099-127-561-433-309,2010-10-15,2010,AT 04757820 T,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,VORRICHTUNG ZUM BE- UND ENTLADEN EINES LAGERBEHÄLTERS BEZÜGLICH EINES TRANSPORTFAHRZEUGS UND ZUGEHÖRIGES SYSTEM UND VERFAHREN,,PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY;;BYRD EDWARD;;THISSE THOR,,https://lens.org/099-127-561-433-309,Granted Patent,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,INACTIVE
50,DE,A1,DE 2417457 A1,099-517-010-532-806,1974-10-31,1974,DE 2417457 A,1974-04-10,US 35016173 A,1973-04-11,VERFAHREN ZUR HERSTELLUNG SUBSTITUIERTER BETA-HYDROXYPROPIONATE,,UNION CARBIDE CORP,BYRD PRISCILLA DEE;;FRITZ HENRY EDWARD,"UNION CARBIDE CORP., 06817 DANBURY, CONN., US (1982-10-21)",https://lens.org/099-517-010-532-806,Patent Application,no,0,0,7,7,0,C07C59/125;;C07C59/125,C09K3/00;;C07C51/00;;C07C59/01;;C07C59/125;;C07C67/00;;C08B11/12,,0,0,,,,DISCONTINUED
51,EP,A1,EP 2634679 A1,027-862-500-329-224,2013-09-04,2013,EP 12157432 A,2012-02-29,EP 12157432 A,2012-02-29,Two-factor rotation input on a touchscreen device,"An electronic device (100) and method are provided for rotating an object displayed at or by the device. The object may be an entire displayed region of a display screen, such as a window, frame, or other region or subregion, or a block element or other type of content component such as an image or map. A first input defining a reference point (310) for the object is detected at a first user interface mechanism (112a). After commencement of the detected first input, a second input (320) at a second user interface mechanism, such as a touchscreen display, is detected. In response to the second input, a rotation transformation is applied to the object, the rotation transformation center being defined by the reference point, and the rotation transformation angle being defined by the second input. The object may be displayed by the touchscreen display, or by a display device external to the electronic device.
",BLACKBERRY LTD,BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN,BLACKBERRY LIMITED (2013-11-27),https://lens.org/027-862-500-329-224,Patent Application,yes,9,3,2,2,0,G06F3/04883;;G06F3/04845;;G06F2203/0381;;G06F2203/04808,G06F3/048,,0,0,,,,DISCONTINUED
52,US,A,US 5726146 A,107-482-098-981-462,1998-03-10,1998,US 34986394 A,1994-12-06,US 34986394 A,1994-12-06,"Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass","Dietary supplement formulation which increases lean body mass without concomitant increase of body fat mass, an effect parallel to that seen with usage of synthetic anabolic steroidal compounds but without adverse side-effects. The formulation composition of the invention comprises creatine, taurine, ribonucleic acid, and optimally, a carbohydrate (starch or a simple saccharide)component for enhancing cellular uptake. Other components such as alpha-ketoglutaric acid and salts thereof, and beta-hydroxy-beta-methyl butyric acid and salts thereof can be added for optimal results. The composition may be taken alone or in combination with a nutrient base, which typically includes protein source(s), carbohydrate(s), vitamin(s), and mineral(s) and other amino acids such as L-Glutamine and other natural L-form non-branched chain or branched chain amino acids. Actual studies in weight trained men show statistically significant increases in lean body mass yet with decreases in fat mass within 28 days.",NATURAL SUPPLEMENT ASS INC,ALMADA ANTHONY L;;BYRD EDWARD A,NATURAL SUPPLEMENT ASSOCIATION INCORPORATED (1997-07-17),https://lens.org/107-482-098-981-462,Granted Patent,yes,6,69,1,1,0,A23L33/175;;A23L33/175;;A23L33/12;;A23L33/12;;A23L33/13;;A23L33/13,A23L1/30;;A23L1/305,514/2;;514/23;;514/54;;514/60;;514/574;;514/578;;514/634;;514/665,14,8,135-385-940-912-09X;;062-454-467-918-364;;032-462-302-731-130;;024-695-526-956-547;;000-759-914-409-499;;149-717-747-482-207;;155-457-342-564-668;;046-798-745-122-892,7817065;;10.2165/00007256-199418040-00005;;10.1152/jappl.1991.70.3.994;;2033014;;10.1055/s-2007-1024704;;1917227;;1727963;;10.1001/jama.1992.03480030075040;;10.1001/jama.267.3.397;;10.1093/ajcn/52.2.224;;2197850;;10.1093/ajcn/51.6.1106;;2349926;;10.1111/j.1753-4887.1992.tb01312.x;;1407744;;2046977;;10.1111/j.1753-4887.1991.tb02997.x,"Gainers Fuel 1000 label (1996).;;Balsom et al, Sports Med., Creatine in Humans with Special Reference to Creatine Supplementation, V. 4 (1994), pp. 268 280.;;Forbes, G.B., American Physiological Society, Exercise and Body Composition, (1991), pp. 994 997.;;Kuipers et al, Int. J. Sports Med., Influence of Anabolic Steroids on Body Composition, Blood Pressure, Lipid Profile and Liver Functions in Body Builders, V. 12, (1991), pp. 413 418.;;Forbes et al, JAMA, Sequence of Changes in Body Composition Induced by Testosterone and Reversal of Changes After Drug Is Stopped, V. 267, No. 3, (Jan. 15, 1992), pp. 397 399.;;Forbes, G.B., American Society for Clinical Nutrition, Do Obese Individuals Gain Weight More Easily Than Nonobese Individuals, V. 52 (1990), pp. 224 227.;;Mazess et al, American Society for Clinical Nutrition, Dual Energy X Ray Absorptiometry for Total Body and Regional Bone Mineral and Soft Tissue Composition, V. 51 (1990), pp. 1106 1112.;;Forbes, G.B., Nutrition Reviews, Exercise and Lean Weight: The Influence of Body Weight, V. 50, No. 6 (Jun. 1992), pp. 157 161.;;Heymsfield et al, Nutrition Reviews, Body Composition in Humans: Advances in the Development of Multicompartment Chemical Models, V. 49, No. 4 (Apr. 1991), pp. 97 108.;;CA 120:208612, Vinnars et al., 1993.;;CA 120:162491, Hultman et al., Feb. 1994.;;CA 119:256552, Trimbo et al., 1993.;;CA 111:213712, Elam et al., 1989.;;Vitamin Bible, Mindell, Warner Books, 1991, pp. 287 290.",EXPIRED
53,AU,A,AU 1971/031815 A,199-365-825-283-201,1973-02-01,1973,AU 1971/031815 A,1971-07-29,US 5999670 A,1970-07-31,DATA SCANNER,,SEARLE MEDIDATA INC,RAWSON EDWARD BYRD;;FERGUSON JOSEPH BRINTON,,https://lens.org/199-365-825-283-201,Patent Application,no,0,0,9,9,0,G06F13/34;;G06F13/34,G06F13/34,,0,0,,,,EXPIRED
54,AU,A,AU 1972/039198 A,043-800-046-361-81X,1973-08-23,1973,AU 1972/039198 A,1972-02-21,US 12755571 A,1971-03-24,SIGNAL PROCESSING SYSTEM FOR ACHILLES TENDON REFLEX TESTING,,SEARLE MEDIDATA INC,RAWSON EDWARD BYRD;;O'RIORDEN DAVID JOSEPH JR,,https://lens.org/043-800-046-361-81X,Patent Application,no,0,0,9,9,0,A61B5/1104;;A61B5/4523;;A61B9/005;;A61B5/7239;;A61B5/6829;;A61B2503/40;;A61B9/005;;A61B5/1104;;A61B5/4523;;A61B5/7239;;A61B5/6829;;A61B2503/40,A61B5/11,,0,0,,,,EXPIRED
55,US,B2,US 8376055 B2,110-141-104-682-737,2013-02-19,2013,US 201113136035 A,2011-07-21,US 201113136035 A;;US 37838309 A,2009-02-13,Shearing tool and methods of use,"A shearing tool for shearing, trimming, or reducing objects being pulled through a drill string and methods for retrieving retrievable tools with fins from the drill string, where the retrievable tools must pass through restrictions in the drill string having interior diameters less than the outer diameters of the fins. The fins, affixed to the retrievable tools, provide stability to the tools, while within the drill string, and can be made of rubber, plastic, other shearable materials, or combinations thereof. The apparatuses and methods include inserting a shearing tool with a flange into a box end of a section of drill string, where the flange keeps the shearing tool in place. The shearing tool further comprising a cutting surface for cutting materials pulled through the shearing tool.",CHAMBERS II JAMES EDWARD;;BYRD GERALD ROBERT,CHAMBERS II JAMES EDWARD;;BYRD GERALD ROBERT,HUNTING ENERGY SERVICES LLC (2019-09-20);;SPECIALTY SUPPLY COMPANIES (2009-02-10);;HUNTING ENERGY SERVICES INC (2016-04-05),https://lens.org/110-141-104-682-737,Granted Patent,yes,1,2,4,4,0,E21B17/1007;;E21B17/1007;;E21B17/10;;E21B17/10;;E21B23/02;;E21B23/02;;E21B23/12;;E21B23/12;;E21B29/00;;E21B29/00,E21B41/00;;E21B23/00;;E21B29/00,166/381;;166/113;;166/173;;166/170,0,0,,,,ACTIVE
56,US,A1,US 2011/0278020 A1,123-720-304-847-864,2011-11-17,2011,US 201113136035 A,2011-07-21,US 201113136035 A;;US 37838309 A,2009-02-13,Shearing tool and methods of use,"A shearing tool for shearing, trimming, or reducing objects being pulled through a drill string and methods for retrieving retrievable tools with fins from the drill string, where the retrievable tools must pass through restrictions in the drill string having interior diameters less than the outer diameters of the fins. The fins, affixed to the retrievable tools, provide stability to the tools, while within the drill string, and can be made of rubber, plastic, other shearable materials, or combinations thereof. The apparatuses and methods include inserting a shearing tool with a flange into a box end of a section of drill string, where the flange keeps the shearing tool in place. The shearing tool further comprising a cutting surface for cutting materials pulled through the shearing tool.",CHAMBERS II JAMES EDWARD;;BYRD GERALD ROBERT,CHAMBERS II JAMES EDWARD;;BYRD GERALD ROBERT,HUNTING ENERGY SERVICES LLC (2019-09-20);;SPECIALTY SUPPLY COMPANIES (2009-02-10);;HUNTING ENERGY SERVICES INC (2016-04-05),https://lens.org/123-720-304-847-864,Patent Application,yes,1,0,4,4,0,E21B17/1007;;E21B17/1007;;E21B17/10;;E21B17/10;;E21B23/02;;E21B23/02;;E21B23/12;;E21B23/12;;E21B29/00;;E21B29/00,E21B41/00;;E21B23/00;;E21B29/00,166/381;;166/113,0,0,,,,ACTIVE
57,US,A1,US 2010/0206581 A1,167-559-144-830-024,2010-08-19,2010,US 37838309 A,2009-02-13,US 37838309 A,2009-02-13,Shearing tool and methods of use,"A shearing tool for shearing, trimming, or reducing objects being pulled through a drill string and methods for retrieving retrievable tools with fins from the drill string, where the retrievable tools must pass through restrictions in the drill string having interior diameters less than the outer diameters of the fins. The fins, affixed to the retrievable tools, provide stability to the tools, while within the drill string, and can be made of rubber, plastic, other shearable materials, or combinations thereof. The apparatuses and methods include inserting a shearing tool with a flange into a box end of a section of drill string, where the flange keeps the shearing tool in place. The shearing tool further comprising a cutting surface for cutting materials pulled through the shearing tool.",CHAMBERS II JAMES EDWARD;;BYRD GERALD ROBERT,CHAMBERS II JAMES EDWARD;;BYRD GERALD ROBERT,HUNTING ENERGY SERVICES LLC (2019-09-20);;HUNTING SPECIALTY SUPPLY L.P (2011-11-04);;HUNTING ENERGY SERVICES INC (2016-04-05);;SPECIALTY SUPPLY CORPORATION (2009-02-10),https://lens.org/167-559-144-830-024,Patent Application,yes,3,2,4,4,0,E21B17/1007;;E21B17/1007;;E21B17/10;;E21B17/10;;E21B23/02;;E21B23/02;;E21B23/12;;E21B23/12;;E21B29/00;;E21B29/00,E21B23/00;;E21B7/00;;E21B29/00;;E21B41/00,166/377;;166/243,0,0,,,,ACTIVE
58,US,B2,US 8854325 B2,005-024-651-619-551,2014-10-07,2014,US 201213408869 A,2012-02-29,US 201213408869 A,2012-02-29,Two-factor rotation input on a touchscreen device,"An electronic device and method are provided for rotating an object displayed at or by the device. The object may be an entire displayed region of a display screen, such as a window, frame, or other region or subregion, or a block element or other type of content component such as an image or map. A first input defining a reference point for the object is detected at a first user interface mechanism. After commencement of the detected first input, a second input at a second user interface mechanism, such as a touchscreen display, is detected. In response to the second input, a rotation transformation is applied to the object, the rotation transformation center being defined by the reference point, and the rotation transformation angle being defined by the second input. The object may be displayed by the touchscreen display, or by a display device external to the electronic device.",BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;BLACKBERRY LTD,BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE,BLACKBERRY LIMITED (2012-06-06);;RESEARCH IN MOTION UK LIMITED (2012-04-23),https://lens.org/005-024-651-619-551,Granted Patent,yes,21,42,3,3,0,G06F2203/04808;;G06F3/04883;;G06F2203/04808;;G06F3/04883;;G06F3/04842;;G06F3/04845;;G06F3/0488,G09G5/00;;G06F3/00;;G06F3/033;;G06F3/041;;G06F3/048;;G06K11/06;;G08C21/00;;G09G5/08,345/173;;345/156;;345/157;;178/18.01;;178/20.01;;715/700;;715/856;;715/863,4,0,,,"Extended European Search Report dated Jul. 27, 2012 from EP 12157432.1, 7 pgs.;;Rubine, D. H.: ""The Automatic Recognition of Gestures"", Thesis for Doctor of Philosophy in Computer Science at Carnegie Mellon University, Dec. 1991, pp. 1-266.;;Microsoft: ""Single-Finger Rotation"", 2011, retrieved from the Internet on Sep. 22, 2011, URL: http://msdn.microsoft.com/en-us/library/windows/desktop/dd562192, 3 pgs.;;Villamor, C., Willis, D., Wroblewski, L.: ""Touch Gesture"", Reference Guide, Apr. 15, 2010, 7 pgs.",INACTIVE
59,US,B2,US 8006769 B2,052-165-715-618-907,2011-08-30,2011,US 37838309 A,2009-02-13,US 37838309 A,2009-02-13,Shearing tool and methods of use,"A shearing tool for shearing, trimming, or reducing objects being pulled through a drill string and methods for retrieving retrievable tools with fins from the drill string, where the retrievable tools must pass through restrictions in the drill string having interior diameters less than the outer diameters of the fins. The fins, affixed to the retrievable tools, provide stability to the tools, while within the drill string, and can be made of rubber, plastic, other shearable materials, or combinations thereof. The apparatuses and methods include inserting a shearing tool with a flange into a box end of a section of drill string, where the flange keeps the shearing tool in place. The shearing tool further comprising a cutting surface for cutting materials pulled through the shearing tool.",SPECIALTY SUPPLY COMPANIES,CHAMBERS II JAMES EDWARD;;BYRD GERALD ROBERT,HUNTING ENERGY SERVICES LLC (2019-09-20);;HUNTING SPECIALTY SUPPLY L.P (2011-11-04);;HUNTING ENERGY SERVICES INC (2016-04-05);;SPECIALTY SUPPLY CORPORATION (2009-02-10),https://lens.org/052-165-715-618-907,Granted Patent,yes,6,4,4,4,0,E21B17/1007;;E21B17/1007;;E21B17/10;;E21B17/10;;E21B23/02;;E21B23/02;;E21B23/12;;E21B23/12;;E21B29/00;;E21B29/00,E21B7/00;;E21B41/00,166/377;;166/243,0,0,,,,ACTIVE
60,US,A1,US 2014/0372914 A1,130-030-934-028-869,2014-12-18,2014,US 201414474849 A,2014-09-02,US 201414474849 A;;US 201213408869 A,2012-02-29,TWO-FACTOR ROTATION INPUT ON A TOUCHSCREEN DEVICE,"An electronic device and method are provided for rotating an object displayed at or by the device. The object may be an entire displayed region of a display screen, such as a window, frame, or other region or subregion, or a block element or other type of content component such as an image or map. A first input defining a reference point for the object is detected at a first user interface mechanism. After commencement of the detected first input, a second input at a second user interface mechanism, such as a touchscreen display, is detected. In response to the second input, a rotation transformation is applied to the object, the rotation transformation center being defined by the reference point, and the rotation transformation angle being defined by the second input. The object may be displayed by the touchscreen display, or by a display device external to the electronic device.",BLACKBERRY LTD,BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE,BLACKBERRY LIMITED (2012-06-06);;RESEARCH IN MOTION UK LIMITED (2012-04-23),https://lens.org/130-030-934-028-869,Patent Application,yes,3,24,3,3,0,G06F2203/04808;;G06F3/04883;;G06F2203/04808;;G06F3/04883;;G06F3/04842;;G06F3/04845;;G06F3/0488,G06F3/0488;;G06F3/0484,715/760;;715/765,0,0,,,,DISCONTINUED
61,US,A1,US 2013/0222275 A1,077-044-597-640-404,2013-08-29,2013,US 201213408869 A,2012-02-29,US 201213408869 A,2012-02-29,TWO-FACTOR ROTATION INPUT ON A TOUCHSCREEN DEVICE,"An electronic device and method are provided for rotating an object displayed at or by the device. The object may be an entire displayed region of a display screen, such as a window, frame, or other region or subregion, or a block element or other type of content component such as an image or map. A first input defining a reference point for the object is detected at a first user interface mechanism. After commencement of the detected first input, a second input at a second user interface mechanism, such as a touchscreen display, is detected. In response to the second input, a rotation transformation is applied to the object, the rotation transformation center being defined by the reference point, and the rotation transformation angle being defined by the second input. The object may be displayed by the touchscreen display, or by a display device external to the electronic device.",BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;RESEARCH IN MOTION LTD,BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE,BLACKBERRY LIMITED (2012-06-06);;RESEARCH IN MOTION UK LIMITED (2012-04-23),https://lens.org/077-044-597-640-404,Patent Application,yes,4,59,3,3,0,G06F2203/04808;;G06F3/04883;;G06F2203/04808;;G06F3/04883;;G06F3/04842;;G06F3/04845;;G06F3/0488,G06F3/041,345/173,0,0,,,,INACTIVE
62,WO,A1,WO 2006/119484 A1,113-423-638-460-914,2006-11-09,2006,US 2006/0017345 W,2006-05-03,US 12150005 A,2005-05-03,GRAYWATER TREATMENT SYSTEM AND METHOD,"A system and method for treating graywater by solely mechanical means includes a filter tank receiving graywater through an inlet. The graywater is directed through a pre-filter and a filter assembly. A filter tank aeration element delivers air to the graywater. Optionally, a water quality sensor determines whether one or more qualities of the aerated and filtered water are outside stored parameters and, if so, drains the aerated and filtered water. The aerated and filtered water is removed from the filter tank without further treatment, optionally to a storage tank. Optionally a storage tank aeration element aerates water in the storage tank.",WATERSMART CORP,SOVA JAMES EDWARD;;BYRD DAVID;;SELEWSKI TIMOTHY GERARD,,https://lens.org/113-423-638-460-914,Patent Application,yes,3,1,1,1,0,C02F1/006;;C02F1/004;;C02F1/74;;C02F2103/002;;C02F2303/24,C02F1/00;;C02F9/02,,0,0,,,,PENDING
63,AU,A,AU 1972/039467 A,109-460-214-496-719,1973-08-30,1973,AU 1972/039467 A,1972-02-29,AU 1972/039467 A,1972-02-29,DATA SYSTEM FOR PATIENT ROUTING,,SEARLE MEDIDATA INC,RAWSON EDWARD BYRD;;LEVY HAROLD;;BEN-AARON MAX,,https://lens.org/109-460-214-496-719,Patent Application,no,0,0,1,1,0,,G06F3/14,,0,0,,,,DISCONTINUED
64,CA,C,CA 2519520 C,030-630-462-524-322,2009-01-27,2009,CA 2519520 A,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/030-630-462-524-322,Granted Patent,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
65,CA,A1,CA 2519520 A1,122-425-350-019-893,2004-10-07,2004,CA 2519520 A,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and t he vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting membe rs raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are als o provided.",PACK RAT MINI MOVER L L C,THISSE THOR ROBERT;;LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON,,https://lens.org/122-425-350-019-893,Patent Application,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
66,EP,A2,EP 1610976 A2,154-629-076-841-125,2006-01-04,2006,EP 04757820 A,2004-03-18,US 2004/0008315 W;;US 39586103 A,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD,,PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/154-629-076-841-125,Patent Application,yes,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
67,GB,A,GB 913032 A,143-534-685-246-830,1962-12-12,1962,GB 2293961 A,1961-06-24,GB 2293961 A,1961-06-24,Improvements in forms for moulding concrete columns,"913,032. Shuttering for casting columns. SONOCO PRODUCTS CO. June 24, 1961, No. 22939/61. Class 20 (2). Shuttering for casting columns comprises an inner tube 12 formed from one or two sheets of mouldable material, and the corners of which engage an outer supporting tube 10, the strips 20 supporting the walls of the inner tube on the outer tube. In Fig. 2, the inner tube constructed from two channels 14 connected together by strips 18 along their edges, strips 21 supporting the strips 18 on the outer tube. In a modification the tube 12 is made from a single sheet either by moulding or slotting and bending. The tube 12 is of compressed fibre and the tube 10 of paper.",SONOCO PRODUCTS CO,REID EDWARD SOLOMON;;DAVIS ARTHUR EMERSON;;GRAY WILLIAM EDWARD;;BYRD HERBERT MILLER,,https://lens.org/143-534-685-246-830,Granted Patent,no,0,2,1,1,0,B28B7/342;;E04G13/02,B28B7/34;;E04G13/02,E1S SSB           SSB;;E1S S120          SSB,0,0,,,,EXPIRED
68,FI,A0,FI 850510 A0,057-231-120-252-058,1985-02-07,1985,FI 850510 A,1985-02-07,US 57815384 A,1984-02-08,BORRHUVUDSKONSTRUKTION OCH FOERFARANDE FOER DESS FRAMSTAELLNING.,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200 DEG F and the cycle is held at temperature for less than four hours.",CAMERON IRON WORKS INC,RAYMOND EDWARD LEE;;BYRD JAMES DONALD;;BEDNAROWICHZ THOMAS A,,https://lens.org/057-231-120-252-058,Patent Application,no,0,0,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,B22F7/08;;C22C19/05;;B23K20/00;;B32B15/01;;C22C38/00;;E21B33/03;;E21B33/035,,0,0,,,,DISCONTINUED
69,WO,A2,WO 2004/085198 A2,167-207-210-180-682,2004-10-07,2004,US 2004/0008315 W,2004-03-18,US 39586103 A,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD,"A device (10) adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members (300) configured to be vertically movable with respect to the vehicle and a vertically-movable member (320) operably engaged with the forward ends of the lifting members (300). A tether (550) is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device (500) is engaged between the vehicle and the vertically-movable member (320) and configured to support the lifting members (300) as well as move the lifting members (300) longitudinally with respect to the vehicle. To unload the container, the vertically-movable member (320) and the lifting members (300) raise the container above the vehicle and then the translatory device (500) longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member (320) and the lifting members (300) and the tethers (550) disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER L L C;;LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/167-207-210-180-682,Patent Application,yes,2,2,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,PENDING
70,AU,A1,AU 2004/223913 A1,161-616-560-306-619,2004-10-07,2004,AU 2004/223913 A,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,Device for loading and unloading a storage container with respect to a transport vehicle and associated system and method,,PACK RAT MINI MOVER L L C,BYRD EDWARD MORTON;;LOCKAMY TIMOTHY AARON;;THISSE THOR ROBERT,,https://lens.org/161-616-560-306-619,Patent Application,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
71,EP,B1,EP 1610976 B1,082-786-152-086-037,2010-09-29,2010,EP 04757820 A,2004-03-18,US 2004/0008315 W;;US 39586103 A,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD,,PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/082-786-152-086-037,Granted Patent,yes,6,2,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
72,US,A1,US 2006/0104802 A1,199-363-839-290-817,2006-05-18,2006,US 29858005 A,2005-12-12,US 29858005 A;;US 39586103 A,2003-03-24,Method for loading and unloading a storage container with respect to a transport vehicle,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY A;;BYRD EDWARD M;;THISSE THOR R,,https://lens.org/199-363-839-290-817,Patent Application,yes,8,2,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,414/812;;414/498,0,0,,,,EXPIRED
73,EP,A3,EP 0152263 A3,111-875-920-501-817,1986-11-20,1986,EP 85300760 A,1985-02-05,US 57815384 A,1984-02-08,WELLHEAD STRUCTURE AND METHOD OF PRODUCING SAME,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200°F and the cycle is held at temperature for less than four hours.","CAMERON IRON WORKS, INC.","RAYMOND, EDWARD LEE;;BYRD, JAMES DONALD;;BEDNAROWICZ, THOMAS A.",,https://lens.org/111-875-920-501-817,Search Report,yes,5,0,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,B22F7/08;;B23K20/00;;B32B15/01;;C22C19/05;;C22C38/00;;E21B33/03;;E21B33/035,,1,0,,,"CHEMICAL ABSTRACTS, vol. 98, no. 8, 21st February 1983, page 232, abstract no. 57932h, Columbus, Ohio, US; Kh.T. KAKHRAMANOV, et al.: ""Study of the galling resistance of materials and coatings on parts of gate valves of wellhead equipment"", & KHIM. NEFT. MASHINOSTR. 1982, (10), 30-1",EXPIRED
74,US,A,US 1258923 A,121-066-854-827-618,1918-03-12,1918,US 21425118 A,1918-01-28,US 21425118 A,1918-01-28,DOME FOR CONCRETE STRUCTURES.,,MARQUA EDWARD C;;UNWERTH HANS VON;;BYRD JOHN H,MARQUA EDWARD C;;UNWERTH HANS VON;;BYRD JOHN H,,https://lens.org/121-066-854-827-618,Granted Patent,no,0,4,1,1,0,E04G11/46;;E04G11/46,,,0,0,,,,EXPIRED
75,US,A1,US 2006/0245878 A1,153-037-706-908-094,2006-11-02,2006,US 43761906 A,2006-05-22,US 43761906 A;;US 39586103 A,2003-03-24,Device for loading and unloading a storage container with respect to a transport vehicle and associated system and method,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY A;;BYRD EDWARD M;;THISSE THOR R,,https://lens.org/153-037-706-908-094,Patent Application,yes,12,3,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,414/498,0,0,,,,EXPIRED
76,DE,D1,DE 3571477 D1,004-801-998-446-300,1989-08-17,1989,DE 3571477 T,1985-02-05,US 57815384 A,1984-02-08,WELLHEAD STRUCTURE AND METHOD OF PRODUCING SAME,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200 DEG F and the cycle is held at temperature for less than four hours.",CAMERON IRON WORKS INC,RAYMOND EDWARD LEE;;BYRD JAMES DONALD;;BEDNAROWICZ THOMAS A,COOPER CAMERON CORP. (N.D. GES. D. STAATES DELAWAR (1996-08-22),https://lens.org/004-801-998-446-300,Granted Patent,no,0,0,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,B22F7/08;;B23K20/00;;B32B15/01;;C22C19/05;;C22C38/00;;E21B33/03;;E21B33/035,,0,0,,,,EXPIRED
77,WO,A3,WO 2004/085198 A3,106-626-601-861-526,2005-11-24,2005,US 2004/0008315 W,2004-03-18,US 39586103 A,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD,"A device (10) adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members (300) configured to be vertically movable with respect to the vehicle and a vertically-movable member (320) operably engaged with the forward ends of the lifting members (300). A tether (550) is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device (500) is engaged between the vehicle and the vertically-movable member (320) and configured to support the lifting members (300) as well as move the lifting members (300) longitudinally with respect to the vehicle. To unload the container, the vertically-movable member (320) and the lifting members (300) raise the container above the vehicle and then the translatory device (500) longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member (320) and the lifting members (300) and the tethers (550) disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER L L C;;LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/106-626-601-861-526,Search Report,yes,6,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,PENDING
78,US,A1,US 2004/0191038 A1,040-207-634-201-55X,2004-09-30,2004,US 39586103 A,2003-03-24,US 39586103 A,2003-03-24,Device for loading and unloading a storage container with respect to a transport vehicle and associated system and method,"
   A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided. 
",LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,PACK-RAT MINI-MOVER L.L.C (2003-06-19),https://lens.org/040-207-634-201-55X,Patent Application,yes,9,11,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,414/498,0,0,,,,EXPIRED
79,US,A1,US 2006/0245879 A1,121-909-533-809-286,2006-11-02,2006,US 43762006 A,2006-05-22,US 43762006 A;;US 39586103 A,2003-03-24,Device and system for loading and unloading a storage container with respect to a transport vehicle,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY A;;BYRD EDWARD M;;THISSE THOR R,,https://lens.org/121-909-533-809-286,Patent Application,yes,9,13,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,414/498,0,0,,,,EXPIRED
80,US,B2,US 7074004 B2,067-990-438-307-311,2006-07-11,2006,US 39586103 A,2003-03-24,US 39586103 A,2003-03-24,Device and system for loading and unloading a storage container with respect to a transport vehicle,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,PACK-RAT MINI-MOVER L.L.C (2003-06-19),https://lens.org/067-990-438-307-311,Granted Patent,yes,13,22,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/00;;B60P1/64,414/549,0,0,,,,EXPIRED
81,HK,A1,HK 1092434 A1,112-728-966-762-277,2007-02-09,2007,HK 06112904 A,2006-11-24,US 39586103 A;;US 2004/0008315 W,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM METHOD,,PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/112-728-966-762-277,Patent Application,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P/;;B60P1/64,,0,0,,,,PENDING
82,AU,B2,AU 2004/223913 B2,123-263-948-428-242,2007-11-01,2007,AU 2004/223913 A,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,Device for loading and unloading a storage container with respect to a transport vehicle and associated system and method,,PACK RAT MINI MOVER L L C,BYRD EDWARD MORTON;;LOCKAMY TIMOTHY AARON;;THISSE THOR ROBERT,,https://lens.org/123-263-948-428-242,Granted Patent,no,4,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
83,NZ,A,NZ 542726 A,190-554-672-173-954,2007-03-30,2007,NZ 54272604 A,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,Device for loading and unloading a storage container with respect to a transport vehicle and associated system and method,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/190-554-672-173-954,Patent Application,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,PENDING
84,EP,B1,EP 0152263 B1,102-422-206-156-309,1989-07-12,1989,EP 85300760 A,1985-02-05,US 57815384 A,1984-02-08,WELLHEAD STRUCTURE AND METHOD OF PRODUCING SAME,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200 DEG F and the cycle is held at temperature for less than four hours.","CAMERON IRON WORKS, INC.","RAYMOND, EDWARD LEE;;BYRD, JAMES DONALD;;BEDNAROWICZ, THOMAS A.",,https://lens.org/102-422-206-156-309,Granted Patent,yes,5,4,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,B22F7/08;;B23K20/00;;B32B15/01;;C22C19/05;;C22C38/00;;E21B33/03;;E21B33/035,,1,0,,,"CHEMICAL ABSTRACTS, vol. 98, no. 8, 21st February 1983, page 232, abstract no. 57932h, Columbus, Ohio, US; Kh.T. KAKHRAMANOV, et al.: ""Study of the galling resistance of materials and coatings on parts of gate valves of wellhead equipment"", & KHIM. NEFT. MASHINOSTR. 1982, (10), 30-1",EXPIRED
85,NO,L,NO 850471 L,096-238-893-173-219,1985-08-09,1985,NO 850471 A,1985-02-07,US 57815384 A,1984-02-08,BROENNHODE-KONSTRUKSJON OG FREMGANGSMAATE TIL FREMSTILLING DERAV,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200 DEG F and the cycle is held at temperature for less than four hours.",CAMERON IRON WORKS INC,RAYMOND EDWARD LEE;;BYRD JAMES DONALD;;BEDNAROWICZ THOMAS A,,https://lens.org/096-238-893-173-219,Abstract,no,0,0,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,B22F7/08;;C22C19/05;;B23K20/00;;B32B15/01;;C22C38/00;;E21B33/03;;E21B33/035,,0,0,,,,DISCONTINUED
86,US,A,US 1254919 A,044-137-350-392-176,1918-01-29,1918,US 14198617 A,1917-01-12,US 14198617 A,1917-01-12,DOME FOR CONCRETE STRUCTURES.,,MARQUA EDWARD C;;UNWERTH HANS VON;;BYRD JOHN H,MARQUA EDWARD C;;UNWERTH HANS VON;;BYRD JOHN H,,https://lens.org/044-137-350-392-176,Granted Patent,no,0,4,1,1,0,B28B7/22;;B28B7/22,,,0,0,,,,EXPIRED
87,FI,L,FI 850510 L,123-258-457-525-471,1985-08-09,1985,FI 850510 A,1985-02-07,US 57815384 A,1984-02-08,BORRHUVUDSKONSTRUKTION OCH FOERFARANDE FOER DESS FRAMSTAELLNING.,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200 DEG F and the cycle is held at temperature for less than four hours.",CAMERON IRON WORKS INC,RAYMOND EDWARD LEE;;BYRD JAMES DONALD;;BEDNAROWICHZ THOMAS A,,https://lens.org/123-258-457-525-471,Abstract,no,0,0,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,B22F7/08;;C22C19/05;;B23K20/00;;B32B15/01;;C22C38/00;;E21B33/03;;E21B33/035,,0,0,,,,DISCONTINUED
88,DE,D1,DE 602004029340 D1,181-157-917-836-782,2010-11-11,2010,DE 602004029340 T,2004-03-18,US 39586103 A;;US 2004/0008315 W,2003-03-24,VORRICHTUNG ZUM BE- UND ENTLADEN EINES LAGERBEHÄLTERS BEZÜGLICH EINES TRANSPORTFAHRZEUGS UND ZUGEHÖRIGES SYSTEM UND VERFAHREN,,PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/181-157-917-836-782,Granted Patent,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
89,EP,A2,EP 0152263 A2,056-934-357-742-906,1985-08-21,1985,EP 85300760 A,1985-02-05,US 57815384 A,1984-02-08,Wellhead structure and method of producing same.,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200°F and the cycle is held at temperature for less than four hours.",CAMERON IRON WORKS INC,RAYMOND EDWARD LEE;;BYRD JAMES DONALD;;BEDNAROWICZ THOMAS A,,https://lens.org/056-934-357-742-906,Patent Application,yes,0,9,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,B22F7/08;;B23K20/00;;B32B15/01;;C22C38/00;;C22C19/05;;E21B33/03;;E21B33/035,,0,0,,,,EXPIRED
90,KR,A,KR 20050110694 A,084-260-203-711-231,2005-11-23,2005,KR 20057017897 A,2005-09-23,US 39586103 A,2003-03-24,DEVICE FOR LOADING AND UNLOADING A STORAGE CONTAINER WITH RESPECT TO A TRANSPORT VEHICLE AND ASSOCIATED SYSTEM AND METHOD,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically- movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER L L C,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT,,https://lens.org/084-260-203-711-231,Patent Application,no,0,0,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64,,0,0,,,,ACTIVE
91,CA,A,CA 1259458 A,092-130-761-252-388,1989-09-19,1989,CA 473477 A,1985-02-04,US 57815384 A,1984-02-08,WELLHEAD STRUCTURE AND METHOD OF PRODUCING SAME,"A wellhead structure having a body of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining the openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200.degree.F and the cycle is held at temperature for less than four hours.",CAMERON IRON WORKS INC,RAYMOND EDWARD L;;BYRD JAMES D;;BEDNAROWICZ THOMAS A,,https://lens.org/092-130-761-252-388,Granted Patent,no,0,0,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,C22C19/05;;B22F7/08;;B23K20/00;;B32B15/01;;C22C38/00;;E21B33/03;;E21B33/035,13-8,0,0,,,,EXPIRED
92,AT,T1,AT E44580 T1,009-956-602-796-709,1989-07-15,1989,AT 85300760 T,1985-02-05,EP 85300760 A;;US 57815384 A,1984-02-08,BOHRLOCHKOPFSTRUKTUR UND HERSTELLUNGSVERFAHREN EINER DERARTIGEN STRUKTUR.,"A wellhead structure having a body 10 of a martensitic alloy with opening therein and a austenitic cladding lining the openings wherein the body, the cladding and the interface therebetween all have a strength of at least 75,000 psi and a ductility of at least ten percent. The method of producing a wellhead structure with an alloy steel body having openings therein and a corrosion resistant alloy cladding lining with openings including the steps of lining openings with the cladding by hot isostatic pressure process wherein the temperature does not exceed 2200 DEG F and the cycle is held at temperature for less than four hours.",CAMERON IRON WORKS INC,RAYMOND EDWARD LEE;;BYRD JAMES DONALD;;BEDNAROWICZ THOMAS A,,https://lens.org/009-956-602-796-709,Granted Patent,no,0,0,12,12,0,B22F7/08;;B32B15/015;;E21B33/03;;C22C27/06,C22C19/05;;B22F7/08;;B23K20/00;;B32B15/01;;C22C38/00;;E21B33/03;;E21B33/035,,0,0,,,,EXPIRED
93,US,B2,US 7241100 B2,088-095-756-887-105,2007-07-10,2007,US 43761906 A,2006-05-22,US 43761906 A;;US 39586103 A,2003-03-24,Device for loading and unloading a storage container with respect to a transport vehicle and associated system and method,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT TED,,https://lens.org/088-095-756-887-105,Granted Patent,yes,12,9,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64;;B60P1/00,414/549;;414/812,0,0,,,,EXPIRED
94,US,A1,US 2007/0261235 A1,103-535-462-582-697,2007-11-15,2007,US 41323706 A,2006-04-29,US 41323706 A,2006-04-29,Electronic device removal tool and carrier,"A tool is used for the removal of a processor from a heat sink for replacement or repair, or for delivery of the processor for servicing. The tool combines the features for the removal of the processor from the heat sink and a covered container for storage and delivery of the processor. The tool has at least one recess therein sized to correspond to the shape of the processor. The recess is sufficiently deep to receive the entire processor without damage to any contact pins that may be on the processor surface. The tool has sufficient rigidity to permit the tool and processor to be rotated relative to the heat sink to which the processor is adhered. The portion of the tool that surrounds the processor comprises a suitable ESD resistant material. The tool includes a removable lid layered with an ESD resistant foam for storage and transport.",LENOVO SINGAPORE PTE LTD,BYRD CHARLES J;;KILLEBREW BRIAN W;;SHUMPERT EDWARD A JR,LENOVO (SINGAPORE) PTE LTD (2006-04-27),https://lens.org/103-535-462-582-697,Patent Application,yes,12,10,1,1,0,H01L21/4871;;H01L21/50;;H01L23/40;;H01L2924/0002;;Y10T29/53274;;Y10T29/49822;;Y10T29/4913;;Y10T29/53274;;Y10T29/49822;;Y10T29/4913;;H01L23/40;;H01L21/4871;;H01L21/50;;H01L2924/0002,H05K3/30;;B23P19/00,29/832;;29/762;;29/426.5,0,0,,,,DISCONTINUED
95,US,B2,US 7270511 B2,130-453-924-735-628,2007-09-18,2007,US 43762006 A,2006-05-22,US 43762006 A;;US 39586103 A,2003-03-24,Device and system for loading and unloading a storage container with respect to a transport vehicle,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT TED,,https://lens.org/130-453-924-735-628,Granted Patent,yes,13,14,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/00;;B60P1/64,414/549;;414/498,0,0,,,,EXPIRED
96,US,B2,US 7264437 B2,083-445-059-330-278,2007-09-04,2007,US 29858005 A,2005-12-12,US 29858005 A;;US 39586103 A,2003-03-24,Method for loading and unloading a storage container with respect to a transport vehicle,"A device adapted to operably engage a vehicle to load and unload a container between the vehicle and a surface, and to cooperate with the vehicle to transport the container, is provided. Such a device includes a pair of laterally separated horizontal lifting members configured to be vertically movable with respect to the vehicle and a vertically-movable member operably engaged with the forward ends of the lifting members. A tether is operably engaged between each lifting member and the container so as to secure the container thereto. A translatory device is engaged between the vehicle and the vertically-movable member and configured to support the lifting members as well as move the lifting members longitudinally with respect to the vehicle. To unload the container, the vertically-movable member and the lifting members raise the container above the vehicle and then the translatory device longitudinally moves the container along the vehicle past a vertical plane defined by the rearward end thereof. The container is then lowered to the surface by the vertically-movable member and the lifting members and the tethers disengaged from the container. The reverse procedure loads the container onto the vehicle. Associated devices, systems, and methods are also provided.",PACK RAT MINI MOVER LLC,LOCKAMY TIMOTHY AARON;;BYRD EDWARD MORTON;;THISSE THOR ROBERT TED,,https://lens.org/083-445-059-330-278,Granted Patent,yes,8,8,28,28,0,B60P1/6427;;B60P7/13;;B60P1/04;;B60P1/6427,B60P1/64;;B60P1/00,414/812,0,0,,,,EXPIRED
97,AU,A,AU 1972/043528 A,046-810-380-472-37X,1973-12-20,1973,AU 1972/043528 A,1972-06-16,US 15456171 A,1971-06-18,CARDIOVASCULAR TEST STATION PRESSUROMETER INTERFACE SYSTEM,,SEARLE MEDIDATA INC,MURPHY WILLIAM JOSEPH JR;;FERGUSON JOSEPH BRINTON;;RAWSON EDWARD BYRD,,https://lens.org/046-810-380-472-37X,Patent Application,no,0,0,12,12,0,A61B5/02208;;A61B5/02208,A61B5/022,,0,0,,,,EXPIRED
98,AU,A,AU 1972/039697 A,163-880-753-619-22X,1973-09-13,1973,AU 1972/039697 A,1972-03-07,US 12193871 A,1971-03-08,DATA COMMUNICATION SYSTEM,,SEARLE MEDIDATA INC,OLDFIELD HOMER RAY JR;;RAWSON EDWARD BYRD;;SCHWARZKOPF DANIEL BENEDICT,,https://lens.org/163-880-753-619-22X,Patent Application,no,0,0,10,10,0,H04L12/403;;H04L12/403,H04L12/403,,0,0,,,,EXPIRED
99,DE,T2,DE 602004008148 T2,016-044-228-739-262,2008-05-08,2008,DE 602004008148 T,2004-06-03,US 45507003 A;;EP 04013089 A,2003-06-05,Polysiloxane zum Beschichten von Oberflächen,,BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,,https://lens.org/016-044-228-739-262,Granted Patent,no,0,0,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C09D183/14;;C08G18/61;;C08G77/455;;C08G77/54;;C09D175/04;;C09D183/04,,0,0,,,,ACTIVE
100,WO,A3,WO 2009/082459 A3,021-057-775-949-473,2009-09-17,2009,US 2008/0013828 W,2008-12-18,US 910707 P,2007-12-24,ANTI-AGING COMPOSITION CONTAINING RESVERATROL AND METHOD OF ADMINISTRATION,"Formulations and methods of treatment and putative prevention for aging (anti- aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.",NATROL INC,YATCILLA MICHAEL TODD;;CLOUATRE DALLAS;;BYRD EDWARD ANTHONY;;ADDINGTON FITZPATRICK AMY,,https://lens.org/021-057-775-949-473,Search Report,yes,5,0,3,3,0,A61K31/05;;A61K31/353;;A61P1/16;;A61P1/18;;A61P19/10;;A61P25/16;;A61P25/28;;A61P35/00;;A61P9/00;;A61K31/353;;A61K31/05,A61K31/05;;A61K31/353,,4,4,006-502-218-702-338;;021-975-460-406-821;;012-429-790-530-847;;111-804-271-855-560,17927823;;pmc2100038;;10.1186/1742-2094-4-25;;10.1021/jf053011q;;16608241;;9678525;;10.1530/eje.0.1380619;;10370872,"CANDELARIO-JALIL EDUARDO ET AL: ""Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia"", 10 October 2007, JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, PAGE(S) 25, ISSN: 1742-2094, XP021037912;;LU KWOK TUNG ET AL.: ""Neuroprotective Effects of Resveratrol on Cerebral Ischemia-Induced Neuron Loss Mediated by Free Radical Scavenging and Cerebral Blood Flow Elevation"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 54, no. 8, 19 April 2006 (2006-04-19), USA, pages 3126 - 3131, XP002524792;;KOPP P.: ""Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the ""French paradox"""", EUROPEAN JOURNAL OF ENDOCRINOLOGY/ EUROPEAN FEDERATION OF ENDOCRINE SOCIETIES, vol. 138, no. 6, June 1998 (1998-06-01), U.K., pages 619 - 620, XP002524793;;CALABRESE G: ""NONALCOHOLIC COMPOUNDS OF WINE: THE PHYTOESTROGEN RESVERATROL AND MODERATE RED WINE CONSUMPTION DURING MENOPAUSE"", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, XX, vol. XXV, no. 2/03, 26 November 1999 (1999-11-26), pages 111 - 114, XP001021116, ISSN: 0378-6501",PENDING
101,EP,A1,EP 1484373 A1,099-494-509-747-970,2004-12-08,2004,EP 04013089 A,2004-06-03,US 45507003 A,2003-06-05,Polysiloxane coatings for surfaces,"The present invention is directed to a method for applying to a substrate having a faying surface, a polysiloxane-containing coating, preferably a polysiloxane(amide-ureide) coating capable of inhibiting corrosion as well as the accumulation of ice. One embodiment of the present invention is directed to a polysiloxane(amide-ureide) that forms a durable, long lasting, anti-corrosive and anti-ice coating when directed to a substrate faying surface.",BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,,https://lens.org/099-494-509-747-970,Patent Application,yes,3,2,11,20,0,C08G18/61;;C09D175/04;;C09D183/04;;C09D183/14;;C25D11/24;;Y10T428/31663;;Y10T428/31663;;C09D183/04;;C09D175/04;;C08G18/61;;C25D11/24;;C09D183/14,C08G18/61;;C09D175/04;;C09D183/04;;C09D183/14,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 0186, no. 82 (M - 1729) 22 December 1994 (1994-12-22)",ACTIVE
102,DE,T3,DE 602004008148 T3,040-335-946-205-249,2013-09-12,2013,DE 602004008148 T,2004-06-03,US 45507003 A;;EP 04013089 A,2003-06-05,Polysiloxane zum Beschichten von Oberflächen,,BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,,https://lens.org/040-335-946-205-249,Amended Patent,no,0,0,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C09D183/14;;C08G18/61;;C08G77/455;;C08G77/54;;C09D175/04;;C09D183/04,,0,0,,,,ACTIVE
103,EP,B2,EP 1484373 B2,030-516-058-888-387,2013-02-27,2013,EP 04013089 A,2004-06-03,US 45507003 A,2003-06-05,Polysiloxane coatings for surfaces,,BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,,https://lens.org/030-516-058-888-387,Granted Patent,yes,5,0,11,20,0,C08G18/61;;C09D175/04;;C09D183/04;;C09D183/14;;C25D11/24;;Y10T428/31663;;Y10T428/31663;;C09D183/04;;C09D175/04;;C08G18/61;;C25D11/24;;C09D183/14,C09D183/14;;C08G18/61;;C08G77/455;;C08G77/54;;C09D175/04;;C09D183/04,,0,0,,,,ACTIVE
104,EP,B1,EP 1484373 B1,163-459-435-032-782,2007-08-15,2007,EP 04013089 A,2004-06-03,US 45507003 A,2003-06-05,Polysiloxane coatings for surfaces,,BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,,https://lens.org/163-459-435-032-782,Granted Patent,yes,3,0,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C09D183/14;;C08G18/61;;C08G77/455;;C08G77/54;;C09D175/04;;C09D183/04,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 0186, no. 82 (M-1729), 22 December 1994 (1994-12-22) & JP 6 270555 A (RICOH CO LTD), 27 September 1994 (1994-09-27)",ACTIVE
105,CA,C,CA 2469979 C,051-791-380-195-958,2007-08-07,2007,CA 2469979 A,2004-06-04,US 45507003 A,2003-06-05,POLYSILOXANE COATINGS FOR SURFACES,"The present invention is directed to a method for applying to a substrate having a faying surface, a polysiloxane-containing coating, preferably a polysiloxane(amide-ureide) coating capable of inhibiting corrosion as well as the accumulation of ice. One embodiment of the present invention is directed to a polysiloxane(amide- ureide) that forms a durable, long lasting, anti-corrosive and anti-ice coating when directed to a substrate faying surface.",BOEING CO,KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE;;BYRD NORMAN R,,https://lens.org/051-791-380-195-958,Granted Patent,no,0,0,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C09D183/04;;C08G18/61;;C09D175/04;;C09D183/10;;C09D183/14,,0,0,,,,INACTIVE
106,US,A1,US 2009/0163580 A1,123-034-267-187-560,2009-06-25,2009,US 31704808 A,2008-12-18,US 31704808 A;;US 910707 P,2007-12-24,Anti-aging composition containing resveratrol and method of administration,"Formulations and methods of treatment and putative prevention for aging (anti-aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.",NATROL INC,YATCILLA MICHAEL TODD;;CLOUATRE DALLAS;;BYRD EDWARD ANTHONY;;FITZPATRICK AMY ADDINGTON,,https://lens.org/123-034-267-187-560,Patent Application,yes,1,31,3,3,0,A61K31/05;;A61K31/353;;A61P1/16;;A61P1/18;;A61P19/10;;A61P25/16;;A61P25/28;;A61P35/00;;A61P9/00;;A61K31/353;;A61K31/05,A61K31/05;;A61K31/085;;A61K31/353;;A61P1/16;;A61P1/18;;A61P9/00;;A61P19/10;;A61P25/16;;A61P25/28;;A61P35/00,514/456;;514/733;;514/720,0,0,,,,DISCONTINUED
107,BR,A,BR PI0401920 A,191-470-675-915-528,2005-02-01,2005,BR PI0401920 A,2004-06-07,US 45507003 A,2003-06-05,Revestimentos de polissiloxana para superfìcies,"""REVESTIMENTOS DE POLISSILOXANA PARA SUPERFìCIES"". A presente invenção refere-se a um método para aplicar a um substrato tendo uma superfície em união, um revestimento contendo polissiloxana, de preferência um revestimento de polissiloxana(amida-ureído) capaz de inibir corrosão bem como o acúmulo de gelo. Uma modalidade da presente invenção refere-se a um polissiloxana(amida-ureído) que forma um revestimento anticorrosivo e antigelo, durável, de longa duração, quando direcionada a uma superfície de união de substrato.",BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,,https://lens.org/191-470-675-915-528,Patent Application,no,0,0,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C08G18/61;;C09D175/04;;C09D183/04;;C09D183/14,,0,0,,,,DISCONTINUED
108,US,A1,US 2022/0022284 A1,164-236-567-404-726,2022-01-20,2022,US 202117374248 A,2021-07-13,US 202117374248 A;;US 202063051987 P,2020-07-15,SYSTEMS AND METHODS FOR PROVIDING MAC-LEVEL WIRELESS MESH NETWORKS INCORPORATING LONG-RANGE PATHWAYS,"In one aspect, a system for providing a wireless mesh network includes a plurality of wireless mesh nodes positioned relative to an outdoor area, with the wireless mesh nodes comprising a plurality of stationary nodes spaced apart from one another across the outdoor area and a plurality of mobile nodes configured to be moved across the outdoor area. Each of the nodes is formed from a respective wireless communication device, with each wireless communication device being configured to function as a Media Access Control (MAC) level device when communicating data across the wireless mesh network. Additionally, the wireless communication device forming each respective mobile node is configured to communicate data across the wireless mesh network using a short-range wireless communications protocol. Moreover, at least a portion the wireless communication devices forming the stationary nodes are configured to communicate data across the wireless mesh network using a long-range wireless communications protocol.",CNH IND AMERICA LLC,FOSTER CHRISTOPHER A;;BYRD JR CHARLES EDWARD;;DA SILVA HILGAD MONTELO,CNH INDUSTRIAL AMERICA LLC (2020-07-09),https://lens.org/164-236-567-404-726,Patent Application,yes,0,2,1,1,0,H04W4/80;;H04W4/40;;H04W84/18;;H04W88/06;;H04W84/18;;H04W4/40,H04W88/06;;H04W4/40,,0,0,,,,PENDING
109,WO,A2,WO 2009/082459 A2,079-138-229-457-315,2009-07-02,2009,US 2008/0013828 W,2008-12-18,US 910707 P,2007-12-24,ANTI-AGING COMPOSITION CONTAINING RESVERATROL AND METHOD OF ADMINISTRATION,"Formulations and methods of treatment and putative prevention for aging (anti- aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.",NATROL INC,YATCILLA MICHAEL TODD;;CLOUATRE DALLAS;;BYRD EDWARD ANTHONY;;ADDINGTON FITZPATRICK AMY,,https://lens.org/079-138-229-457-315,Patent Application,yes,0,5,3,3,0,A61K31/05;;A61K31/353;;A61P1/16;;A61P1/18;;A61P19/10;;A61P25/16;;A61P25/28;;A61P35/00;;A61P9/00;;A61K31/353;;A61K31/05,A61K31/05;;A61K31/353,,0,0,,,,PENDING
110,CA,A1,CA 2469979 A1,047-424-009-997-850,2004-12-05,2004,CA 2469979 A,2004-06-04,US 45507003 A,2003-06-05,POLYSILOXANE COATINGS FOR SURFACES,"The present invention is directed to a method for applying to a substrate having a faying surface, a polysiloxane-containing coating, preferably a polysiloxane(amide-ureide) coating capable of inhibiting corrosion as well as the accumulation of ice. One embodiment of the present invention is directed to a polysiloxane(amide- ureide) that forms a durable, long lasting, anti-corrosive and anti-ice coating when directed to a substrate faying surface.",BOEING CO,LALLY EDWARD DAVID;;PERALTA CESARE;;KEENER STEVEN G;;BYRD NORMAN R,,https://lens.org/047-424-009-997-850,Patent Application,no,0,0,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C08G18/61;;C09D175/04;;C09D183/04;;C09D183/14,,0,0,,,,INACTIVE
111,US,A1,US 2003/0232201 A1,046-434-551-089-943,2003-12-18,2003,US 45507003 A,2003-06-05,US 45507003 A;;US 43601503 A;;US 16482602 A,2002-06-07,Polysiloxane coatings for surfaces,"
   The present invention is directed to a method for applying to a substrate having a faying surface, a polysiloxane-containing coating, preferably a polysiloxane(amide-ureide) coating capable of inhibiting corrosion as well as the accumulation of ice. One embodiment of the present invention is directed to a polysiloxane(amide-ureide) that forms a durable, long lasting, anti-corrosive and anti-ice coating when directed to a substrate faying surface. 
",BYRD NORMAN R.;;KEENER STEVEN G.;;LALLY EDWARD DAVID;;PERALTA CESARE,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,BOEING COMPANY THE (2003-11-06),https://lens.org/046-434-551-089-943,Patent Application,yes,3,14,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C08G18/61;;C09D175/04;;C09D183/04;;C09D183/14,428/447,0,0,,,,EXPIRED
112,US,B2,US 6809169 B2,093-929-264-723-445,2004-10-26,2004,US 45507003 A,2003-06-05,US 45507003 A;;US 43601503 A;;US 16482602 A,2002-06-07,Polysiloxane coatings for surfaces,"
    The present invention is directed to a method for applying to a substrate having a faying surface, a polysiloxane-containing coating, preferably a polysiloxane(amide-ureide) coating capable of inhibiting corrosion as well as the accumulation of ice. One embodiment of the present invention is directed to a polysiloxane(amide-ureide) that forms a durable, long lasting, anti-corrosive and anti-ice coating when directed to a substrate faying surface. 
",BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,BOEING COMPANY THE (2003-11-06),https://lens.org/093-929-264-723-445,Granted Patent,yes,3,43,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C08G18/61;;C09D175/04;;C09D183/04;;C09D183/14,528/28;;528/31;;428/447;;427/387,0,0,,,,EXPIRED
113,DE,D1,DE 602004008148 D1,152-861-899-122-758,2007-09-27,2007,DE 602004008148 T,2004-06-03,US 45507003 A;;EP 04013089 A,2003-06-05,Polysiloxane zum Beschichten von Oberflächen,,BOEING CO,BYRD NORMAN R;;KEENER STEVEN G;;LALLY EDWARD DAVID;;PERALTA CESARE,,https://lens.org/152-861-899-122-758,Granted Patent,no,0,0,11,20,0,C09D183/04;;C09D183/04;;C08G18/61;;C08G18/61;;C09D175/04;;C09D175/04;;C09D183/14;;C09D183/14;;C25D11/24;;C25D11/24;;Y10T428/31663;;Y10T428/31663,C09D183/14;;C08G18/61;;C08G77/455;;C08G77/54;;C09D175/04;;C09D183/04,,0,0,,,,ACTIVE
114,CH,A,CH 512783 A,039-575-614-830-264,1971-09-15,1971,CH 1372069 A,1969-09-11,US 75938968 A,1968-09-12,Vorrichtung zur Gewinnung und Verarbeitung von medizinischen Daten bei der Reihenuntersuchung von Patienten,,SEARLE MEDIDATA INC,JOSEPH BRINTON FERGUSON;;EDWARD BYRD RAWSON;;DANIEL BENEDICT SCHWARZKOPF;;JAY HAROLD BALL,,https://lens.org/039-575-614-830-264,Granted Patent,no,0,0,7,7,0,A61B5/02;;H04L12/403;;Y10S128/906;;G16H10/20;;G16H40/63;;G16H10/60;;H04L12/403;;A61B5/02;;Y10S128/906;;Y10S707/99934;;G16H40/63;;G16H10/20;;G16H10/60,A61B5/02;;G16H40/63;;G06Q50/00;;H04L12/403,,0,0,,,,EXPIRED
115,DE,A1,DE 2422231 A1,101-215-830-249-076,1974-11-28,1974,DE 2422231 A,1974-05-08,US 35864073 A,1973-05-09,VERFAHREN ZUM SCHUTZ GEGEN OELVERSCHMUTZUNG MIT HILFE VON MIKROORGANISMEN,,EXXON RESEARCH ENGINEERING CO,MOHAN RAAM R;;BUCKER EDWARD R;;NIXON JAMES;;BYRD JUN GEORGE H,,https://lens.org/101-215-830-249-076,Patent Application,no,0,3,9,9,0,C02F1/681;;C09K3/32;;Y10S435/83;;Y10S435/824;;Y10S435/859;;Y02W10/37;;C02F1/681;;C09K3/32;;Y10S435/859;;Y10S435/83;;Y10S435/824;;Y02W10/37,C02F3/34;;C02F1/68;;C09K3/32;;C12N1/00;;C12N1/26,,0,0,,,,DISCONTINUED
116,US,A1,US 2015/0059905 A1,001-845-144-192-330,2015-03-05,2015,US 201314018834 A,2013-09-05,US 201314018834 A,2013-09-05,HYBRID MARMAN CLAMP DESIGN,"A pipe assembly for an exhaust system having a pipe with first end and a second end. The first end of the pipe having a shoulder with an inclined lip. The inclined lip facing outward from the first end of the pipe. Further, the pipe assembly includes a corrugated conduit having a collared end. The collared end abuts the inclined lip on the first end of the pipe thereby forming a joint with the pipe. Further, a shim ring is disposed on the joint. Furthermore, the assembly includes a clamp configured to circumference the joint and compresses the shim ring there between to form a seal at the joint.",CATERPILLAR INC,JONES DOUGLAS EDWARD;;HARTZLER AARON LEE;;BYRD JEREMY DANIEL;;MELLENCAMP KEITH WILLIAM,CATERPILLAR INC (2013-08-28),https://lens.org/001-845-144-192-330,Patent Application,yes,11,4,2,2,0,F01N13/1816;;F01N13/1816;;F01N13/1844;;F01N13/1844;;F16L23/08;;F16L23/08;;F16L33/26;;F16L33/26,F16L19/065,138/109,0,0,,,,DISCONTINUED
117,CA,A,CA 1021708 A,152-253-142-356-780,1977-11-29,1977,CA 199138 A,1974-05-07,US 35864073 A,1973-05-09,METHOD OF PROTECTING BEACHES AGAINST OIL CONTAMINATION BY MEANS OF MICROORGANISMS,,EXXON RESEARCH ENGINEERING CO,MOHAN RAAM R;;BUCKER EDWARD R;;NIXON JAMES;;BYRD GEORGE H JR,,https://lens.org/152-253-142-356-780,Granted Patent,no,0,0,9,9,0,C02F1/681;;C09K3/32;;Y10S435/83;;Y10S435/824;;Y10S435/859;;Y02W10/37;;C02F1/681;;C09K3/32;;Y10S435/859;;Y10S435/83;;Y10S435/824;;Y02W10/37,C02F3/34;;C02F1/68;;C09K3/32;;C12N1/00;;C12N1/26,195-44,0,0,,,,EXPIRED
118,US,A,US 2991533 A,174-901-356-364-250,1961-07-11,1961,US 72960958 A,1958-04-21,US 72960958 A,1958-04-21,Form for concrete columns,,SONOCO PRODUCTS CO,REID EDWARD S;;DAVIS ARTHUR E;;GRAY WILLIAM E;;BYRD HERBERT M,,https://lens.org/174-901-356-364-250,Granted Patent,no,6,23,1,1,0,E04G13/02;;E04G13/02,E04G13/02,,0,0,,,,EXPIRED
119,US,A,US 3871957 A,123-622-414-607-15X,1975-03-18,1975,US 35864073 A,1973-05-09,US 35864073 A,1973-05-09,USE OF MICROORGANISMS TO DISPERSE AND DEGRADE OIL SPILLS,"A new and novel method of preparation and application of specified microorganisms for the rapid dispersal of oil spills found in open seas, along beaches, in coastal areas and along the shore lines and also for protecting beaches and solid surfaces against oil contamination.",EXXON RESEARCH ENGINEERING CO,MOHAN RAAM R;;BYRD JR GEORGE H;;NIXON JAMES;;BUCKER EDWARD R,,https://lens.org/123-622-414-607-15X,Granted Patent,no,2,39,9,9,0,C02F1/681;;C09K3/32;;Y10S435/83;;Y10S435/824;;Y10S435/859;;Y02W10/37;;C02F1/681;;C09K3/32;;Y10S435/859;;Y10S435/83;;Y10S435/824;;Y02W10/37,C02F1/68;;C02F3/34;;C09K3/32;;C12N1/00;;C12N1/26,195/2,0,0,,,,EXPIRED
120,DE,A1,DE 1946005 A1,192-115-168-747-902,1970-03-19,1970,DE 1946005 A,1969-09-11,US 75938968 A,1968-09-12,Anlage fuer medizinische Untersuchungen,,MEDIDATA SCIENCES INC,BRINTON FERGUSON JOSEPH;;BYRD RAWSON EDWARD;;BENEDICT SCHWARZKOPF DANIEL;;HAROLD BALL JAY,,https://lens.org/192-115-168-747-902,Patent Application,no,0,0,7,7,0,A61B5/02;;H04L12/403;;Y10S128/906;;G16H10/20;;G16H40/63;;G16H10/60;;H04L12/403;;A61B5/02;;Y10S128/906;;Y10S707/99934;;G16H40/63;;G16H10/20;;G16H10/60,A61B5/02;;G06Q50/00;;G16H40/63;;H04L12/403,,0,0,,,,DISCONTINUED
121,CA,A1,CA 2763917 A1,058-934-319-987-964,2012-08-17,2012,CA 2763917 A,2012-01-16,US 201113030001 A,2011-02-17,"APPARATUS, AND ASSOCIATED METHOD, FOR SELECTING INFORMATION DELIVERY MANNER USING FACIAL RECOGNITION","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.",RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,,https://lens.org/058-934-319-987-964,Patent Application,no,0,0,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04W4/18;;G06F3/00;;G06F17/00;;G06K9/20;;G06K9/62;;H04M1/72403;;H04M1/72436;;H04M1/72448,,0,0,,,,ACTIVE
122,CN,A,CN 102647367 A,192-570-580-872-590,2012-08-22,2012,CN 201210023326 A,2012-01-17,US 201113030001 A,2011-02-17,"Apparatus, and associated method, for selecting information delivery manner using facial recognition","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.",RESEARCH IN MOTION LTD,ALLEN HYMEL JAMES;;EDWARD BYRD THOMAS;;CAMILLE PAUL-CAVALLIER JULIEN;;MICHAEL O'CARROLL FINBARR,,https://lens.org/192-570-580-872-590,Patent Application,no,3,0,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04L12/58;;G06K9/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04W4/12,,0,0,,,,DISCONTINUED
123,CA,C,CA 2763917 C,127-350-725-214-061,2016-04-12,2016,CA 2763917 A,2012-01-16,US 201113030001 A,2011-02-17,"APPARATUS, AND ASSOCIATED METHOD, FOR SELECTING INFORMATION DELIVERY MANNER USING FACIAL RECOGNITION","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.",RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,,https://lens.org/127-350-725-214-061,Granted Patent,no,0,0,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04W4/18;;G06F3/00;;G06F17/00;;G06K9/20;;G06K9/62;;H04M1/72403;;H04M1/72436;;H04M1/72448,,0,0,,,,ACTIVE
124,EP,A3,EP 2490418 A3,171-202-799-056-749,2013-05-22,2013,EP 11169085 A,2011-06-08,US 201113030001 A,2011-02-17,"Apparatus, and associated method, for selecting information delivery manner using facial recognition","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.
",RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,BLACKBERRY LIMITED (2013-11-27),https://lens.org/171-202-799-056-749,Search Report,yes,3,0,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04M1/60;;H04M1/72403;;H04M1/72436;;H04M1/72448,,0,0,,,,DISCONTINUED
125,US,B2,US 8531536 B2,001-473-906-496-898,2013-09-10,2013,US 201113030001 A,2011-02-17,US 201113030001 A,2011-02-17,"Apparatus, and associated method, for selecting information delivery manner using facial recognition","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.",HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL;;BLACKBERRY LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,BLACKBERRY LIMITED (2013-07-09);;RESEARCH IN MOTION UK LIMITED (2011-02-21);;MALIKIE INNOVATIONS LIMITED (2023-05-11);;RESEARCH IN MOTION CORPORATION (2011-03-08),https://lens.org/001-473-906-496-898,Granted Patent,yes,23,2,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04N5/232;;H04L29/08;;H04M1/72403;;H04M1/72436;;H04M1/72448,348/211.2;;455/414.4,4,0,,,"Extended European Search report mailed Apr. 22, 2013, in corresponding European patent application No. 11169085.5.;;Busso, C et al., ""Analysis of Emotion Recognition Using Facial Expressions, Speech and"", http://graphics.usc.edu/cgit/pdf/papers/ICMI2004-emotionrecog-upload.pdf, pp. 1-7, retrieved May 19, 2005.;;Mack, B. , ""Toshiba Brings Facial Recognition to Cars, Wired.com"", http://www.wired.com/autopia/2009/06/facial-recognition/, pp. 1-4, Jun. 1, 2009.;;Scott, M. , ""This Computer May Be Too Smart,"", http://www.businessweek.com/globalbiz/content/jul2006/gb20060713-595118.htm?chan=tcl; BusinessWeek Online, Jul. 13, 2006 pp. 1-3, retrieved Jul. 18, 2006.",ACTIVE
126,US,B2,US 8749651 B2,188-117-485-643-220,2014-06-10,2014,US 201313961477 A,2013-08-07,US 201313961477 A;;US 201113030001 A,2011-02-17,"Apparatus, and associated method, for selecting information delivery manner using facial recognition","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.",BLACKBERRY LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,BLACKBERRY LIMITED (2013-07-09);;RESEARCH IN MOTION UK LIMITED (2011-02-21);;MALIKIE INNOVATIONS LIMITED (2023-05-11);;RESEARCH IN MOTION CORPORATION (2011-03-08),https://lens.org/188-117-485-643-220,Granted Patent,yes,31,0,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04N5/232;;B60Q1/00;;G08B23/00;;H04L29/08;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04N5/222,348/211.2;;348/333.03;;455/414.4;;340/439;;340/576,4,0,,,"Busso, C. et al., ""Analysis of Emotion Recognition Using Facial Expressions, Speech and Multimodal Information"", http://graphics.usc.edu/cgit/pdf/papers/ICMI2004-emotionrecog-upload.pdf, pp. 1-7, retrieved May 19, 2005.;;Mack, B., ""Toshiba Brings Facial Recognition to Cars"", Wired.com, http://www.wired.com/autopia/2009/06/facial-recognition/, pp. 1-4, Jun. 1, 2009.;;Scott, M., ""This Computer May Be Too Smart,"", http://www.businessweek.com/globalbiz/content/jul2006/gb20060713-595118.htm?chan=tcl; BusinessWeek Online, Jul. 13, 2006, pp. 1-3, retrieved Jul. 18, 2006.;;Extended European Search report mailed Apr. 22, 2013, in corresponding European patent application No. 11169085.5.",ACTIVE
127,US,A1,US 2012/0212629 A1,152-397-932-888-75X,2012-08-23,2012,US 201113030001 A,2011-02-17,US 201113030001 A,2011-02-17,"APPARATUS, AND ASSOCIATED METHOD, FOR SELECTING INFORMATION DELIVERY MANNER USING FACIAL RECOGNITION","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.",HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL;;RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,BLACKBERRY LIMITED (2013-07-09);;RESEARCH IN MOTION UK LIMITED (2011-02-21);;MALIKIE INNOVATIONS LIMITED (2023-05-11);;RESEARCH IN MOTION CORPORATION (2011-03-08),https://lens.org/152-397-932-888-75X,Patent Application,yes,21,2,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04N5/225;;G06K9/00;;H04M1/72403;;H04M1/72436;;H04M1/72448,348/207.1;;382/118;;X348E07085,0,0,,,,ACTIVE
128,EP,A2,EP 2490418 A2,115-424-492-615-975,2012-08-22,2012,EP 11169085 A,2011-06-08,US 201113030001 A,2011-02-17,"Apparatus, and associated method, for selecting information delivery manner using facial recognition","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.
",RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,BLACKBERRY LIMITED (2013-11-27),https://lens.org/115-424-492-615-975,Patent Application,yes,0,0,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,H04M1/60;;H04M1/72403;;H04M1/72436;;H04M1/72448,,0,0,,,,DISCONTINUED
129,US,A1,US 2013/0321266 A1,040-806-640-840-23X,2013-12-05,2013,US 201313961477 A,2013-08-07,US 201313961477 A;;US 201113030001 A,2011-02-17,"APPARATUS, AND ASSOCIATED METHOD, FOR SELECTING INFORMATION DELIVERY MANNER USING FACIAL RECOGNITION","An apparatus, and an associated method, selects a manner by which to deliver received information at a wireless, or other electronic, device. A facial recognition indication is obtained and analyzed. Responsive to the analysis of the facial recognition indication, selection is made of the manner by which to deliver the information. If the facial recognition indication indicates the recipient to exhibit a serious demeanor, the information is provided in aural form, thereby to permit delivery of the information without requiring the recipient to read, or otherwise view, the information.",BLACKBERRY LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PAUL-CAVALLIER JULIEN CAMILLE;;O'CARROLL FINBARR MICHAEL,BLACKBERRY LIMITED (2013-07-09);;RESEARCH IN MOTION UK LIMITED (2011-02-21);;MALIKIE INNOVATIONS LIMITED (2023-05-11);;RESEARCH IN MOTION CORPORATION (2011-03-08),https://lens.org/040-806-640-840-23X,Patent Application,yes,0,0,9,9,0,H04M1/6075;;H04M2250/12;;H04M2250/52;;G10L13/00;;H04M1/72403;;H04M1/72436;;H04M1/72448;;H04M2250/52;;H04M1/6075;;H04M2250/12;;G10L13/00;;H04M1/72403;;H04M1/72448;;H04M1/72436;;G06V40/174,G06K9/00;;H04M1/72403;;H04M1/72436;;H04M1/72448,345/156,0,0,,,,ACTIVE
130,WO,A1,WO 2013/020206 A1,169-775-426-694-445,2013-02-14,2013,CA 2011050479 W,2011-08-08,CA 2011050479 W,2011-08-08,METHODS AND APPARATUS TO OBTAIN AND PRESENT INFORMATION,"Example methods and apparatus to display information are described. On example method includes a method including a mobile device exchanging information with at least one other mobile device; controlling transmission of media, to the mobile device and the at least one other mobile device, based on attributes of the mobile devices; and presenting the received media.",RESEARCH IN MOTION LTD;;HYMEL JAMES ALLEN;;BOUCHARD JEAN PHILIPPE;;KIKIC EDVARD;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER,HYMEL JAMES ALLEN;;BOUCHARD JEAN PHILIPPE;;KIKIC EDVARD;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER,,https://lens.org/169-775-426-694-445,Patent Application,yes,5,0,4,4,0,H04N5/74;;H04M1/0272;;H04W4/18;;G06F3/1454;;G09G3/002;;G09G2330/021;;G09G2340/0407;;G09G2350/00;;G09G2370/025;;G09G2370/04;;G09G2370/16;;H04N9/3147;;H04N9/3173;;H04N9/3194;;H04M1/72412;;H04N5/74;;H04M1/0272;;H04W4/18;;G09G2330/021;;G09G3/002;;H04N9/3194;;G09G2370/04;;G09G2350/00;;G06F3/1454;;G09G2340/0407;;G09G2370/025;;H04N9/3173;;G09G2370/16;;H04N9/3147;;H04M1/72412;;G09G5/00,H04W88/02;;H04N5/74,,1,0,,,See also references of EP 2742770A4,PENDING
131,EP,B1,EP 2618549 B1,108-384-080-393-168,2014-04-02,2014,EP 12151824 A,2012-01-19,EP 12151824 A,2012-01-19,Improving the efficiency of electronic message communications between mobile communication devices,,BLACKBERRY LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE,BLACKBERRY LIMITED (2013-11-27),https://lens.org/108-384-080-393-168,Granted Patent,yes,13,0,4,4,0,H04M3/42348;;H04M2201/18;;H04M2201/38;;H04M2203/2094;;H04M2203/551;;H04M2207/18;;H04M2242/14;;H04M2242/30;;H04M2250/60;;H04M1/72436;;H04M1/72451;;H04M1/72457,H04M3/42;;H04M1/72436;;H04M1/72451;;H04M1/72457,,0,0,,,,ACTIVE
132,EP,A1,EP 2742770 A1,159-135-374-081-162,2014-06-18,2014,EP 11870673 A,2011-08-08,CA 2011050479 W,2011-08-08,METHODS AND APPARATUS TO OBTAIN AND PRESENT INFORMATION,,BLACKBERRY LTD,HYMEL JAMES ALLEN;;BOUCHARD JEAN PHILIPPE;;KIKIC EDVARD;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER,,https://lens.org/159-135-374-081-162,Patent Application,yes,0,0,4,4,0,H04N5/74;;H04M1/0272;;H04W4/18;;G06F3/1454;;G09G3/002;;G09G2330/021;;G09G2340/0407;;G09G2350/00;;G09G2370/025;;G09G2370/04;;G09G2370/16;;H04N9/3147;;H04N9/3173;;H04N9/3194;;H04M1/72412;;H04N5/74;;H04M1/0272;;H04W4/18;;G09G2330/021;;G09G3/002;;H04N9/3194;;G09G2370/04;;G09G2350/00;;G06F3/1454;;G09G2340/0407;;G09G2370/025;;H04N9/3173;;G09G2370/16;;H04N9/3147;;H04M1/72412;;G09G5/00,H04W88/02;;H04N5/74,,0,0,,,,DISCONTINUED
133,CA,C,CA 2802040 C,025-763-210-466-638,2016-04-12,2016,CA 2802040 A,2013-01-15,EP 12151824 A,2012-01-19,IMPROVING THE EFFICIENCY OF ELECTRONIC MESSAGE COMMUNICATIONS BETWEEN MOBILE COMMUNICATION DEVICES,"A disclosure provides mobile communication devices that receive information corresponding to users associated with target mobile communication device, via a near field communication protocol. The information is stored in a storage device either within the mobile communication device or within a separate server. If it is determined that the target mobile communication device is within a predetermined distance of the mobile communication device, data entries associated with the stored information are created and retrieved, in real time. The data entries are displayed on the mobile communication device. The data entries may include personal information or email messages from prior communication sessions, which are employed in future communications between the mobile communication devices.",RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE,,https://lens.org/025-763-210-466-638,Granted Patent,no,0,0,4,4,0,H04M3/42348;;H04M2201/18;;H04M2201/38;;H04M2203/2094;;H04M2203/551;;H04M2207/18;;H04M2242/14;;H04M2242/30;;H04M2250/60;;H04M1/72436;;H04M1/72451;;H04M1/72457,H04W8/20;;H04B5/00;;H04M1/72436;;H04M1/72451;;H04M1/72457,,0,0,,,,ACTIVE
134,EP,A4,EP 2742770 A4,031-182-585-339-661,2015-03-18,2015,EP 11870673 A,2011-08-08,CA 2011050479 W,2011-08-08,METHODS AND APPARATUS TO OBTAIN AND PRESENT INFORMATION,,BLACKBERRY LTD,HYMEL JAMES ALLEN;;BOUCHARD JEAN PHILIPPE;;KIKIC EDVARD;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER,,https://lens.org/031-182-585-339-661,Search Report,no,4,0,4,4,0,H04N5/74;;H04M1/0272;;H04W4/18;;G06F3/1454;;G09G3/002;;G09G2330/021;;G09G2340/0407;;G09G2350/00;;G09G2370/025;;G09G2370/04;;G09G2370/16;;H04N9/3147;;H04N9/3173;;H04N9/3194;;H04M1/72412;;H04N5/74;;H04M1/0272;;H04W4/18;;G09G2330/021;;G09G3/002;;H04N9/3194;;G09G2370/04;;G09G2350/00;;G06F3/1454;;G09G2340/0407;;G09G2370/025;;H04N9/3173;;G09G2370/16;;H04N9/3147;;H04M1/72412;;G09G5/00,H04W88/02;;H04N5/74,,1,0,,,See also references of WO 2013020206A1,DISCONTINUED
135,US,B2,US 8606300 B2,110-842-140-238-897,2013-12-10,2013,US 201213354091 A,2012-01-19,US 201213354091 A,2012-01-19,Efficiency of electronic message communications between mobile communication devices,"A disclosure provides mobile communication devices that receive information corresponding to users associated with target mobile communication device, via a near field communication protocol. The information is stored in a storage device either within the mobile communication device or within a separate server. If it is determined that the target mobile communication device is within a predetermined distance of the mobile communication device, data entries associated with the stored information are created and retrieved, in real time. The data entries are displayed on the mobile communication device. The data entries may include personal information or email messages from prior communication sessions, which are employed in future communications between the mobile communication devices.",HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE;;BLACKBERRY LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE,BLACKBERRY LIMITED (2013-07-09);;MALIKIE INNOVATIONS LIMITED (2023-05-11),https://lens.org/110-842-140-238-897,Granted Patent,yes,20,0,2,2,0,H04W4/023;;H04W4/21;;H04W4/21;;H04W4/023,H04W4/21;;H04W24/00,455/456.3;;455/404.2;;455/412.1;;455/412.2;;455/414.1,3,0,,,"Extended European Search report mailed May 22, 2012, in corresponding European patent application No. 12151824.5.;;Nokia 6212 classic delivers tap-to-share NFC technology; http://www.knowyourcell.com/news/353627/nokia-6212-classic-delivers-taptoshare-nfc-technology.html. Published on Nov. 6, 2009 and retrieved on Mar. 5, 2011.;;Yang, Guang; Social Proximity Networks on Cruise Ships; http://mirw08.offis.de/paper/15.pdf, 2008.",ACTIVE
136,EP,A1,EP 2618549 A1,118-322-853-779-484,2013-07-24,2013,EP 12151824 A,2012-01-19,EP 12151824 A,2012-01-19,Improving the efficiency of electronic message communications between mobile communication devices,"A disclosure provides mobile communication devices that receive information corresponding to users associated with target mobile communication device, via a near field communication protocol. The information is stored in a storage device either within the mobile communication device or within a separate server. If it is determined that the target mobile communication device is within a predetermined distance of the mobile communication device, data entries associated with the stored information are created and retrieved, in real time. The data entries are displayed on the mobile communication device. The data entries may include personal information or email messages from prior communication sessions, which are employed in future communications between the mobile communication devices.
",RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE,BLACKBERRY LIMITED (2013-11-27),https://lens.org/118-322-853-779-484,Patent Application,yes,13,1,4,4,0,H04M3/42348;;H04M2201/18;;H04M2201/38;;H04M2203/2094;;H04M2203/551;;H04M2207/18;;H04M2242/14;;H04M2242/30;;H04M2250/60;;H04M1/72436;;H04M1/72451;;H04M1/72457,H04M3/42;;H04M1/72436;;H04M1/72451;;H04M1/72457,,0,0,,,,ACTIVE
137,CA,A1,CA 2802040 A1,173-670-206-973-059,2013-07-19,2013,CA 2802040 A,2013-01-15,EP 12151824 A,2012-01-19,IMPROVING THE EFFICIENCY OF ELECTRONIC MESSAGE COMMUNICATIONS BETWEEN MOBILE COMMUNICATION DEVICES,"A disclosure provides mobile communication devices that receive information corresponding to users associated with target mobile communication device, via a near field communication protocol. The information is stored in a storage device either within the mobile communication device or within a separate server. If it is determined that the target mobile communication device is within a predetermined distance of the mobile communication device, data entries associated with the stored information are created and retrieved, in real time. The data entries are displayed on the mobile communication device. The data entries may include personal information or email messages from prior communication sessions, which are employed in future communications between the mobile communication devices.",RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE,,https://lens.org/173-670-206-973-059,Patent Application,no,0,0,4,4,0,H04M3/42348;;H04M2201/18;;H04M2201/38;;H04M2203/2094;;H04M2203/551;;H04M2207/18;;H04M2242/14;;H04M2242/30;;H04M2250/60;;H04M1/72436;;H04M1/72451;;H04M1/72457,H04W8/20;;H04B5/00;;H04M1/72436;;H04M1/72451;;H04M1/72457,,0,0,,,,ACTIVE
138,US,A1,US 2013/0207882 A1,178-005-028-035-52X,2013-08-15,2013,US 201113635317 A,2011-08-08,CA 2011050479 W,2011-08-08,METHODS AND APPARATUS TO OBTAIN AND PRESENT INFORMATION,"Example methods and apparatus to display information are described. On example method includes a method including a mobile device exchanging information with at least one other mobile device; controlling transmission of media, to the mobile device and the at least one other mobile device, based on attributes of the mobile devices; and presenting the received media.",HYMEL JAMES ALLEN;;BOUCHARD JEAN PHILIPPE;;KIKIC EDVARD;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER,HYMEL JAMES ALLEN;;BOUCHARD JEAN PHILIPPE;;KIKIC EDVARD;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER,BLACKBERRY LIMITED (2011-10-31);;RESEARCH IN MOTION UK LIMITED (2011-11-02),https://lens.org/178-005-028-035-52X,Patent Application,yes,11,3,4,4,0,H04N5/74;;H04M1/0272;;H04W4/18;;G06F3/1454;;G09G3/002;;G09G2330/021;;G09G2340/0407;;G09G2350/00;;G09G2370/025;;G09G2370/04;;G09G2370/16;;H04N9/3147;;H04N9/3173;;H04N9/3194;;H04M1/72412;;H04N5/74;;H04M1/0272;;H04W4/18;;G09G2330/021;;G09G3/002;;H04N9/3194;;G09G2370/04;;G09G2350/00;;G06F3/1454;;G09G2340/0407;;G09G2370/025;;H04N9/3173;;G09G2370/16;;H04N9/3147;;H04M1/72412;;G09G5/00,G09G5/00,345/2.3,0,0,,,,DISCONTINUED
139,US,A1,US 2013/0190015 A1,197-021-567-721-19X,2013-07-25,2013,US 201213354091 A,2012-01-19,US 201213354091 A,2012-01-19,EFFICIENCY OF ELECTRONIC MESSAGE COMMUNICATIONS BETWEEN MOBILE COMMUNICATION DEVICES,"A disclosure provides mobile communication devices that receive information corresponding to users associated with target mobile communication device, via a near field communication protocol. The information is stored in a storage device either within the mobile communication device or within a separate server. If it is determined that the target mobile communication device is within a predetermined distance of the mobile communication device, data entries associated with the stored information are created and retrieved, in real time. The data entries are displayed on the mobile communication device. The data entries may include personal information or email messages from prior communication sessions, which are employed in future communications between the mobile communication devices.",HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE;;RESEARCH IN MOTION LTD,HYMEL JAMES ALLEN;;BYRD THOMAS EDWARD;;PATON WILLIAM ALEXANDER;;KIKIC EDVARD;;BOUCHARD JEAN PHILIPPE,BLACKBERRY LIMITED (2013-07-09);;MALIKIE INNOVATIONS LIMITED (2023-05-11),https://lens.org/197-021-567-721-19X,Patent Application,yes,0,1,2,2,0,H04W4/023;;H04W4/21;;H04W4/21;;H04W4/023,H04W4/21,455/456.3,0,0,,,,ACTIVE
140,US,S,US D0922352 S,150-218-133-066-283,2021-06-15,2021,US 201929675792 F,2019-01-04,US 201929675792 F,2019-01-04,Speaker,,DOLBY LABORATORIES LICENSING CORP,BYRD GRAYSON H;;PROKSA CODY MICHAEL;;SAULE LUCAS E;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;VORON VINCENT,DOLBY LABORATORIES LICENSING CORPORATION (2019-02-13),https://lens.org/150-218-133-066-283,Design Right,no,66,8,2,2,0,,,1401;;D14/214;;D14/204,6,0,,,"Alume Cube Clock, (c) 2018 [online], [retrieved May 29, 2020], Retrieved from internet, URL: <https://store.moma.org/clocks/alume-cube-clock/121324-121324.html?flow_enabled=false&gclid=EAlalQobChMI-K70isDZ6QIVGrblCh1TKAAmEAQY%E2%80%A6> (Year: 2018).;;Mini Box Speaker, (c) 2010 [online], [retrieved May 29, 2020], Retrieved from internet, URL: <https://www.amazon.co.uk/Audio-4-Inch-Dual-Range-Speaker/dp/B0048FB4OY/ref=sr_1_5?dchild=1&keywords=cube+speaker&qid=1590770436&sr%E2%80%A6> (Year: 2010).;;KitSound Boom Cube, Dec. 28, 2017 [online], [retrieved May 29, 2020], Retrieved from internet, URL: <https://www.amazon.co.uk/KitSound-Portable-Wireless-Bluetooth-Speaker/dp/B0711SHD8V/ref=sr_1_13?dchild=1&keywords=cube+speaker&qid=15%E2%80%A6> (Year: 2017).;;NuForce Cube Portable Speaker, May 30, 2012 [online], [retrieved Jun. 5, 2020], Retrieved from internet, URL: <https://gadgetsin.com/nuforce-cube-portable-speaker.htm> (Year: 2012).;;Ion Audio Flash Cube, 2018 [online], [retrieved Jun. 5, 2020], Retrieved from internet, URL: <https://www.shopmyexchange.com/ion-audio-flash-cube/8190092> (Year: 2018).;;Carbon Fiber Seamless Texture, Sep. 20, 2017 [online], [retrieved Jun. 5, 2020], Retrieved from internet, URL: <https://www.renderhub.com/renderhub/carbon-fiber-seamless-texture> (Year: 2017).",ACTIVE
141,US,S,US D0958109 S,163-213-701-001-568,2022-07-19,2022,US 202129794817 F,2021-06-15,US 202129794817 F;;US 201929675792 F,2019-01-04,Speaker,,DOLBY LABORATORIES LICENSING CORP,BYRD GRAYSON H;;PROKSA CODY MICHAEL;;SAULE LUCAS E;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;VORON VINCENT,DOLBY LABORATORIES LICENSING CORPORATION (2019-02-13),https://lens.org/163-213-701-001-568,Design Right,no,89,1,2,2,0,,,1401;;D14/204;;D14/214,9,0,,,"Urbanears Ralis Portable Bluetooth Speaker, date first available: May 22, 2019, [retrieved Dec. 14, 2021], Retrieved from Internet, URL: <https://www.amazon.com/Urbanears-Ralis-Portable-Bluetooth-Speaker/dp/B07QP4W2XP?th=1> (Year: 2019).;;VIZIO Sound Bar for TV, date first available: Oct. 1, 2018, [retrieved Dec. 14, 2021], Retrieved from Internet, URL: <https://www.amazon.com/VIZIO-SB46312-F6-46-Premium-Wireless-Subwoofer/dp/B07GTQWMHR/ref=asc_df_B07GTQWMHR/?tag=hyprod-20&link%E2%80%A6> (Year: 2018).;;Damson S-Series review, Jul. 5, 2018, [retrieved Dec. 14, 2021], Retrieved from Internet, URL: <https://www.techradar.com/reviews/damson-s-series> (Year: 2018).;;Ion Audio Flash Cube, 2018 [online], [retrieved Jun. 5, 2020], Retrieved from internet, URL: <https://www.shoprnyexchange.com/ion-audio-flash-cube/8190092> (Year: 2018).;;Carbon Fiber Seamless Texture, Sep. 20, 2017 [online], [retrieved Jun. 5, 2020], Retrieved from internet, U RL: <https://www.renderhub.com/renderhub/carbon-fiber-searnless-texture> (Year: 2017).;;Alume Cube Clock, (c) 2018 [online], [retrieved May 29, 2020], Retrieved from internet, URL: <https://store.morna.org/clocks/alume-cube-clockl121324-121324.htrnl?flow_enabled=false&gclid=EAIalQobChMI-K70isOZ6QIVGrblCh1TKAAmEAQY%E2%80%A6> (Year: 2018).;;Mini Box Speaker, (c) 2010 [online], [retrieved May 29, 2020], Retrieved from internet, URL: <https://www.arnazon.co.uklAudio-4-Inch-Oual-Range-Speaker/dp/B0048 FB40Y/ref=sr_1_5?dchild = 1 &keywords=cube+speaker&qid=1590770436&sr% E2%80%A6> (Year: 2010).;;KitSound Boom Cube, Dec. 28, 2017 [online], [retrieved May 29, 2020], Retrieved from internet, U RL: <https://www.amazon.co.uklKitSound-Portable-Wireless-Bluetooth-Speaker/dp/B0711 SH 08V/ref=sr_1_13?dchild=1&keywords=cube+speaker&qid= 15% E2%80%A6> (Year: 2017).;;NuForce Cube Portable Speaker, May 30, 2012 [online], [retrieved Jun. 5, 2020], Retrieved from internet, URL: <https://gadgetsin.com/nuforce-cube-portable-speaker.htrn> (Year: 2012).",ACTIVE
142,US,A1,US 2014/0208766 A1,130-894-458-660-617,2014-07-31,2014,US 201313755434 A,2013-01-31,US 201313755434 A,2013-01-31,Waste Heat Recovery Fuel Gas Heater Control Method and Algorithm,"A method of operating a fuel heating system is provided. The method includes performing pre-ignition diagnostic checks on a plurality of components of the fuel heating system, wherein at least one inlet damper and at least one outlet damper of an exhaust flow circuit are each in a closed position. The method also includes purging the fuel heating system of unburned hydrocarbons. The method further includes operating the fuel heating system in a normal operating condition. The method yet further includes operating the fuel heating system in a cool down condition, wherein the at least one inlet damper is in the closed position.",GEN ELECTRIC,AMIN RUSHI MAHESH;;BYRD DOUGLAS SCOTT;;ERICKSON DEAN MATTHEW;;MARIANI MICHAEL JOHN;;POMPEY CHRISTINA RENEE;;RENDO KOREY FREDERIC;;SWEET BRYAN EDWARD,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2013-01-29),https://lens.org/130-894-458-660-617,Patent Application,yes,13,6,7,7,0,F02C7/224;;F02C7/224;;F02C7/232;;F02C7/26;;F02C7/26;;F02C9/26;;F05D2230/31;;F05D2230/312;;F05D2260/80;;F05D2270/08,F02C7/224;;F02C7/26,60/778,0,0,,,,ACTIVE
143,EP,A2,EP 2762709 A2,008-638-163-883-324,2014-08-06,2014,EP 14152273 A,2014-01-23,US 201313755434 A,2013-01-31,Method of operating a fuel heating system,"A method 400 of operating a fuel heating system is provided. The method includes performing 404 pre-ignition diagnostic checks on a plurality of components of the fuel heating system, wherein at least one inlet damper and at least one outlet damper of an exhaust flow circuit are each in a closed position. The method also includes purging 414 the fuel heating system of unburned hydrocarbons. The method further includes operating 424 the fuel heating system in a normal operating condition. The method yet further includes operating 426 the fuel heating system in a cool down condition, wherein the at least one inlet damper is in the closed position.
",GEN ELECTRIC,AMIN RUSHI MAHESH;;BYRD DOUGLAS SCOTT;;ERICKSON DEAN MATTHEW;;MARIANI MICHAEL JOHN;;POMPEY CHRISTINA RENEE;;RENDO KOREY FREDERIC;;SWEET BYRAN EDWARD,"GENERAL ELECTRIC TECHNOLOGY GMBH, CH (2023-11-23)",https://lens.org/008-638-163-883-324,Patent Application,yes,0,1,7,7,0,F02C7/224;;F02C7/224;;F02C7/232;;F02C7/26;;F02C7/26;;F02C9/26;;F05D2230/31;;F05D2230/312;;F05D2260/80;;F05D2270/08,F02C7/224,,0,0,,,,ACTIVE
144,JP,A,JP 2014148973 A,101-536-374-380-210,2014-08-21,2014,JP 2014010858 A,2014-01-24,US 201313755434 A,2013-01-31,METHOD OF OPERATING FUEL HEATING SYSTEM,"PROBLEM TO BE SOLVED: To provide a method of operating a fuel heating system.SOLUTION: The method includes performing pre-ignition diagnostic checks on a plurality of components of the fuel heating system, where at least one inlet damper and at least one outlet damper of an exhaust flow circuit are each in a closed position. The method also includes purging the fuel heating system of unburned hydrocarbons. The method further includes operating the fuel heating system in a normal operating condition. The method yet further includes operating the fuel heating system in a cool down condition, where the at least one inlet damper is in the closed position.",GEN ELECTRIC,RUSHI MAHESH AMIN;;BYRD DOUGLAS SCOTT;;ERICKSON DEAN MATHEW;;MICHAEL JOHN MARIANI;;CHRISTINA RENEE POMPEY;;KOREY FREDERIC RENDO;;SWEET BRYAN EDWARD,,https://lens.org/101-536-374-380-210,Patent Application,no,12,0,7,7,0,F02C7/224;;F02C7/224;;F02C7/232;;F02C7/26;;F02C7/26;;F02C9/26;;F05D2230/31;;F05D2230/312;;F05D2260/80;;F05D2270/08,F02C7/224;;F02C7/232;;F02C7/26,,0,0,,,,ACTIVE
145,EP,B1,EP 2762709 B1,074-324-582-644-338,2019-03-20,2019,EP 14152273 A,2014-01-23,US 201313755434 A,2013-01-31,Method of operating a fuel heating system,,GEN ELECTRIC,AMIN RUSHI MAHESH;;BYRD DOUGLAS SCOTT;;ERICKSON DEAN MATTHEW;;MARIANI MICHAEL JOHN;;POMPEY CHRISTINA RENEE;;RENDO KOREY FREDERIC;;SWEET BYRAN EDWARD,"GENERAL ELECTRIC TECHNOLOGY GMBH, CH (2023-11-23)",https://lens.org/074-324-582-644-338,Granted Patent,yes,4,0,7,7,0,F02C7/224;;F05D2230/312;;F05D2260/80;;F05D2270/08;;F02C9/26;;F02C7/232;;F05D2230/31;;F02C7/26;;F02C7/224;;F02C7/26,F02C7/224;;F02C6/18;;F02C7/232;;F02C7/26;;F02C9/26;;F02C9/46,,0,0,,,,ACTIVE
146,EP,A3,EP 2762709 A3,060-197-745-693-672,2018-02-07,2018,EP 14152273 A,2014-01-23,US 201313755434 A,2013-01-31,Method of operating a fuel heating system,"A method 400 of operating a fuel heating system is provided. The method includes performing 404 pre-ignition diagnostic checks on a plurality of components of the fuel heating system, wherein at least one inlet damper and at least one outlet damper of an exhaust flow circuit are each in a closed position. The method also includes purging 414 the fuel heating system of unburned hydrocarbons. The method further includes operating 424 the fuel heating system in a normal operating condition. The method yet further includes operating 426 the fuel heating system in a cool down condition, wherein the at least one inlet damper is in the closed position.
",GEN ELECTRIC,AMIN RUSHI MAHESH;;BYRD DOUGLAS SCOTT;;ERICKSON DEAN MATTHEW;;MARIANI MICHAEL JOHN;;POMPEY CHRISTINA RENEE;;RENDO KOREY FREDERIC;;SWEET BYRAN EDWARD,"GENERAL ELECTRIC TECHNOLOGY GMBH, CH (2023-11-23)",https://lens.org/060-197-745-693-672,Search Report,yes,4,0,7,7,0,F02C7/224;;F02C7/224;;F02C7/232;;F02C7/26;;F02C7/26;;F02C9/26;;F05D2230/31;;F05D2230/312;;F05D2260/80;;F05D2270/08,F02C7/224;;F02C6/18;;F02C7/232;;F02C7/26;;F02C9/26;;F02C9/46,,0,0,,,,ACTIVE
147,US,B2,US 9429075 B2,143-440-089-206-966,2016-08-30,2016,US 201313755434 A,2013-01-31,US 201313755434 A,2013-01-31,Method of operating a fuel heating system,"A method of operating a fuel heating system is provided. The method includes performing pre-ignition diagnostic checks on a plurality of components of the fuel heating system, wherein at least one inlet damper and at least one outlet damper of an exhaust flow circuit are each in a closed position. The method also includes purging the fuel heating system of unburned hydrocarbons. The method further includes operating the fuel heating system in a normal operating condition. The method yet further includes operating the fuel heating system in a cool down condition, wherein the at least one inlet damper is in the closed position.",GEN ELECTRIC,AMIN RUSHI MAHESH;;BYRD DOUGLAS SCOTT;;ERICKSON DEAN MATTHEW;;MARIANI MICHAEL JOHN;;POMPEY CHRISTINA RENEE;;RENDO KOREY FREDERIC;;SWEET BRYAN EDWARD,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2013-01-29),https://lens.org/143-440-089-206-966,Granted Patent,yes,15,0,7,7,0,F02C7/224;;F02C7/224;;F02C7/232;;F02C7/26;;F02C7/26;;F02C9/26;;F05D2230/31;;F05D2230/312;;F05D2260/80;;F05D2270/08,F02C7/224;;F02C7/26,,0,0,,,,ACTIVE
148,US,A1,US 2003/0133659 A1,173-450-716-252-644,2003-07-17,2003,US 35480003 A,2003-01-30,US 35480003 A;;US 80939301 A,2001-03-15,Wide-bandwidth chirped fiber bragg gratings with low delay ripple amplitude,"
   A device including a chirped Bragg grating, said grating having (a) a reflection bandwidth having a full-width at half maximum that is greater than 6 nm, and (b) a reflection delay ripple amplitude of less than 50 ps. 
",3M INNOVATIVE PROPERTIES CO,BRENNAN JAMES F;;HERNANDEZ EDWARD;;VALENTI JOHN A;;SINHA PRANAY G;;MATTHEWS MICHAEL R;;ELDER DALE E;;BEAUCHESNE GERALD A;;BYRD CHAD H,CORNING RESEARCH & DEVELOPMENT CORPORATION (2018-06-01),https://lens.org/173-450-716-252-644,Patent Application,yes,0,0,10,10,0,G02B6/02085;;G02B6/02085;;G02B6/02138;;G02B6/02138;;G02B6/02142;;G02B6/02142;;G02B6/02147;;G02B6/02147;;G02B6/02152;;G02B6/02152,G02B6/122;;G02B6/02;;G02B6/10;;G02B6/26;;G02B6/34,385/37,0,0,,,,EXPIRED
149,US,B2,US 6741773 B2,006-280-188-559-356,2004-05-25,2004,US 35480003 A,2003-01-30,US 35480003 A;;US 80939301 A,2001-03-15,Wide-bandwidth chirped fiber bragg gratings with low delay ripple amplitude,"
    A device including a chirped Bragg grating, said grating having (a) a reflection bandwidth having a full-width at half maximum that is greater than 6 nm, and (b) a reflection delay ripple amplitude of less than 50 ps. 
",3M INNOVATIVE PROPERTIES CO,BRENNAN III JAMES F;;HERNANDEZ EDWARD;;VALENTI JOHN A;;SINHA PRANAY G;;MATTHEWS MICHAEL R;;ELDER DALE E;;BEAUCHESNE GERALD A;;BYRD CHAD H,CORNING RESEARCH & DEVELOPMENT CORPORATION (2018-06-01),https://lens.org/006-280-188-559-356,Granted Patent,yes,5,1,10,10,0,G02B6/02085;;G02B6/02085;;G02B6/02138;;G02B6/02138;;G02B6/02142;;G02B6/02142;;G02B6/02147;;G02B6/02147;;G02B6/02152;;G02B6/02152,G02B6/122;;G02B6/02;;G02B6/10;;G02B6/26;;G02B6/34,385/37;;385/122,17,12,053-327-745-933-081;;013-226-148-549-811;;045-327-135-543-764;;141-885-670-669-293;;048-382-437-416-42X;;051-129-148-183-710;;020-712-706-093-917;;187-102-576-455-382;;006-503-301-753-237;;046-458-697-027-143;;041-866-349-423-087;;019-912-722-308-333,10.1109/50.618372;;10.1364/bgpp.1999.bb1;;10.1016/s0030-4018(98)00324-1;;10.1109/68.502279;;10.1109/68.752556;;10.1109/68.839044;;10.1109/68.841265;;10.1109/68.803093;;10.1109/68.826939;;10.1109/68.531855;;10.1109/50.818912;;10.1109/68.969899,"A. Asseh, et al; ""A Writting Technique for Long Fiber Bragg Gratings with Complex Reflectivity Profiles"", Journal of Lighwave Technology(Aug. 1997); vol. 15, No. 8; pp. 1419-1423.;;R. KASHYAP, et al; ""Infinite Length Grantings"", Bragg Gratings, Photosensitivity, and Poling in Glass Waveguides, Optical Society of America, Technical Digest (Sept. 23-25, 1999); pp. 38/ThD3-1 -40/ThD3-3.;;H. ROURKE, et al; ""Fabrication of Extremely Long Fibre Gratings by pahse Matched Concatenation of Multiple Short Sections"", Brag Gratings, Photosensitvity , and Poling in Glass Waveguides, Optical Society of America, Technical Digest (Sept. 23-25, 1999); pp. 32/ThD1-3.;;KOMUKAI, T., et al, ""Fabrication of Non-Linearly Chirped Fiber Bragg Gratings for Higher-Order Dispersion Compensation"", Optics CommunicationsNorth-Holand Publ. Co., Amsterdam, NL; vol. 154, No. 1-3, AUg. 15, 1998; pp, 5-8.;;LOH, W.H., et al, ""Dispersion Compensation Over Distance in Excess of 500km for 10-Gb/s Systems Using Chirped Fiber Gratings"", IEEE Phontonics Technology Letters, vol.8, No. 7, Jul. 1996; pp. 944-946.;;GARRETT, L.D.D, et al. ""16x10 Gb/s WDM Transmission Over 840-km SMF Using a Slope-Compensating Fiber-Gratings"", IEEE Photonics Technology Letters , Vol.11, No.4, Apr. 1999; pp. 484-486.;;GNAUCK, A.H., et al. ""16x10 Gb/s 400-km WDN Transmission Over NZDSF Using a Slope-Compensating Fiber-Grantings Module"", IEEE Photonics Technology Letters, vol. 12, No.4, Apr. 2000; pp. 437-439.;;FUGII, K., et al, ""Broadband Chirped Fiber Bragg Grating for Dispersion Compensator"", European Confernce on Optical Communication, 26-30 Sept. 1999; Nice, France; pp. I-160--I-161.;;IBSEN, M., et al, ""Custom Design of long Chirped Bragg Gratings: Application to Gain-Flattening Filter with Incorporated Dispersion Compensation"", IEEE Photonics Technology Letters, vol. 12, No.5, May 2000; pp. 498-500.;;GNAUCK, A.H., et al. ""4x40 Gb/s 75-km WDM Transmission Over Convertional Fiber Using a Broad-Band Fiber Grating"", IEEE Photonics Technology Letters, vol.11 No. 11, Nov. 1999; pp. 1503-1504.;;ROCGA, Monica L., et al., ""System Impact of the Physical Length of Unapodised Chirped Fiber Bragg Gratings on Dispersion Compersation"", SBMO/IEEE MTT-S IMOC '99 Proceedings1999 IEEE; pp. 565-596.;;GARRETT, L.D., et al, ""Cascaded Cguroed Fuber Gratings for 18-nm-Bandwidth Dispersion Compensation"", IEEE Photonics Technology Letters, vol.12, No.3, March 2000; pp. 356-358.;;IBSEN, Morton, et al, ""Long Continunsly Chirped Fibre Bragg Gratings for Compesation of Linear-and 3rd Order-Dispersion"", European Conference on Optical Communication, 1997.;;LOH, W.H., et al, ""10 Gb/s Transmission Over 700 km of Standard Single-Mode Fiber with 10-cm Chirped Fiber Grating Compensator and Duobinary Transmitter"", IEEE Photonics Technology Letters , vol.8 No.9, Sept. 1996; pp. 1258-1260.;;FECED, R., and ZERVAS, M.N., ""Effects of Random Phase and Amplitude Errors in Optical Fiber Bragg Gratings"", Journal of Lightwave Technology Letters , vol. 18, No.1, Jan. 2000; pp. 90-101.;;NIEMI, T., et al., ""Measurements of Dense Group Relay Ripple Using the Phase Shift Method: Effect of Modulation Frequency"", Conference: Proceedings of Symposium on Optical Fiber Measurements, Sponsor: NIST, IEEE Lasers & Eletro-Opt. Soc, Opt.Soc.America, 26-28 Sep. 2000; Boulder CO; pp. 165-167.;;NIEMI, T., et al, ""Limitations of Phase-Shift Method in Measuring Dense Group Delay Ripple of Fiber Bragg Gratings"", IEEE Photonics Technology Letters, Vol. 13, No. 12, Dec. 2001; pp. 1334-1336.",EXPIRED
150,CA,A1,CA 2439540 A1,025-245-745-836-594,2002-09-26,2002,CA 2439540 A,2002-03-14,US 80939301 A;;US 0207737 W,2001-03-15,WIDE-BANDWIDTH CHIRPED FIBER BRAGG GRATINGS WITH LOW DELAY RIPPLE AMPLITUDE,"A device including a chirped Bragg grating, said grating having (a) a reflection bandwidth having a full-width at half maximum that is greater tha n 6 nm, and (b) a reflection delay ripple amplitude of less than .plusmn. 50 p s.",3M INNOVATIVE PROPERTIES CO,HERNANDEZ EDWARD;;BRENNAN JAMES F III;;BEAUCHESNE GERARD A;;SINHA PRANAY G;;MATTHEWS MICHAEL R;;VALENTI JOHN A;;ELDER DALE E;;BYRD CHAD H,,https://lens.org/025-245-745-836-594,Patent Application,no,0,0,10,10,0,G02B6/02085;;G02B6/02085;;G02B6/02138;;G02B6/02138;;G02B6/02142;;G02B6/02142;;G02B6/02147;;G02B6/02147;;G02B6/02152;;G02B6/02152,G02B6/122;;G02B6/02;;G02B6/10;;G02B6/26;;G02B6/34,,0,0,,,,DISCONTINUED
151,US,B2,US 6577792 B2,045-622-579-433-920,2003-06-10,2003,US 80939301 A,2001-03-15,US 80939301 A,2001-03-15,Wide-bandwidth chirped fiber Bragg gratings with low delay ripple amplitude,"
    A device including a chirped Bragg grating, said grating having (a) a reflection bandwidth having a full-width at half maximum that is greater than 6 nm, and (b) a reflection delay ripple amplitude of less than 50 ps. 
",3M INNOVATIVE PROPERTIES CO,BRENNEN III JAMES F;;HERNANDEZ EDWARD;;VALENTI JOHN A;;SINHA PRANAY G;;MATTHEWS MICHAEL R;;ELDER DALE E;;BEAUCHESNE GERAD A;;BYRD CHAD H,3M INNOVATIVE PROPERTIES COMPANY (2001-03-15);;PROXIMION FIBER SYSTEMS AB (2008-04-16),https://lens.org/045-622-579-433-920,Granted Patent,yes,7,6,10,10,0,G02B6/02085;;G02B6/02085;;G02B6/02138;;G02B6/02138;;G02B6/02142;;G02B6/02142;;G02B6/02147;;G02B6/02147;;G02B6/02152;;G02B6/02152,G02B6/122;;G02B6/02;;G02B6/10;;G02B6/26;;G02B6/34,385/37;;385/122,11,10,141-885-670-669-293;;048-382-437-416-42X;;051-129-148-183-710;;020-712-706-093-917;;187-102-576-455-382;;063-097-214-420-174;;006-503-301-753-237;;045-327-135-543-764;;087-457-332-902-729;;046-458-697-027-143,10.1109/68.502279;;10.1109/68.752556;;10.1109/68.839044;;10.1109/68.841265;;10.1109/68.803093;;10.1109/imoc.1999.866245;;10.1109/68.826939;;10.1016/s0030-4018(98)00324-1;;10.1049/cp:19971414;;10.1109/68.531855,"W. H. Loh, et al., ""Dispersion Compensation Over Distances in Excess of 500 km for 10-Gb/s Systems Using Chirped Fiber Gratings"", IEEE Photonics Technology Letters, vol. 8, No. 7, Jul. 1996, pp. 944-946.;;L. D. Garrett, et al., ""16x10 Gb/s WDM Transmission Over 840-km SMF Using Eleven Broad-Band Chirped Fiber Gratings"", IEEE Phototonics Technology Letters, vol. 11, No. 4, Apr. 1999, pp. 484-486.;;A. H. Gnauck, et al., ""16x20-Gb/s, 400-km WDM Transmission Over NZDSF Using a Slope-Compensating Fiber-Grating Module"", IEEE Photonics Technology Letters, vol. 12, No. 4, Apr. 2000, pp. 437-439.;;K. Fugii, et al., ""Broadband Chirped Fiber Bragg Grating for Dispersion Compensator"", European Conference on Optical Communication, Sep. 26-30, 1999, Nice, France, pp. I-160-I-161.;;M. Ibsen, et al., ""Custom Design of Long Chirped Bragg Gratings: Application to Gain-Flattening Filter with Incorporated Dispersion Compensation"", IEEE Photonics Technology Letters, vol. 12, No. 5, May 2000, pp. 498-500.;;A. H. Gnauck, et al., ""4x40 Gb/s 75-km WDM Transmission Over Conventional Fiber Using a Broad-Band Fiber Grating"", IEEE Photonics Technology Letters, vol. 11, No. 11, Nov. 1999, pp. 1503-1504.;;Monica L. Rocha, et al., ""System Impact of the Physical Length of Unapodised Chirped Fiber Bragg Gratings on Dispersion Compensation"", SBMO/IEEE MTT-S IMOC '99 Proceedings, 1999 IEEE, pp. 565-569.;;L. D. Garrett, et al., ""Cascaded Chirped Fiber Gratings for 18-nm-Bandwidth Dispersion Compensation"", IEEE Photonics Technology Letters, vol. 12, No. 3, Mar. 2000, pp. 356-358.;;Komukai, T., et al., ""Fabrication of Non-Linearly Chirped Fiber Bragg Gratings for Higher-Order Dispersion Compensation"", Optics Communications, North-Holland Publishing Co., Amsterdam, NL, vol. 154, No. 1-3, Aug. 15, 1998, pp. 5-8.;;Morten Ibsen et al., ""Long Continuously Chirped Fibre Bragg Gratings for Compensation of Linear-and 3rd Order-Dispersion"", European Conference on Optical Communication, 1997.;;W. H. Loh, et al., ""10 Gb/s Transmission over 700 km of Standard Single-Mode Fiber with 10-cm Chirped Fiber Grating Compensator and Duobinary Transmitter"", IEEE Photonics Technology Letters, vol. 8, No. 9, Sep. 1996, pp. 1258-1260.",EXPIRED
152,US,A1,US 2002/0164121 A1,043-106-894-509-75X,2002-11-07,2002,US 80939301 A,2001-03-15,US 80939301 A,2001-03-15,Wide-bandwidth chirped fiber bragg gratings with low delay ripple amplitude,"
   A device including a chirped Bragg grating, said grating having (a) a reflection bandwidth having a full-width at half maximum that is greater than 6 nm, and (b) a reflection delay ripple amplitude of less than 50 ps. 
",3M INNOVATIVE PROPERTIES CO,BRENNAN III JAMES F;;HERNANDEZ EDWARD;;VALENTI JOHN A;;SINHA PRANAY G;;MATTHEWS MICHAEL R;;ELDER DALE E;;BEAUCHESNE GERARD A;;BYRD CHAD H,3M INNOVATIVE PROPERTIES COMPANY (2001-03-15);;PROXIMION FIBER SYSTEMS AB (2008-04-16),https://lens.org/043-106-894-509-75X,Patent Application,yes,0,52,10,10,0,G02B6/02085;;G02B6/02085;;G02B6/02138;;G02B6/02138;;G02B6/02142;;G02B6/02142;;G02B6/02147;;G02B6/02147;;G02B6/02152;;G02B6/02152,G02B6/122;;G02B6/02;;G02B6/10;;G02B6/26;;G02B6/34,385/37;;385/15,0,0,,,,EXPIRED
153,US,A1,US 2018/0116453 A1,179-495-706-003-481,2018-05-03,2018,US 201715795423 A,2017-10-27,US 201715795423 A;;US 201662414381 P,2016-10-28,KAMADO STYLE COOKER SYSTEM,"A cast iron kamado style cooker system includes a cooker base and a cooker top hingedly connected to the cooker base. The cooker base includes a top end and a bottom end. The cooker base also includes a base cavity having a top opening at the top end, a side wall, and a bottom wall. The cast iron kamado style cooker system includes at least one support leg within the base cavity that extends inwardly from the side wall of the base cavity and upwardly from the bottom wall of the base cavity. The cooker top is hingedly connected to the cooker base.",GFMCO LLC DBA GOLDENS FOUNDRY & MACHINE COMPANY,BOYD SR GEORGE GOLDEN;;BOYD JR GEORGE GOLDEN;;BOYD SR EDWARD SPROUSE;;BOYD II JOHN THOMAS;;TOLAND JOHN;;BYRD DAVID;;HERNANDEZ AURELIO;;SIMS JR WALLACE,GFMCO LLC DBA GOLDENS' FOUNDRY & MACHINE CO (2017-11-01),https://lens.org/179-495-706-003-481,Patent Application,yes,5,3,1,1,0,A47J37/0704;;A47J37/0704;;A47J36/02;;A47J36/02;;A47J37/0694;;A47J37/0694,A47J37/07;;A47J36/02;;A47J37/06,,0,0,,,,DISCONTINUED
154,US,S,US D1004573 S,046-300-136-318-24X,2023-11-14,2023,US 202129800095 F,2021-07-19,US 202129800095 F;;US 201829657811 F,2018-07-25,Speaker,,DOLBY LABORATORIES LICENSING CORP,WALCOTT DREW ALEXANDER;;BYRD GRAYSON H;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;PROKSA CODY MICHAEL;;VORON VINCENT;;MEHTA SRIPAL S;;SEEFELDT ALAN J,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-09),https://lens.org/046-300-136-318-24X,Design Right,no,16,0,2,2,0,,,1401;;D14/216,0,0,,,,ACTIVE
155,US,S,US D0928738 S,059-849-474-166-680,2021-08-24,2021,US 201829657531 F,2018-07-23,US 201829657531 F,2018-07-23,Speaker,,DOLBY LABORATORIES LICENSING CORP,WALCOTT DREW ALEXANDER;;BYRD GRAYSON H;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;PROKSA CODY MICHAEL;;VORON VINCENT;;MEHTA SRIPAL S;;SEEFELDT ALAN J,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-09),https://lens.org/059-849-474-166-680,Design Right,no,33,5,2,2,0,,,1401;;D14/216,0,0,,,,ACTIVE
156,US,S,US D1004572 S,087-434-948-343-484,2023-11-14,2023,US 202129800094 F,2021-07-19,US 202129800094 F;;US 201829657531 F,2018-07-23,Speaker,,DOLBY LABORATORIES LICENSING CORP,WALCOTT DREW ALEXANDER;;BYRD GRAYSON H;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;PROKSA CODY MICHAEL;;VORON VINCENT;;MEHTA SRIPAL S;;SEEFELDT ALAN J,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-09),https://lens.org/087-434-948-343-484,Design Right,no,16,0,2,2,0,,,1401;;D14/216,0,0,,,,ACTIVE
157,US,A1,US 2018/0078090 A1,129-628-482-152-404,2018-03-22,2018,US 201715712699 A,2017-09-22,US 201715712699 A;;US 201662398238 P,2016-09-22,KAMADO STYLE COOKER SYSTEM,"A kamado style cooker system includes a kamado style cooker and a cooker cart. The kamado style cooker includes a pot and a cover hingedly connected to the pot. The cooker cart includes a base having a first side, a second side opposite the first side, and at least one horizontal base support on which the cooker sits.",GOLDENS FOUNDRY & MACHINE COMPANY,BOYD SR GEORGE GOLDEN;;BOYD JR GEORGE GOLDEN;;BOYD SR EDWARD SPROUSE;;BOYD II JOHN THOMAS;;TOLAND JOHN;;BYRD DAVID;;SIMS JR WALLACE;;HERNANDEZ AURELIO,GOLDENS' FOUNDRY & MACHINE COMPANY (2018-01-24),https://lens.org/129-628-482-152-404,Patent Application,yes,6,12,1,1,0,A47J37/0704;;B62B3/005;;A47J37/0763;;A47J37/0786;;B62B3/10;;B62B5/061;;A47J37/0763;;A47J37/0786;;A47J36/12;;A47J36/34;;B62B3/10;;B62B5/061;;A47J37/0704;;B62B3/005,A47J37/07;;A47J36/12;;A47J36/34;;B62B3/10;;B62B5/06,,0,0,,,,DISCONTINUED
158,US,S,US D0922351 S,078-785-473-532-836,2021-06-15,2021,US 202029725718 F,2020-02-26,US 202029725718 F;;US 201829657810 F,2018-07-25,Speaker,,DOLBY LABORATORIES LICENSING CORP,WALCOTT DREW ALEXANDER;;BYRD GRAYSON H;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;PROKSA CODY MICHAEL;;VORON VINCENT;;MEHTA SRIPAL S;;SEEFELDT ALAN J,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-09),https://lens.org/078-785-473-532-836,Design Right,no,90,4,3,3,0,,,1401;;D14/209.1,0,0,,,,ACTIVE
159,US,S,US D0928739 S,137-965-798-959-623,2021-08-24,2021,US 201829657811 F,2018-07-25,US 201829657811 F,2018-07-25,Speaker,,DOLBY LABORATORIES LICENSING CORP,WALCOTT DREW ALEXANDER;;BYRD GRAYSON H;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;PROKSA CODY MICHAEL;;VORON VINCENT;;MEHTA SRIPAL S;;SEEFELDT ALAN J,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-09),https://lens.org/137-965-798-959-623,Design Right,no,33,5,2,2,0,,,1401;;D14/216,0,0,,,,ACTIVE
160,US,S,US D0947814 S,106-095-894-290-973,2022-04-05,2022,US 202129794819 F,2021-06-15,US 202129794819 F;;US 202029725718 F;;US 201829657810 F,2018-07-25,Speaker,,DOLBY LABORATORIES LICENSING CORP,WALCOTT DREW ALEXANDER;;BYRD GRAYSON H;;MICHAELIAN PETER;;RENZ BRIAN EDWARD;;STEWART JOHN CARSON;;PROKSA CODY MICHAEL;;VORON VINCENT;;MEHTA SRIPAL S;;SEEFELDT ALAN J,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-09),https://lens.org/106-095-894-290-973,Design Right,no,99,4,3,3,0,,,1401;;D14/209.1;;D14/216;;D14/228,0,0,,,,ACTIVE
161,US,S,US D0904337 S,023-715-440-296-778,2020-12-08,2020,US 201929696050 F,2019-06-25,US 201929696050 F;;US 201829638590 F;;US 201629556705 F,2016-03-02,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2016-05-05),https://lens.org/023-715-440-296-778,Design Right,no,106,5,3,3,0,,,1401;;D14/205,6,0,,,"Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.;;U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,703 to Saute et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,708 to Saute et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).",ACTIVE
162,US,S,US D0872049 S,084-003-895-019-168,2020-01-07,2020,US 201829657545 F,2018-07-24,US 201829657545 F;;US 201629556706 F,2016-03-02,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2016-05-05),https://lens.org/084-003-895-019-168,Design Right,no,84,47,3,3,0,,,1401;;D14/205,6,0,,,"U.S. Appl. No. 29/556,705 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,703 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,708 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.",ACTIVE
163,US,S,US D0871368 S,137-942-433-834-893,2019-12-31,2019,US 201829662004 F,2018-08-31,US 201829662004 F,2018-08-31,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-07),https://lens.org/137-942-433-834-893,Design Right,no,130,36,4,4,0,,,1401;;D14/205,7,0,,,"Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.;;U.S. Appl. No. 29/556,703 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,705 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U,S. Appl. No. 29/556,708 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).",ACTIVE
164,US,S,US D0913990 S,002-961-826-790-279,2021-03-23,2021,US 201929714175 F,2019-11-21,US 201929714175 F;;US 201829662004 F,2018-08-31,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2018-08-07),https://lens.org/002-961-826-790-279,Design Right,no,156,9,4,4,0,,,1401;;D14/205;;D14/206,7,0,,,"Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.;;U.S. Appl. No. 29/556,703 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,705 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,708 to Saule et al., titled “Headphones”, filed Mar. 2, 2016.",ACTIVE
165,US,S,US D0858481 S,130-518-939-998-249,2019-09-03,2019,US 201829638655 F,2018-02-28,US 201829638655 F;;US 201629556708 F,2016-03-02,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,,https://lens.org/130-518-939-998-249,Design Right,no,85,62,2,2,0,,,1401;;D14/205,6,0,,,"U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,703 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,705 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.",ACTIVE
166,US,S,US D0857655 S,188-666-405-199-329,2019-08-27,2019,US 201829638590 F,2018-02-28,US 201829638590 F;;US 201629556705 F,2016-03-02,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2016-05-05),https://lens.org/188-666-405-199-329,Design Right,no,89,39,3,3,0,,,1401;;D14/205,6,0,,,"U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,703 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,708 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.",ACTIVE
167,US,S,US D0921607 S,061-895-041-822-274,2021-06-08,2021,US 201929714806 F,2019-11-26,US 201929714806 F;;US 201829657545 F;;US 201629556706 F,2016-03-02,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAUREN;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2016-05-05),https://lens.org/061-895-041-822-274,Design Right,no,176,7,3,3,0,,,1401;;D14/205,7,0,,,"Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.;;U.S. Appl. No. 29/556,703 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,705 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,708 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).",ACTIVE
168,US,S,US D0851062 S,186-093-993-486-528,2019-06-11,2019,US 201729625435 F,2017-11-09,US 201729625435 F;;US 201629556703 F,2016-03-02,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2016-05-05),https://lens.org/186-093-993-486-528,Design Right,no,72,32,1,1,0,,,1401;;D14/205,6,0,,,"U.S. Appl. No. 29/556,705 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;U.S. Appl. No. 29/556,708 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (unpublished).;;Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.",ACTIVE
169,US,S,US D0909341 S,033-828-891-261-770,2021-02-02,2021,US 201829662267 F,2018-09-04,US 201829662267 F,2018-09-04,Dock for headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2018-09-06),https://lens.org/033-828-891-261-770,Design Right,no,18,4,2,2,0,,,1403;;D14/217,2,0,,,"Koninklijke Philips Electronics N.V., JPO Publicly Known Design No. HJ21076356, available at least as early as Jul. 19, 2019 (2 pages).;;VETAC, p. 9, SW3053, JPO Publicly Known Design No. HD30002293, available at least as early as Jul. 19, 2019 (3 pages).",ACTIVE
170,US,S,US D0913989 S,143-825-191-940-486,2021-03-23,2021,US 201929697041 F,2019-07-03,US 201929697041 F;;US 201829638655 F;;US 201629556708 F,2016-03-02,Headphones,,DOLBY LABORATORIES LICENSING CORP,SAULE LUCAS E;;VORON VINCENT;;MICHAELIAN PETER;;JIN GUANGYU;;KILPATRICK KEVIN J;;LUKIC BRANKO;;TAKAYAMA STEVEN RYUTARO;;BYRD GRAYSON H;;KONIAK ADAM SCOTT;;FISCHER ARIEL LAURENT;;BORCHERS ROBERT EDWARD,DOLBY LABORATORIES LICENSING CORPORATION (2016-05-05),https://lens.org/143-825-191-940-486,Design Right,no,123,2,2,2,0,,,1401;;D14/205;;D14/219,6,0,,,"Images of Beoplay H7 headphones, available at least as early as Mar. 2, 2016.;;Image of Audeze EL-8 headphones, available at least as early as Mar. 2, 2016.;;Image of Sony h.ear on headphones, available at least as early as Mar. 2, 2016.;;U.S. Appl. No. 29/556,706 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,703 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).;;U.S. Appl. No. 29/556,708 to Saule et al., titled “Headphones”, filed Mar. 2, 2016 (abandoned).",ACTIVE
171,US,A1,US 2018/0140233 A1,081-420-087-293-845,2018-05-24,2018,US 201815863027 A,2018-01-05,US 201815863027 A;;US 2017/0049919 W;;US 201662384409 P,2016-09-07,"HIGH FIDELITY SYSTEMS, APPARATUS, AND METHODS FOR COLLECTING NOISE EXPOSURE DATA","Systems, apparatus, and methods for collecting, interpreting, and utilizing noise exposure data may include sensors to obtain an analog signal representative of impulse noise sound pressure and an analog signal representative of continuous noise sound pressure. At least one ADC may generate digital signals by sampling the analog signals at rates equal to or greater than twice the reciprocal of a minimum impulse noise rise time. Accelerometers may obtain data in close proximity to and remote from the sensors. At least one processor may include a first combining node to combine the digital signals to represent both the continuous noise and the impulse noise, a shock-artifact detection filter to identify a time frame including a shock artifact based on the accelerometry data, a frequency filter to generate a background-removed audio signal, an adaptive filter to estimate the shock artifact, and a second combining node to produce a shock-artifact-free audio signal.",MASSACHUSETTS INST TECHNOLOGY,LACIRIGNOLA JOSEPH J;;VIAN TRINA RAE;;SMALT CHRISTOPHER J;;AUBIN JR DAVID F;;MAURER DAVID C;;BYRD MARY KATHERINE;;WESTON CHRISTINE M;;JOHNSON KERRY A;;DAVIS SHAKTI;;TOWNSEND OLHA;;CALAMIA PAUL T;;CHEN EDWARD H;;COLLINS PAULA P,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2017-08-10),https://lens.org/081-420-087-293-845,Patent Application,yes,9,16,2,3,0,G01H3/14;;A61B2560/0242;;A61B5/125;;A61B5/6814;;A61B5/721;;A61B2562/0204;;A61B2562/0219;;A61B2503/20;;A61B5/725;;A61B5/6803;;A61B5/125;;A61B5/721;;A61B5/6814;;G01H3/12;;G01H3/14;;A61B2560/0242,A61B5/00;;A61B5/12;;G01H3/12,,0,0,,,,ACTIVE
172,US,B2,US 10264999 B2,196-218-710-377-479,2019-04-23,2019,US 201815863027 A,2018-01-05,US 201815863027 A;;US 2017/0049919 W;;US 201662384409 P,2016-09-07,"High fidelity systems, apparatus, and methods for collecting noise exposure data","Systems, apparatus, and methods for collecting, interpreting, and utilizing noise exposure data may include sensors to obtain an analog signal representative of impulse noise sound pressure and an analog signal representative of continuous noise sound pressure. At least one ADC may generate digital signals by sampling the analog signals at rates equal to or greater than twice the reciprocal of a minimum impulse noise rise time. Accelerometers may obtain data in close proximity to and remote from the sensors. At least one processor may include a first combining node to combine the digital signals to represent both the continuous noise and the impulse noise, a shock-artifact detection filter to identify a time frame including a shock artifact based on the accelerometry data, a frequency filter to generate a background-removed audio signal, an adaptive filter to estimate the shock artifact, and a second combining node to produce a shock-artifact-free audio signal.",MASSACHUSETTS INST TECHNOLOGY,LACIRIGNOLA JOSEPH J;;VIAN TRINA RAE;;SMALT CHRISTOPHER J;;AUBIN JR DAVID F;;MAURER DAVID C;;BYRD MARY KATHERINE;;WESTON CHRISTINE M;;JOHNSON KERRY A;;DAVIS SHAKTI;;TOWNSEND OLHA;;CALAMIA PAUL T;;CHEN EDWARD H;;COLLINS PAULA P,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2017-08-10),https://lens.org/196-218-710-377-479,Granted Patent,yes,43,5,2,3,0,G01H3/14;;A61B2560/0242;;A61B5/125;;A61B5/6814;;A61B5/721;;A61B2562/0204;;A61B2562/0219;;A61B2503/20;;A61B5/725;;A61B5/6803;;A61B5/125;;A61B5/721;;A61B5/6814;;G01H3/12;;G01H3/14;;A61B2560/0242,G01H3/14;;A61B5/00;;A61B5/12;;G01H3/12,,65,32,002-422-056-681-881;;012-703-631-442-056;;050-339-403-373-36X;;099-925-021-982-194;;097-547-982-671-16X;;079-015-935-256-772;;076-079-665-207-228;;015-412-051-410-719;;030-837-492-307-802;;124-238-913-733-409;;059-175-162-342-472;;048-985-436-394-09X;;025-582-131-020-512;;067-491-337-490-202;;018-989-112-329-136;;020-382-222-066-93X;;013-356-831-769-451;;057-758-943-636-862;;136-788-935-160-893;;028-668-913-327-03X;;029-111-107-662-974;;016-833-572-059-25X;;041-013-598-690-499;;093-109-935-842-32X;;012-112-835-408-226;;011-361-496-155-877;;009-139-619-418-931;;055-864-059-738-063;;031-176-594-209-227;;043-546-781-496-445;;076-135-760-564-294;;078-066-922-247-563,21173491;;10.4103/1463-1741.73992;;10.3397/1.2408407;;10.3397/1.2832055;;pmc8855867;;25469968;;10.7205/milmed-d-14-00100;;21428511;;pmc3188614;;10.1121/1.3533691;;10.1121/1.1928141;;4815750;;1880289;;10.1121/1.402344;;10.1044/1059-0889(2011/10-0033);;21474555;;3745686;;10.1121/1.394052;;pmc4659422;;25236152;;10.1121/1.4865269;;10.1080/15459620490465839;;15238316;;10.1016/j.apacoust.2004.11.007;;10.1121/1.382606;;10.1007/978-1-4419-9523-0_13;;10.1016/s0890-6955(01)00108-0;;10.1121/1.4933614;;18025753;;10.4103/1463-1741.36978;;25826345;;10.7205/milmed-d-14-00204;;6939113;;10.1121/1.401291;;1880292;;10.1007/978-1-4684-5176-4_28;;18189569;;10.1121/1.2785810;;17225417;;10.1121/1.2372455;;10.1121/1.4799813;;23654391;;pmc3663850;;10.7205/milmed.169.6.429;;15281670;;10.1121/1.393035;;4031257;;10.1177/1541931215591223;;10.1016/j.apacoust.2015.10.004;;10.1093/epirev/mxu005;;25600417;;10.1121/1.380835;;1249315;;10.1111/j.1559-3584.1999.tb01234.x;;10.1016/j.heares.2016.02.017;;26969259,"International Search Report and Written Opinion dated May 1, 2018 for International Application No. PCT/US2017/049919, 14 pages.;;“Advanced Personal Noise Monitoring”, 3M Occupational Health & Environment Safety Division NoisePro Brochure (2013), 4 pages.;;“Etymotic takes the cost and complication our of noise dosimetry”, Etymotic Research Inc., Information Sheet ER078105-C (2010), 2 pages.;;“Noise Sentry”, Data Sheet (2009), 5 pages.;;“Personal Sound Exposure Meter,” Casella CEL Brochure (2011), 8 pages.;;“Preventing Occupational Hearing Loss—A Practical Guide”, National Institute for Occupational Safety and Health, Publication No. 96-110 (1996), 5 pages.;;“Super-duty Noise Dosimeters”, Spark Family of Noise Dosimeters, Larson Davis A PCB Piezotronics Div., Information Sheet (2009), 4 pages.;;Ahroon et al., “Analysis of Army-wide hearing conservation database for hearing proles related to crew-served and individual weapon systems,” Noise & Health 13, pp. 76-83 (2011).;;American Institute of Biological Sciences (AIBS), Peer Review of Impulse Noise Injury Models, Nov. 9, 2010), 15 pages.;;American National Standards Institute (ANSI), Specification for Sound Level Meters, S1.4-1983 (R2006) (ANSI 1983), 32 pages.;;ANSI, Specification for Personal Noise Dosimeters, S1.25-1991 (ASA 98-1991) (ANSI 1991), 20 pages.;;Basch, “A wearable pocket noise dosimeter”, Conference Date: Apr. 18-27, Program of the 83rd meeting of the Acoustical Society of America, 180, vol. 52, No. 1 (Part 1) (1972), 1 page.;;Boroditsky et al., “Predicting shipboard noise using 3-d acoustic modeling,” Noise Control Eng. J. 55, 246-56 (2007).;;Bruel, “Do we measure damaging noise correctly?” Noise Control Eng. J. 8, 52-60 (1997).;;Cooper et al., “The Department of Defense epidemiologic and economic burden of hearing loss study,” Military Med. 179, 1458-64 (2014).;;Defence Res. & Dev. Canada, Toronto Research Centre, DRDC-RDDC-2015-R243, “A comparison of metrics for impulse noise exposure,” (2015), 52 pages.;;Fowler, “Instrumentation for noise and vibration measurement (excerpts from Chapter 6, Handbook of Noise Measurement)”, Conference Date: May 13-17, Proceedings of the Short Courses, Fundamentals of Noise Control and Reduction of Machinery Noise, pp. 124-139 (1974).;;Goley et al., “Kurtosis-corrected sound pressure level as a noise metric for risk assessment of occupational noises,” J. Acoustical Society of America 129, 1475-81 (2011).;;Hamernik et al., “Interaction of continuous and impulse noise: Audiometric and histological effects,” J. Acoustical Society of America 55, 117-21 (1974).;;Hamernik et al., “The energy spectrum of an impulse: Its relation to hearing loss,” J. Acoustical Society of America 90, 197-204 (1991).;;Helfer et al, “Noise-induced hearing injury and comorbidities among postdeployment US Army soldiers: Apr. 2003-Jun. 2009,” Am. J. Audiology 20, 33-41 (2011).;;Henderson et al., “Impulse noise: critical review”, Acoustical Society of America, vol. 80, No. 2, pp. 569-584 (1986).;;Johnson, “New Auditory Damage Risk Criteria and Standard for Impulse Noise”, RTO HFM Lecture Series, pp. 2-9 (2000).;;Kardous et al., “Evaluation of smartphone sound measurement applications,” J. Acoustical Society of America, 135, EL186-EL192 (2014), 8 pages.;;Kardous et al., “Limitations of using dosimeters in impulse noise environments,” J. Occup. & Envt'l Hygiene 1, 456-62 (2004).;;Kardous et al., “Noise dosimeter for monitoring exposure to impulse noise,” Applied Acoustics 66, 974-85 (2005).;;Stevin, “Integrating sound level meter for the measurement of continuous and impulse noise”, Revue d'Acoustique , vol. 13 , No. 55 , pp. 241-244 (1980).;;Kenna, “Impulse Noise Measurement Systems.” Proceedings—1981 International Conference on Noise Control Engineering, Internoise 81: Practice of Noise Control Engineering, pp. 985-988 (1981).;;Knowles Electronics, Inc., Walk induced head vibrations and hearing aid design TB5; 1-4 (1961).;;Kryter, “The Effects of Noise on Man,” (Academic 1985); 96 pages.;;Kuhn, “The pressure transformation from a diffuse sound field to the external ear and to the body and head surface,” J. Acoustical Society of America 65, 991-1000 (1979).;;Le Prell et al., “Prevention of Noise-Induced Hearing Loss: Potential Therapeutic Agents,” in Springer Handbook of Auditory Res., 40:285-338 (Springer 2012).;;Li, “A brief review: acoustic emission method for tool monitoring during turning”, International Journal of Machine Tools & Manufacture 42, pp. 157-165 (2002).;;McKinley, “LIAeq100ms, an a-duration adjusted impulsive noise damage risk criterion,” J. Acoustical Society of America 138:1774; http://asa.scitation.org/doi/10.1121/1.4933614. Abstract, 3 pages.;;Nakashima et al., “Hearing, communication and cognition in low-frequency noise from armoured vehicles,” Noise & Health 9:35-41 (2007).;;Nakashima et al., “Review of weapon noise measurement and damage risk criteria: Considerations for auditory protection and performance,” Military Med. 180:402-408 (2015).;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority in International Application No. PCT/US2014/69116, filed Dec. 8, 2014, dated Aug. 13, 2015, 9 pages.;;Passchier-Vermeer et al., “Measurement of impulse noise at workplaces: relation between oscilloscopic measurements with an ordinary precision sound level meter”, Conference Date: Aug. 25-27, 1980, Scandinavian Audiology Supplementum , No. 12 , pp. 85-97 (1980).;;Price et al., “Insights into hazard from intense impulses from a mathematical model of the ear,” J. Acoustical Society of America 90:219-27 (1991).;;Price, “Assumptions in the measurement of impulse noise”, Sound and Vibration , vol. 15 , No. 10 , pp. 8-9 (1981).;;Price, “Implications of a critical level in the ear for assessment of noise hazard at high intensities”, Journal of Acoustical Society of America, vol. 69, pp. 171-177, (1981).;;Price, “Impulse noise hazard as a function of level and spectral distribution,” in Salvi et al., Basic and Applied Aspects of Noise-Induced Hearing Loss, pp. 379-392 (Springer 1986).;;Price, “Validation of the Auditory Hazard Assessment Algorithm for the Human with impulse noise data,” J. Acoustical Society of America 122:2786-2802 (2007).;;Qiu et al., “The kurtosis metric as an adjunct to energy in the prediction of trauma from continuous, non-Gaussian noise exposures,” J. Acoustical Society of America 120:3901-06 (2006).;;Qiu et al., “The value of a kurtosis metric in estimating the hazard to hearing of complex industrial noise exposures,” J. Acoustical Society of America, 133:2856-66 (2013).;;Rovig et al., “Hearing health risk in a population of aircraft carrier flight deck personnel,” Military Med. 169:429-32 (2004).;;Shaw et al., “Transformation of sound-pressure level from the free field to the eardrum presented in numerical form,” J. Acoustical Society of America 78:1120-23 (1985).;;Sheeld et al., “The relationship between hearing acuity and operational performance in dismounted combat,” in Proceedings of the Human Factors and Ergonomics Society Annual Meeting 59:1346-50 (2015).;;Singh, “Wearable Noise Dosimeter”, Noise Control Vibration Reduction, 4/6, pp. 250-254 (1973).;;Sun et al., “Development and validation of a new adaptive weighting for auditory risk assessment of complex noise,” Applied Acoustics 103:30-36 (2016).;;Theodoroff et al., “Hearing impairment and tinnitus: Prevalence, risk factors, and outcomes in US service members and veterans deployed to the Iraq and Afghanistan wars,” Epidem. Rev., 37:71-85 (2015).;;U.S. Army Med. Res. & Dev. Command, Blast overpressure studies with animals and man: Walk-up study (1993), 71 pages.;;U.S. Army Res. Lab., ARL-RP-0521, Mathematical Model of the Ear's Response to Weapons Impulses (2015), 26 pages.;;U.S. Department of Veterans Affairs, Annual Benefits Report Fiscal Year 2015 (2015), 224 pages.;;U.S. Dept. of Defense, 6055.12, Hearing Conservation Program (2010), 26 pages.;;U.S. Dept. of Health & Human Services, 98-126, Criteria for a Recommended Standard: Occupational Noise Exposure (1998).;;U.S. Dept. of Health & Human Services, EPHB 309-05h, An Analysis of the Blast Overpressure Study Data Comparing Three Exposure Criteria (2009), 61 pages.;;U.S. Dept. of Interior, Bureau of Mines, Response Variations of a Microphone Worn on the Human Body 53 pages. (1973).;;U.S. Navy, 5100.19E, Safety and Occupational Health (SOH) Program Manual for Force Afloat ch. B4 (2007), 230 pages.;;Von Gierke et al., “Daily Noise Exposure of Populations,” 10th International Congress on Acoustics. vol. 3: Contributed Papers Continued (1980), 2 pages.;;Ward et al., “Effective quiet and moderate TTS: Implications for noise exposure standards,” J. Acoustical Society of America, 59:160-65 (1976).;;Xiangfeng, “Application of sound analysis technique to monitor tool wear during the turning process”, ICPMT2006—Progress of Machining Technology—Proceedings of the 8th International Conference on Progress of Machining Technology (2006), 1 page.;;Yankaskas et al., “Landing on the roof: CVN noise,” Naval Eng. J., 111:23-34 (1999).;;Zagadou et al., “Impulse noise injury prediction based on the cochlear energy,” Hearing Research 1-16 (2016).;;U.S. Department of Defense, Design Criteria Standard Noise Limits. Released Apr. 15, 2015. 123 pages.",ACTIVE
